0001376339-16-000160.txt : 20160510 0001376339-16-000160.hdr.sgml : 20160510 20160510161043 ACCESSION NUMBER: 0001376339-16-000160 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 66 CONFORMED PERIOD OF REPORT: 20160331 FILED AS OF DATE: 20160510 DATE AS OF CHANGE: 20160510 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MIMEDX GROUP, INC. CENTRAL INDEX KEY: 0001376339 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 900300868 STATE OF INCORPORATION: FL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35887 FILM NUMBER: 161635867 BUSINESS ADDRESS: STREET 1: 1775 W OAK COMMONS COURT, NE CITY: MARIETTA STATE: GA ZIP: 30062 BUSINESS PHONE: 678-384-6720 MAIL ADDRESS: STREET 1: 1775 W OAK COMMONS COURT, NE CITY: MARIETTA STATE: GA ZIP: 30062 FORMER COMPANY: FORMER CONFORMED NAME: Alynx, Co. DATE OF NAME CHANGE: 20060922 10-Q 1 mdxg-2016331x10xq.htm 10-Q SEC Document



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
x
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the Quarterly Period Ended March 31, 2016
OR
¨
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _____________________to______________________

Commission file number 001-35887

MIMEDX GROUP, INC.
(Exact name of registrant as specified in its charter)

Florida
 
26-2792552
(State or other jurisdiction of incorporation)
 
(I.R.S. Employer Identification Number)
1775 West Oak Commons Ct NE
Marietta, GA
 
30062
(Address of principal executive offices)
 
(Zip Code)

(770) 651-9100
(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes x No ¨
 
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes x     No ¨
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer x
Accelerated filer ¨
Non-accelerated filer ¨
(Do not check if a smaller reporting company)
Smaller reporting company ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes ¨ No x
 
As of April 15, 2016, there were 109,548,431 shares of the registrant’s common stock outstanding.




Table of Contents
 
Part I     FINANCIAL INFORMATION
 
Item 1
Condensed Consolidated Financial Statements
 
 
Condensed Consolidated Balance Sheets (unaudited) March 31, 2016 and December 31, 2015

 
Condensed Consolidated Statements of Operations (unaudited) Three Months Ended March 31, 2016 and 2015

 
Condensed Consolidated Statement of Stockholders' Equity (unaudited) for Three Months Ended March 31, 2016

 
Condensed Consolidated Statements of Cash Flows (unaudited) Three Months Ended March 31, 2016 and 2015

 
Notes to the Unaudited Condensed Consolidated Financial Statements Three Months Ended March 31, 2016 and 2015
8

Item 2
Management’s Discussion and Analysis of Financial Condition and Results of Operations

Item 3
Quantitative and Qualitative Disclosures About Market Risk

Item 4
Controls and Procedures

Part II   OTHER INFORMATION
Item 1
Legal Proceedings

Item 1A
Risk Factors

Item 2
Unregistered Sales of Equity Securities and Use of Proceeds

Item 3
Defaults upon Senior Securities

Item 4
Mine Safety Disclosures

Item 5
Other Information

Item 6
Exhibits

Signatures
 


2



Forward-Looking Statements
 
This Form 10-Q and certain information incorporated herein by reference contain forward-looking statements and information within the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934.  This information includes assumptions made by, and information currently available to management, including statements regarding future economic performance and financial condition, liquidity and capital resources, acceptance of our products by the market, and management’s plans and objectives. In addition, certain statements included in this and our future filings with the Securities and Exchange Commission (“SEC”), in press releases, and in oral and written statements made by us or with our approval, which are not statements of historical fact, are forward-looking statements. Words such as “may,” “could,” “should,” “would,” “believe,” “expect,” “expectation,” “anticipate,” “estimate,” “intend,” “seeks,” “plan,” “project,” “continue,” “predict,” “will,” “should,” and other words or expressions of similar meaning are intended by us to identify forward-looking statements, although not all forward-looking statements contain these identifying words.  These forward-looking statements are found at various places throughout this report and in the documents incorporated herein by reference.  These statements are based on our current expectations about future events or results and information that is currently available to us, involve assumptions, risks, and uncertainties, and speak only as of the date on which such statements are made.
Our actual results may differ materially from those expressed or implied in these forward-looking statements.  Factors that may cause such a difference include, but are not limited to, those discussed in Part II, Item 1A, “Risk Factors,” below and in our most recent Annual Report on Form 10-K, as well as other reports we file with the SEC.  Except as expressly required by the federal securities laws, we undertake no obligation to update any such factors, or to publicly announce the results of, or changes to any of the forward-looking statements contained herein to reflect future events, developments, changed circumstances, or for any other reason.
As used herein, the terms “MiMedx,” “the Company,” “we,” “our” and “us” refer to MiMedx Group, Inc., a Florida corporation, and its consolidated subsidiaries as a combined entity, except where it is clear that the terms mean only MiMedx Group, Inc.



3




Part I - FINANCIAL INFORMATION
Item 1. Condensed Consolidated Financial Statements

 

MIMEDX GROUP, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share data)
 
March 31, 2016
(unaudited)
 
December 31,
 2015

ASSETS
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
15,117

 
$
28,486

Short term investments
2,500

 
3,000

Accounts receivable, net
53,882

 
53,755

Inventory, net
17,967

 
7,460

Prepaid expenses and other current assets
5,774

 
3,609

Total current assets
95,240

 
96,310

Property and equipment, net of accumulated depreciation
12,123

 
9,475

Goodwill
30,730

 
4,040

Intangible assets, net of accumulated amortization
33,710

 
10,763

Deferred tax asset, net
4,940

 
14,838

Deferred financing costs and other assets
477

 
487

Total assets
$
177,220

 
$
135,913

LIABILITIES AND STOCKHOLDERS' EQUITY
 
 
 
Current liabilities:
 
 
 
Accounts payable
$
13,059

 
$
6,633

Accrued compensation
9,394

 
15,034

Accrued expenses
5,137

 
4,644

Other current liabilities
1,252

 
466

Total current liabilities
28,842

 
26,777

Earn out liability
33,240

 

Other liabilities
895

 
1,148

Total liabilities
62,977

 
27,925

Commitments and contingencies (Note 14)


 


Stockholders' equity:
 
 
 
Preferred stock; $.001 par value; 5,000,000 shares authorized and 0 shares issued and outstanding

 

Common stock; $.001 par value; 150,000,000 shares authorized;
109,539,420 issued and 109,466,073 outstanding at March 31, 2016 and 109,467,416 issued and 107,361,471 outstanding at December 31, 2015
109

 
109

Additional paid-in capital
151,659

 
163,133

Treasury stock at cost:
73,347 shares at March 31, 2016 and 2,105,945 shares at December 31, 2015
(592
)
 
(17,124
)
Accumulated deficit
(36,933
)
 
(38,130
)
Total stockholders' equity
114,243

 
107,988

Total liabilities and stockholders' equity
$
177,220

 
$
135,913

See notes to condensed consolidated financial statements

4



MIMEDX GROUP, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except share and per share data)
(unaudited)
 
Three Months Ended March 31,
 
 
2016
 
2015
 

 
 
 
 
Net sales
$
53,367

 
$
40,767

 
Cost of sales
7,946

 
5,148

 
Gross margin
45,421

 
35,619

 
 
 
 
 
 
Operating expenses:
 
 
 
 
Research and development expenses
2,496

 
1,831

 
Selling, general and administrative expenses
40,648

 
29,308

 
Amortization of intangible assets
810

 
233

 
Operating income
1,467

 
4,247

 
 
 
 
 
 
Other income (expense), net
 
 
 
 
Interest (expense), net
(56
)
 
(14
)
 
 
 
 
 
 
Income before income tax provision
1,411

 
4,233

 
Income tax provision
(214
)
 
(146
)
 
 
 
 
 
 
Net income
$
1,197

 
$
4,087

 
 
 
 
 
 
Net income per common share - basic
$
0.01

 
$
0.04

 
 
 
 
 
 
Net income per common share - diluted
$
0.01

 
$
0.04

 
 
 
 
 
 
Weighted average shares outstanding - basic
105,538,271

 
105,820,335

 
 
 
 
 
 
Weighted average shares outstanding - diluted
112,039,860

 
113,638,551

 
See notes to condensed consolidated financial statements

5




MIMEDX GROUP, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
(in thousands, except share data)
(unaudited)



 
 
Common Stock Issued

Treasury Stock
 
 
 
 
Shares
Amount
Additional Paid - in Capital
Shares
Amount
Accumulated Deficit
Total
Balance December 31, 2015
 
109,467,416

$
109

$
163,133

2,105,945

$
(17,124
)
$
(38,130
)
$
107,988

Share-based compensation expense
 


4,615




4,615

Exercise of stock options
 
72,004


(3,259
)
(536,713
)
4,397


1,138

Issuance of restricted stock
 


(12,750
)
(1,576,579
)
12,750



Restricted stock shares cancelled/forfeited
 


378

45,263

(378
)


Shares issued for services performed
 


4

(20,406
)
169


173

Stock repurchase
 



415,252

(3,530
)

(3,530
)
Shares repurchased for tax withholding
 



81,594

(684
)

(684
)
Shares issued in conjunction with acquisition
 


(462
)
(441,009
)
3,808


3,346

Net income
 





1,197

1,197

Balance March 31, 2016
 
109,539,420

$
109

$
151,659

73,347

$
(592
)
$
(36,933
)
$
114,243


See notes to condensed consolidated financial statements

6



MIMEDX GROUP, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(unaudited)
 
Three Months Ended March 31,
 
2016
 
2015
Cash flows from operating activities:
 
 
 
Net income
$
1,197

 
$
4,087

Adjustments to reconcile net income to net cash from operating activities:
 
 
 
Depreciation
734

 
354

Amortization of intangible assets
810

 
233

Amortization of inventory fair value step - up
734

 

Amortization of deferred financing costs
49

 

Share-based compensation
4,615

 
3,933

Increase (decrease) in cash, net of effects of acquisition, resulting from changes in:
 
 
 
  Accounts receivable
1,874

 
(4,329
)
  Inventory
(264
)
 
885

  Prepaid expenses and other current assets
(2,066
)
 
(801
)
  Other assets
209

 
(26
)
  Accounts payable
(4,265
)
 
1,789

  Accrued compensation
(5,640
)
 
(2,803
)
  Accrued expenses
493

 
1,111

  Other liabilities
543

 
(223
)
Net cash flows from operating activities
(977
)
 
4,210

 
 
 
 
Cash flows from investing activities:
 
 
 
 Purchases of equipment
(2,008
)
 
(1,347
)
 Purchase of Stability Inc., net of cash acquired
(7,631
)
 

 Fixed maturity securities redemption
500

 
500

 Patent application costs
(147
)
 
(201
)
Net cash flows from investing activities
(9,286
)
 
(1,048
)
 
 
 
 
Cash flows from financing activities:
 
 
 
 Proceeds from exercise of stock options
1,138

 
1,276

 Stock repurchase under repurchase plan
(3,530
)
 
(12,295
)
Stock repurchase for tax withholdings on vesting of restricted stock
(684
)
 

Deferred financing costs
(20
)
 

Payments under capital lease obligations
(10
)
 
(29
)
Net cash flows from financing activities
(3,106
)
 
(11,048
)
 
 
 
 
Net change in cash
(13,369
)
 
(7,886
)
 
 
 
 
Cash and cash equivalents, beginning of period
28,486

 
46,582

Cash and cash equivalents, end of period
$
15,117

 
$
38,696

See notes to condensed consolidated financial statements

7



MIMEDX GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THREE MONTHS ENDED MARCH 31, 2016 AND 2015
1.
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) from interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X.  Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.  Changes to GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of Accounting Standards Updates (“ASU’’) to the FASB’s Accounting Standards Codification (“ASC”).  In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the results of operations for the periods presented have been included.  Operating results for the three months ended March 31, 2016 and 2015, are not necessarily indicative of the results that may be expected for the fiscal year.  The balance sheet at December 31, 2015, has been derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements. 
You should read these condensed consolidated financial statements together with the historical consolidated financial statements of the Company for the year ended December 31, 2015, included in the Company's Annual Report on Form 10-K for the year ended December 31, 2015, filed with the SEC on February 29, 2016. 
The Company operates in one business segment, Regenerative Biomaterials, which includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories. The Company's biomaterial platform technologies include tissue technologies, AmnioFix® and EpiFix®, amniotic fluid derived allograft, OrthoFlo, and anticipated device technology, CollaFix™, which the Company has yet to commercialize. Through the recent acquisition of Stability Inc., our newest proprietary platforms include Physio™, a unique bone grafting material comprised of 100% bone tissue with no added carrier, thus maximizing bone forming potential, a demineralized bone matrix (DBM) to complement our product portfolio offerings within the Orthopedic market and AlloBurn, a skin product for burns.
2.
Significant Accounting Policies
Please see Note 2 to the Company's Consolidated Financial Statements included in the Company’s Form 10-K for the fiscal year ended December 31, 2015, for a description of all significant accounting policies. 
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. 
Accounts Receivable
Accounts receivable represent amounts due from customers for which revenue has been recognized. Generally, the Company does not require collateral or any other security to support its receivables.
The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing receivables. The Company determines the allowance based on factors such as historical collection experience, customers' current creditworthiness, customer concentrations, age of accounts receivable balance and general economic conditions that may affect the customers' ability to pay. 
Inventories
Inventory is valued at the lower of cost or market value. The Company assesses the valuation of its inventory on a periodic basis and makes adjustments to the value for estimated excess and obsolete inventory based on estimates about future demand. The excess balance determined by this analysis becomes the basis for the Company's excess inventory charge. The Company's excess inventory review process includes analysis of sales forecasts, managing product rollovers and working with operations to maximize recovery of excess inventory. The value of inventory as of March 31, 2016 includes a fair value step - up connected with the January 2016 acquisition of Stability Inc. of approximately $1.6 million, which is comprised of approximately $2.3 million as of the date of the acquisition less amortization of approximately $734,000 during the quarter. Please see Note 4 contained herein.



8



Revenue Recognition
The Company sells its products through a combination of a direct sales force and independent stocking distributors and representatives in the U.S. and independent distributors in international markets. The Company recognizes revenue when title to the goods transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance. In cases where the Company utilizes distributors or ships product directly to the end user, it recognizes revenue upon shipment provided all other revenue recognition criteria have been met. A portion of the Company's revenue is generated from inventory maintained at hospitals, clinics and doctor's offices. For these products, revenue is recognized at the time the product has been used or implanted. The Company records estimated sales returns, discounts and allowances as a reduction of net sales in the same period revenue is recognized.  
Acquisitions
Results of operations of acquired companies are included in the Company’s results of operations as of the respective acquisition dates. The purchase price of each acquisition is allocated to the net assets acquired based on estimates of their fair values at the date of the acquisition. Any purchase price in excess of these net assets is recorded as goodwill. The allocation of purchase price in certain cases may be subject to revision based on the final determination of fair values during the measurement period, which may be up to one year from the acquisition date.

Contingent consideration is recognized at the estimated fair value on the acquisition date. Subsequent changes to the fair value of contingent payments are recognized in earnings. Contingent payments related to acquisitions consist of an earn out based on sales less direct production costs, and are valued using discounted cash flow techniques. The fair value of these payments is based upon probability-weighted future revenue estimates and increases or decreases as revenue estimates or expectation of timing of payments changes.
Patent Costs
The Company incurs certain legal and related costs in connection with patent applications for tissue-based products and processes. The Company capitalizes such costs to be amortized over the expected life of the patent to the extent that an economic benefit is anticipated from the resulting patent or alternative future use is available to the Company and are included in Intangible Assets in the Condensed Consolidated Balance Sheets. The Company capitalized approximately $147,000 of patent costs during the first three months of 2016. The Company capitalized approximately $201,000 of patent costs during the first three months of 2015.
Treasury Stock
The Company accounts for the purchase of treasury stock under the cost method. Treasury stock which is reissued for the exercise of option grants and the issuance of restricted stock grants is accounted for on a first - in first - out (FIFO) basis.
Recent Accounting Pronouncements 
The Company considers the applicability and impact of all Accounting Standards Updates ("ASUs") issued both effective and not yet effective. In May 2014, the FASB issued ASU 2014-09, “Revenue Recognition - Revenue from Contracts with Customers” (ASU 2014-09) that requires companies to recognize revenue when a customer obtains control rather than when companies have transferred substantially all risks and rewards of a good or service. This update is effective for annual reporting periods beginning on or after December 15, 2017 and interim periods therein and requires expanded disclosures. The Company is currently assessing the impact the adoption of ASU 2014-09 will have on our condensed consolidated financial statements.

In November 2015, the FASB issued ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes. ASU 2015-17 simplifies the presentation of deferred taxes by requiring deferred tax assets and liabilities be classified as noncurrent on the balance sheet. ASU 2015-17 is effective for public companies for annual reporting periods beginning after December 15, 2016, and interim periods within those fiscal years. The guidance may be adopted prospectively or retrospectively and early adoption is permitted. The Company adopted this standard, prospectively, at the beginning of the fourth quarter 2015 to simplify reporting with the release of the valuation allowance as disclosed in Note 12. Prior periods were not retrospectively adjusted.
In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from leases.  ASU 2016-02 is effective for public companies for annual reporting periods beginning after December 15, 2018, and interim periods within those fiscal years.  The guidance may be adopted prospectively or retrospectively and early adoption is permitted.  The Company is currently assessing the impact the adoption of ASU 2016-02 will have on its consolidated financial statements.
In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718). The standard is intended to simplify several areas of accounting for share - based compensation arrangements, including the income tax impact,

9



classification on the statement of cash flows and forfeitures. This ASU is effective for fiscal years beginning after December 15, 2016. The Company is currently assessing the impact the adoption of ASU 2016-09 will have on its consolidated financial statements.
All other ASUs issued and not yet effective for the three months ended March 31, 2016, and through the date of this report, were assessed and determined to be either not applicable or are expected to have minimal impact on the Company's financial position or results of operations.

3.
Liquidity and Management’s Plans
As of March 31, 2016, the Company had approximately $15,117,000 of cash and cash equivalents.  The Company reported total current assets of approximately $95,240,000 and current liabilities of approximately $28,842,000 as of March 31, 2016.  The Company believes that its anticipated cash from operating and financing activities, existing cash and cash equivalents, short term investments and availability under its line of credit will enable the Company to meet its operational liquidity needs and fund its planned investing activities for the next twelve months.




4. Acquisition of Stability Inc.

On January 13, 2016, the Company completed the acquisition of Stability Inc., d/b/a Stability Biologics, a provider of human tissue products to surgeons, facilities, and distributors serving the surgical, spine, and orthopedic sectors of the healthcare industry. As a result of this transaction, the Company acquired all of the outstanding shares of Stability in exchange for $6,000,000 cash, $3,346,000 in stock, represented by 441,009 shares of our common stock, and assumed debt of $1,771,000. Additional one time costs incurred in connection with the transaction totaled $713,000. Contingent consideration may be payable in a formula determined by sales less certain expenses for the years 2016 and 2017. As of March 31, 2016, the contingent consideration was valued at $33,240,000 and is shown in the schedule below as fair value of earn-out. The Company used a third party specialist to assist us with the valuation. The contingent consideration was classified as a liability. The Company has evaluated the contingent consideration for accounting purposes under GAAP and has determined that the contingent consideration is within the scope of ASC 480 Distinguishing Liabilities from Equity whereby a financial instrument other than an outstanding share, that embodies a conditional obligation that the issuer may settle by issuing a variable number of its equity shares, shall be classified as a liability if, at inception, the monetary value of the obligation is based solely or predominantly on variations in something other than the fair value of the issuer’s equity shares.

The actual purchase price was based on cash paid, the fair value of our stock on the date of the acquisition, and direct costs associated with the combination. The actual purchase price has been preliminarily allocated as of March 31, 2016 (in thousands) and is subject to change:


10



 
 
 
Cash paid at closing
 
$
6,000

Common stock issued (441,009 shares valued at $9.07 per share)
 
3,346

Assumed debt
 
1,771

Fair value of earn - out
 
33,240

Total fair value of purchase price
 
$
44,357

 
 
 
Net assets acquired:
 
 
Debt-free working capital
 
$
2,382

Other assets, net
 
199

Property, plant and equipment
 
1,375

Deferred tax liability
 
(9,899
)
Subtotal
 
(5,943
)
Intangible assets:
 
 
Customer relationships
 
8,920

Patents and know-how
 
10,230

Trade names and trademarks
 
1,000

Non compete agreements
 
2,700

Licenses and permits
 
760

Subtotal
 
23,610

Goodwill
 
26,690

Total Assets Purchased
 
$
44,357

 


Working capital and other assets were composed of the following (in thousands):

Working capital:
 
 
Cash
 
$
140

Prepaid Expenses and other current assets
 
100

Accounts Receivable
 
2,001

Federal and state taxes receivable
 
28

Inventory
 
10,977

Accounts payable and accrued expenses
 
(10,864
)
Debt-free working capital
 
$
2,382

 
 
 
Current portion of long term debt
 
$
(194
)
Long-term debt
 
(560
)
Line of credit
 
(932
)
Shareholder loan
 
(85
)
Net working capital
 
$
611

 
 
 
Other assets:
 
 
Other long term assets
 
$
199


The acquisition was accounted for as a purchase business combination as defined by FASB Topic 805 - Business Combinations.
The fair value of the contingent consideration is measured as a Level 3 instrument. The contingent consideration liability is recorded at fair value on the acquisition date and will be remeasured quarterly based on the assessed fair value and adjusted if necessary. The increases or decreases in the fair value of contingent consideration can result from changes in anticipated revenue levels and changes in assumed discount periods and rates. As the fair value measured is based on significant inputs that are not observable in the market, they are categorized as Level 3. The income valuation approach was applied in determining

11



the fair value of the contingent consideration using a discounted cash flow valuation technique with significant unobservable inputs comprised of projected sales and certain expenses. The values assigned to intangible assets are subject to amortization. The intangible assets were assigned the following lives for amortization purposes:


 
Estimated useful
 
life (in years)
Intangible asset:
 
Customer relationships
12
Patents and know-how
20
Trade names and trademarks
indefinite
Non compete agreements
4
Licenses and permits
2

Goodwill consists of the excess of the purchase price paid over the identifiable net assets and liabilities acquired at fair value. Goodwill was determined using the residual method based on an independent appraisal of the assets and liabilities acquired in the transaction and is preliminary as of March 31, 2016 and is subject to change. Goodwill is tested for impairment as defined by FASB Topic 350 - Intangibles - Goodwill and Other.
 
The following unaudited pro forma summary financial information presents the consolidated results of operations as if the acquisition had occurred on January 1, 2015. The pro forma results are shown for illustrative purposes only and do not purport to be indicative of the results that would have been reported if the acquisition had occurred on the date indicated or indicative of the results that may occur in the future.

Unaudited pro forma information for the three months ended March 31, 2016 and 2015 (in thousands) is as follows:
 
Three months ended March 31,
 
2016
2015
Revenues
$
53,915

$
45,921

 
 
 
Net income
$
1,611

$
2,879

 
 
 
Income per share, fully diluted
$
0.01

$
0.03


The 2016 supplemental pro forma earnings were adjusted to exclude $713,000 of acquisition-related legal, audit and other costs, net of tax. The 2015 supplemental pro forma earnings were adjusted to include $577,000 of amortization costs related to recorded intangible assets with defined useful lives, and $1,038,000 of inventory step up charges as a result of the acquisition for comparability to 2016. The shares outstanding used in calculating the income per share for 2015 was adjusted to include 441,009 shares issued as part of the purchase price and assumed to be issued on January 1, 2015.

5.
Short Term Investments
Short term investments consist of approximately $2,500,000 of FDIC insured certificates of deposit held with various financial institutions as of March 31, 2016. Short term investments consisted of approximately $3,000,000 of FDIC insured certificates of deposit at December 31, 2015. The cost of these instruments approximates their fair market value at March 31, 2016 and December 31, 2015.




12







6. Inventories
Inventories consisted of the following items as of March 31, 2016, and December 31, 2015 (in thousands):
 
March 31, 2016
 
December 31, 2015
Raw materials
$
1,127

 
$
602

Work in process
4,786

 
3,850

Finished goods
12,658

 
3,405

 Inventory, gross
18,571

 
7,857

Reserve for obsolescence
(604
)
 
(397
)
 Inventory, net
$
17,967

 
$
7,460


7. Property and Equipment 
Property and equipment consist of the following as of March 31, 2016, and December 31, 2015 (in thousands):
 
March 31,
2016
 
December 31,
2015
Leasehold improvements
$
3,233

 
$
2,684

Lab and clean room equipment
7,528

 
4,564

Furniture and office equipment
5,730

 
4,577

Construction in progress
1,539

 
2,629

   Property and equipment, gross
18,030

 
14,454

Less accumulated depreciation
(5,907
)
 
(4,979
)
   Property and equipment, net
$
12,123

 
$
9,475

Included in net property and equipment is approximately $427,000 of equipment covered under capital leases. The corresponding liability of approximately $103,000 is included in other liabilities in the accompanying Condensed Consolidated Balance Sheets. Interest rates for these leases range from approximately 3% to 12% with maturity dates from September 2016 to January 2018.
Also included is approximately $1.0 million in leasehold improvements paid for by the landlord of the Company's main facility with a corresponding liability included in other liabilities which is amortized over the term of the lease.
Depreciation expense for the three months ended March 31, 2016 and 2015, was approximately $734,000 and $354,000, respectively.



13



8.
Intangible Assets and Royalty Agreement
Intangible assets are summarized as follows (in thousands):
 
Weighted
Average
Amortization
Lives
 
March 31, 2016
 
December 31, 2015
 
 
 
Cost
 
Cost
Licenses (a) (b) (d)
7 years
 
$
1,769

 
$
1,009

Patents & Know How (b) (d)
19 years
 
18,233

 
8,001

Customer & Supplier Relationships (b) (d)
13 years
 
12,681

 
3,761

Tradenames & Trademarks (b) (d)
indefinite
 
2,008

 
1,008

Non - compete agreements (d)
4 years
 
2,700

 

In Process Research & Development (b)
n/a
 
25

 
25

Patents in Process (c)
n/a
 
1,969

 
1,823

Total
 
 
39,385

 
15,627

Less Accumulated amortization
 
 
(5,675
)
 
(4,864
)
Net
 
 
$
33,710

 
$
10,763

(a)
On January 29, 2007, the Company acquired a license from Shriners Hospitals for Children and University of South Florida Research Foundation, Inc. in the amount of $996,000.  Within 30 days after the receipt by the Company of approval by the FDA allowing the sale of the first licensed product, the Company is required to pay an additional $200,000 to the licensor.  Due to its contingent nature, this amount is not recorded as a liability. The Company will also be required to pay a royalty of 3% on all commercial sales revenue from the licensed products. The Company is also obligated to pay a $50,000 minimum annual royalty payment over the life of the license.
(b)
On January 5, 2011, the Company acquired Surgical Biologics, LLC.  As a result, the Company recorded intangible assets for Customer & Supplier Relationships of $3,761,000, Patents & Know-How of $7,690,000, Licenses of $13,000, Tradenames & Trademarks of $1,008,000 and In-Process Research & Development of $25,000. For the three months ended March 31, 2016, approximately $1,000 of costs associated with patents granted during the period were capitalized and included in Patents & Know-How subject to amortization.
(c)
Patents in Process consist of capitalized external legal and other registration costs in connection with internally developed tissue-based patents that are pending. Once issued, the costs associated with a given patent will be included in Patents & Know-How under intangible assets subject to amortization.
(d)
On January 13, 2016, the Company acquired Stability Inc. As a result, the Company recorded intangible assets for Patents & Know - How of $10,230,000, Customer Relationships of$8,920,000, Non - compete agreements of $2,700,000, Tradenames & Trademarksy of $1,000,000 and Licenses of $760,000.
Amortization expense for the three months ended March 31, 2016 and 2015, was approximately $810,000 and $233,000, respectively.

14



Expected future amortization of intangible assets as of March 31, 2016, is as follows (in thousands):
Year ending December 31,
Estimated
Amortization
Expense
2016 (a)
$
2,434

2017
3,156

2018
2,766

2019
2,766

2020
2,091

Thereafter
18,489

 
$
31,702

(a) Estimated amortization expense for the year ending December 31, 2016, includes only amortization to be recorded after March 31, 2016.




15



9. Credit Facility

On October 12, 2015, the Company and its subsidiaries entered into a Credit Agreement (the "Credit Agreement") with certain lenders and Bank of America, N.A., as administrative agent. The Credit Agreement establishes a senior secured revolving credit facility in favor of the Company with a maturity date of October 12, 2018 and an aggregate lender commitment of up to $50 million. The Credit Agreement also provides for an uncommitted incremental facility of up to $35 million, which can be exercised as one or more revolving commitment increases or new term loans, all subject to certain customary terms and conditions set forth in the Credit Agreement. Borrowings under the facility will bear interest at LIBOR plus 1.5% to 2.25%.  Fees paid in connection with the initiation of the credit facility totaled approximately $500,000.  These deferred financing costs are being amortized to interest expense over the three-year life of the facility. The Credit Agreement contains customary representations, warranties, covenants, and events of default. As of March 31, 2016, there were no outstanding revolving loans under the credit facility.


10. Net Income Per Share
Basic net income per common share is computed using the weighted-average number of common shares outstanding during the period.  Diluted net income per common share is computed using the weighted-average number of common and dilutive common equivalent shares from stock options, restricted stock, and warrants using the treasury stock method. 
The following table sets forth the computation of basic and diluted net income per share (in thousands except share data):
 
Three Months Ended March 31,
 
2016
 
2015
Net income
$
1,197

 
$
4,087

Denominator for basic earnings per share - weighted average shares
105,538,271

 
105,820,335

Effect of dilutive securities: Stock options, restricted stock, and warrants outstanding(a)
6,501,589

 
7,818,216

Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities
112,039,860

 
113,638,551

Income per common share - basic
$
0.01

 
$
0.04

Income per common share - diluted
$
0.01

 
$
0.04

(a) Securities outstanding that are included in the computation above, utilizing the treasury stock method are as follows:
 
Three Months Ended March 31,
 
2016
 
2015
Outstanding Stock Options
5,981,250

 
7,392,355

Outstanding Warrants

 
42,400

Restricted Stock Awards
520,339

 
383,461

 
6,501,589

 
7,818,216




11. Equity
Stock Incentive Plans 
The Company has three share-based compensation plans: the MiMedx Group, Inc. Assumed 2006 Stock Incentive Plan (the “Assumed 2006 Plan”), the MiMedx Inc. 2007 Assumed Stock Plan (the “Assumed 2007 Plan”) and the MiMedx Group Inc. Amended and Restated Assumed 2005 Stock Plan (the “Assumed 2005 Plan”) which provide for the granting of qualified incentive and non-qualified stock options, stock appreciation awards and restricted stock awards to employees, directors, consultants and advisors. The awards are subject to a vesting schedule as set forth in each individual agreement. The Company

16



intends to use only the Assumed 2006 Plan to make future grants. The number of assumed options under the Assumed 2005 Plan and Assumed 2007 Plan outstanding at March 31, 2016 totaled 70,000. The maximum number of shares of common stock that can be issued under the Assumed 2006 Plan was 26,500,000 at March 31, 2016.
During the three months ended March 31 2016, 20,406 shares of common stock valued at approximately $173,000 were issued under the Assumed 2006 Plan to a consultant in return for services performed.
Activity with respect to the stock options is summarized as follows:
 
Number
 of
Shares
 
Weighted-
Average
Exercise
Price
 
Weighted-Average
Remaining
Contractual Term
(in years)
 
Aggregate
Intrinsic
Value
Outstanding at January 1, 2016
14,019,629

 
$
3.62

 
 
 
 
Granted

 
$

 
 
 
 
Exercised
(608,717
)
 
$
1.87

 
 
 
 
Unvested options forfeited
(120,563
)
 
$
6.05

 
 
 
 
Vested options expired
(12,497
)
 
$
6.34

 
 
 
 

Outstanding at March 31, 2016
13,277,852

 
$
3.69

 
6.3
 
$
67,341,642

Vested at March 31, 2016
11,714,483

 
$
3.24

 
6.1
 
$
64,456,036

Vested or expected to vest at March 31, 2016 (a)
13,210,155

 
$
3.67

 
6.3
 
$
67,231,821

(a)
Includes forfeiture adjusted unvested shares.
The intrinsic value of the options exercised during the three months ended March 31, 2016, was approximately $4,440,694
Following is a summary of stock options outstanding and exercisable at March 31, 2016:
 
Options Outstanding
 
Options Exercisable
Range of Exercise Prices
Number outstanding
 
Weighted-Average
Remaining
Contractual Term
(in years)
 
Weighted-
Average
Exercise
Price
 
Number Exercisable
 
Weighted-
Average
Exercise Price
$0.50 - $0.76
441,429

 
3.2
 
$
0.72

 
441,429

 
$
0.72

$0.87 - $1.35
4,431,970

 
5.4
 
1.19

 
4,431,970

 
1.19

$1.40 - $2.45
1,460,924

 
4.7
 
1.92

 
1,460,924

 
1.92

$2.66 - $3.99
894,120

 
6.6
 
3.06

 
894,120

 
3.06

$4.19 - $6.38
3,426,178

 
7.2
 
5.35

 
2,897,570

 
5.26

$6.45 - $9.78
2,512,065

 
7.9
 
7.29

 
1,556,144

 
7.24

$9.90- $10.99
111,166

 
8.6
 
10.44

 
32,326

 
10.51

 
13,277,852

 
6.3
 
$
3.69

 
11,714,483

 
$
3.24

 
Total unrecognized compensation expense related to granted stock options at March 31, 2016, was approximately $4,501,863 and will be charged to expense ratably over a weighted average period through April 2017. 
The fair value of options granted by the Company is estimated on the date of grant using the Black-Scholes-Merton option-pricing model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate.  Expected volatilities are based on historical volatility of peer companies and other factors estimated over the expected term of the options.  The term of employee options granted is derived using the “simplified method,” which computes expected term as the mid point between the weighted average time to vesting and the contractual maturity. The simplified method was used due to the Company's lack of sufficient historical data to provide a reasonable basis upon which to estimate the expected term due to the limited period of time its equity shares have been publicly traded.  The term for non-employee options is generally based upon the contractual term of the option.  The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term or contractual term as described.
The assumptions used in calculating the fair value of options using the Black-Scholes-Merton option-pricing model are set forth in the following table:

17



 
Three Months Ended March 31,
 
2016
 
2015
Expected volatility
n/a
 
56.8 - 58.1%

Expected life (in years)
n/a
 
6.0

Expected dividend yield
n/a
 

Risk-free interest rate
n/a
 
1.57% - 1.66%

Their were no options granted during the three months ended March 31, 2016.
Restricted Stock Awards                                                    
Activity with respect to restricted stock awards is summarized as follows: 
 
Number
of
Shares
 
Weighted-Average Grant Date
Fair Value
Unvested at January 1, 2016
2,613,267

 
$9.14
Granted
1,576,579

 
8.18
Vested
(644,903
)
 
8.42
Forfeited
(45,263
)
 
8.87

Unvested at March 31, 2016
3,499,680

 
$8.84
As of March 31, 2016, there was approximately $24,965,395 of total unrecognized stock-based compensation related to time-based, nonvested restricted stock.  That expense is expected to be recognized on a straight-line basis over a weighted-average period of 2.3 years, which approximates the remaining vesting period of these grants. All shares noted above as unvested are considered issued and outstanding at March 31, 2016.
For the three months ended March 31, 2016 and 2015, the Company recognized stock-based compensation as follows (in thousands): 
 
Three Months Ended March 31,
 
2016
 
2015
Cost of sales
$
96

 
$
95

Research and development
205

 
186

Selling, general and administrative
4,314

 
3,652

 
$
4,615

 
$
3,933



Treasury Stock
On May 12, 2014, our Board of Directors authorized the repurchase of up to $10 million of our common stock from time to time, through December 31, 2014. The Board subsequently extended the program until December 31, 2016. In December 2014, the Board increased the authorization to $20 million and further increased the authorization in 2015 to $60 million. The timing and amount of repurchases will depend upon the Company's stock price, economic and market conditions, regulatory requirements, and other corporate considerations. The Company may initiate, suspend or discontinue purchases under the stock repurchase program at any time.
For the three months ended March 31, 2016, the Company purchased 415,252 shares of its common stock for a purchase price of approximately $3,518,000, before brokerage commissions of approximately $12,000 bringing the total amount spent under the program to approximately $49,244,000 since inception. As of March 31, 2016, the Company had approximately $10,756,000 remaining under the repurchase program. In addition, the Company purchased during the quarter 81,594 shares surrendered by employees to satisfy tax withholding obligations upon vesting of restricted stock.

18



Additionally, for the three months ended March 31, 2016, the Company reissued 2,529,444 shares from the Treasury for common and restricted stock grants and stock option exercises, net of forfeitures, and the acquisition of Stability Inc. with an aggregate carrying value of approximately $20,746,000.
12. Income taxes 

The effective tax rates for continuing operations of 15.2% and 3.40% for the three months ended March 31, 2016 and March 31, 2015, respectively, were determined using an estimated annual effective tax rate and includes in 2016 the impact of a discrete item of approximately $350,000. The effective tax rate increased 11.8% when compared to the same period of 2015, primarily due to the $15.4 million valauation allowance release recorded in 2015 and discussed in our annual report on Form 10-K for the year ended December 31, 2015. Due to the valuation allowance previously recorded against the Company's U.S. deferred tax assets, the effective tax rate for the three months ended March 31, 2015, did not include the expense of the current period U.S. taxable income. As of the end of March 2016, the projected annual effective tax rate for 2016 is 40.4%.


13. Supplemental disclosure of cash flow and non-cash investing and financing activities:
    
Selected cash payments, receipts, and noncash activities are as follows (in thousands):
 
Three Months Ended March 31,
 
2016
 
2015
Cash paid for interest, net
$
56

 
$
14

Income taxes paid
139

 
363

Stock issuance of 441,009 shares in connection with acquisition
3,346

 

Stock issuance of 20,406 and 11,321 shares in exchange for services performed, respectively
173

 
108


14. Contractual Commitments and Contingencies
Contractual Commitments
In addition to the capital leases noted above in Note 7, the Company has entered into operating lease agreements for facility space and equipment. These leases expire over the next six years and generally contain renewal options. The Company anticipates that most of these leases will be renewed or replaced upon expiration. The Company also has commitments for meeting space and to various charitable organizations. The estimated annual lease payments, meeting space and charitable organization commitments are as follows (in thousands):
12-month period ended March 31
2017
$
2,998

2018
2,246

2019
2,199

2020
1,742

Thereafter
765

 
$
9,950


Rent expense for the three months ended March 31, 2016 and 2015, was approximately $423,000 and $284,000, respectively, and is allocated among cost of sales, research and development, and selling, general and administrative expenses.

Letters of Credit
As a condition of the lease for the Company's main facility, the Company is obligated under standby letters of credit in the amount of approximately $235,000. These obligations are reduced at various times over the life of the lease.



19



FDA Untitled Letter, Draft Guidance and Related Litigation
FDA Untitled Letter and Draft Guidance

On August 28, 2013, the FDA issued an Untitled Letter alleging that the Company's micronized allografts do not meet the criteria for regulation solely under Section 361 of the Public Health Service Act and that, as a result, MiMedx would need a biologics license to lawfully market those micronized products. Since the issuance of the Untitled Letter, the Company has been in discussions with the FDA to communicate its disagreement with the FDA's assertion that the Company's allografts are more than minimally manipulated. To date, the FDA has not changed its position that the Company's micronized products are not eligible for marketing solely under Section 361 of the Public Health Service Act, but discussions are continuing. The Company continues to market its micronized products but is also pursuing the Biologics License Application (“BLA”) process for certain of its micronized products.

On December 22, 2014, the FDA issued for comment “Draft Guidance for Industry and FDA Staff: Minimal Manipulation of Human Cells, Tissues, and Cellular and Tissue-Based Products.” Essentially the Minimal Manipulation draft guidance takes the same position with respect to micronized amniotic tissue that it took in the Untitled Letter to MiMedx 16 months earlier. The Company submitted comments asserting that the Minimal Manipulation draft guidance represents agency action that goes far beyond the FDA’s statutory authority, is inconsistent with existing HCT/P regulations and the FDA’s prior positions, and is internally inconsistent and scientifically unsound. On October 28, 2015, the FDA issued for comment, "Draft Guidance for Industry and FDA Staff: Homologous Use of Human Cells, Tissues, and Cellular and Tissue-Based Products." The Company submitted comments on this Homologous Use draft guidance. The FDA has indicated that it will hold a public hearing on September 12 and 13, 2016 to obtain input on the Homologous Use draft guidance and the previously released Minimal Manipulation draft guidance, as well as other recently issued guidance documents on HCT/Ps. The hearing was originally scheduled for April 13, 2016, but was rescheduled to allow stakeholders additional time to provide comments due to the considerable interest in the hearing. The Company has requested an opportunity to speak at the rescheduled hearing.

If the FDA does allow the Company to continue to market a micronized form of its sheet allografts without a biologics license either prior to or after finalization of the draft guidance documents, it may impose conditions, such as labeling restrictions and compliance with cGMP. Although the Company is preparing for these requirements in connection with its pursuit of a BLA for certain of its micronized products, earlier compliance with these conditions would require significant additional time and cost investments by the Company. It is also possible that the FDA will not allow the Company to market any form of a micronized product without a biologics license even prior to finalization of the draft guidance documents and could even require the Company to recall its micronized products. Revenues from micronized products comprised approximately 12% of the Company's revenues for fiscal-year 2015.

Related Litigation



Following the publication of the Untitled Letter from the FDA regarding the Company’s micronized products in September 2013, the trading price of the Company’s stock declined and several putative shareholder class action lawsuits were filed against the Company and certain of its executive officers asserting violations of the Securities Exchange Act of 1934. The cases were consolidated in the United States District Court for the Northern District of Georgia. On November 17, 2015, the parties entered into a stipulation of settlement to settle the consolidated case in its entirety. The stipulation of settlement was filed with the Court on November 18, 2015 and preliminarily approved by the Court on November 19, 2015. The final settlement hearing was held on April 5, 2016 and the Court approved the settlement. The Company does not believe the terms of the settlement will have a material adverse effect on its operating results or financial condition.
Patent Litigation
MiMedx continues to diligently enforce its intellectual property against several entities. Currently, there are four actions pending, as described below:

The Liventa Action

First, there is an action pending against several entities in the in the United States District Court for the Northern District of Georgia, i.e., “the Liventa Action”. On April 22, 2014, the Company filed a patent infringement lawsuit against Liventa Bioscience, Inc. ("Liventa"), Medline Industries, Inc. ("Medline") and Musculoskeletal Transplant Foundation, Inc. ("MTF") for permanent injunctive relief and unspecified damages. In addition to the allegations of infringement of MiMedx's patents, the lawsuit asserts that Liventa and Medline knowingly and willfully made false and misleading representations about their

20



respective products to providers, patients, and in some cases, prospective investors. The Liventa Action was filed in the United States District Court for the Northern District of Georgia.

MiMedx asserts that Liventa (formerly known as AFCell Medical, Inc.), Medline and MTF infringed and continue to infringe certain of the Company's patents relating to the MiMedx dehydrated human amnion/chorion membrane ("dHACM") allografts. MTF is the tissue processor while Liventa and Medline are the distributors of the allegedly infringing products. On May 30, 2014, defendants filed answers to the Complaint, denying the allegations in the Complaint. They also raised affirmative defenses of non-infringement, invalidity, laches and estoppel. MTF and Medline also filed counterclaims seeking declaratory judgments of non-infringement and invalidity.

On June 30, 2014, fact discovery began and the parties have engaged in extensive fact discovery.

MiMedx served Infringement Contentions on August 29, 2014, and Defendants served Invalidity Contentions and Responses to Infringement Contentions on September 29, 2014. After a protracted series of meet and confers, MiMedx required Defendants to supplement their invalidity contentions in view of parallel Inter Partes Review ("IPR")(see further discussion, infra) proceedings. MTF complied on June 26, 2015.

In September 2015, the Defendants filed a renewed Motion to Stay in light of the Patent Trial and Appeal Board's ("PTAB") decisions to institute IPRs on the ’437 and ’687 Patents, seeking a partial stay of the litigation as to the ’437, ’687, and ’494 Patents (i.e., the ’437 Patent family). MiMedx opposed the Motion to Stay with respect to the ’494 Patent and once again successfully defeated Defendants’ motion to stay.

Claim Construction proceedings began in October 2014. The parties submitted proposed constructions for key terms for the ’701, ’092, ’437, ’687, ’207, and ’494 Patents. Briefing was completed in March 2015.

On December 22, 2015, a Markman Hearing was held before Special Master Sumner C. Rosenberg. Over thirty disputed claim terms were at issue. One week later, on December 30, 2015, the Special Master issued its Report and Recommendation. Except for one term, the Special Master’s Report essentially adopted MiMedx’s proposed constructions. The parties are awaiting a final Court decision pending their respective objections. On March 9, 2016, the Court adopted the Special Master’s Report. Since then the Court has entered a scheduling order in this action.  Notably, fact discovery is set to close on May 25, 2016. Expert discovery begins in June 2016 and is expected to close in early September 2016.

The Bone Bank Action

On May 16, 2014, the Company also filed a patent infringement lawsuit against Transplant Technology, Inc. d/b/a Bone Bank Allografts ("Bone Bank") and Texas Human Biologics, Ltd. ("Biologics") for permanent injunctive relief and unspecified damages (the "Bone Bank Action"). The Bone Bank Action was filed in the United States District Court for the Western District of Texas. This lawsuit similarly asserts that Bone Bank and Biologics infringed certain of the Company's patents through the manufacturing and sale of their placental-derived tissue graft products. On July 10, 2014, defendants filed an answer to the Complaint, denying the allegations in the Complaint. They also raised affirmative defenses of non-infringement and invalidity and filed counterclaims seeking declaratory judgments of non-infringement and invalidity. The Bone Bank Action is in an advanced stage. The parties have (i) substantially completed document production; (ii) taken several fact depositions (both party and non-party); and (iii) completed claim construction briefing. The Markman hearing in this case was held on October 2, 2015. Except for one term, the Court adopted MiMedx’s proposed construction of the disputed terms. The parties have submitted a proposed scheduling order to the Court and are awaiting the Court’s order in this regard. Meanwhile, the parties continue with fact discovery in view of recent depositions.

The NuTech Action

On March 2, 2015, the Company filed a patent infringement lawsuit against NuTech Medical, Inc. ("NuTech") and DCI Donor Services, Inc. ("DCI") for permanent injunctive relief and unspecified damages. This lawsuit was filed in the United States District Court for the Northern District of Alabama. The lawsuit alleges that NuTech and DCI have infringed and continue to infringe the Company's patents through the manufacture, use, sale, and/or offering of their tissue graft product. The lawsuit also asserts that NuTech knowingly and willfully made false and misleading representations about its products to customers and/or prospective customers.

On April 17, 2015, NuTech filed a motion to dismiss the case purportedly for lack of patentable subject matter, which the Company opposed. NuTech also filed a motion to stay the case pending disposition of the motion to dismiss, which MiMedx also opposed, and on which the Court declined to rule. Hearing on the motion to dismiss occurred on August 20, 2015. On

21



November 24, 2015, the court ruled on NuTech’s Motion to Dismiss, granting in part, and denying in part. MiMedx still has claims against NuTech for infringement of the ‘494 and ‘687 patents, as well as violations of the Lanham Act; these claims shall proceed.

On December 30, 2015, the parties submitted a Joint Rule 26(f) Report of Parties’ Planning Meeting and Proposed Case Management Order to the Court. In the Report, the parties requested that the Court stay the proceedings with respect to the ’687 patent pending the completion of the inter partes review on that patent.

On January 8, 2016, MiMedx served its infringement contentions. Judge Hopkins entered the parties’ Case Management Order and granted the parties’ request to stay proceedings with respect to the ’687 patent pending the completion of the inter partes review. 

On January 8, 2016, the parties submitted their Initial Disclosures, and MiMedx submitted its preliminary infringement contentions.  On March 14, 2016, Defendants submitted their preliminary invalidity contentions.  On April 15, 2016, the parties exchanged proposed terms for construction and over the next several months the parties will engage in claim construction briefing. Discovery is ongoing.

 The Vivex Action

On April 1, 2016, the Company also filed a patent infringement lawsuit against Vivex BioMedical (“Vivex”) for permanent injunctive relief and unspecified damages (the "Vivex Action").  The lawsuit was filed in the United States District Court for the Northern District of Georgia. The patent at issue is the ’494 patent.

Pending IPRs

In addition to defending the claims in the pending district court litigations, defendants in the Liventa and Bone Bank cases have challenged certain of the Company's patents in several IPR proceedings to avoid the high burden of proof of proving invalidity by "clear and convincing evidence" in the district court litigations. An inter partes review (or "IPR") is a request for a specialized group within the United States Patent and Trademark Office to review the validity of a plaintiff's patent claims. The defendants in the Bone Bank Action have challenged the validity of the Company's 8,597,687 and 8,709,494 patents (the "'687" and "'494" patents, respectively); while the defendants in the Liventa Action have challenged the validity of the Company's 8,372,437 and 8,323,701 patents (the "'437" and "'701" patents, respectively).

On June 29, 2015, the Patent Trial and Appeals Board ("PTAB") denied defendants' request for institution of an IPR with respect to the '494 patent on all seven challenged grounds. On August 18, 2015, the PTAB also denied defendants' request for institution of an IPR with respect to the '701 patent on all six challenged grounds. That is, the PTAB decided in each case that the defendants failed to establish a reasonable likelihood that defendants would prevail in showing any of the challenged claims of the '494 or the '701 patent were unpatentable.

On July 10, 2015 the PTAB issued an opinion allowing a review of the '687 patent to proceed, although on only two of the five challenged grounds. The PTAB also adopted MiMedx's construction of the claims which will govern the Board's review of the '687 patent. The parties decided to forego oral arguments. A decision is expected no later than July 10, 2016.  On August 18, 2015, the PTAB issued an opinion allowing a review of the '437 patent to proceed, although only on one of the seven challenged grounds. Briefing and expert discovery is ongoing.  Oral argument is scheduled for April 26, 2016.  A decision is expected no later than August of 2016.
15. Subsequent Events
None





22



Schedule II Valuation and Qualifying Accounts
MIMEDX GROUP, INC. AND SUBSIDIARIES
SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS
 Three Months Ended March 31, 2016 and 2015 (in thousands)
 
 
 
 
 
 
 
 
Balance at
Beginning of Period
Additions charged to Expense or Revenue
Deductions
and write-offs
Balance at
End of Period
For the three months ended March 31, 2016
 
 
 
 
 
 Allowance for doubtful accounts
 
$
3,270

$
602

$

$
3,872

 Allowance for product returns
 
1,262

1,300

(911
)
1,651

 Allowance for obsolescence
 
397

235

(28
)
604

 
 
 
 
 
 
For the three months ended March 31, 2015
 
 
 
 
 
 Allowance for doubtful accounts
 
$
1,750

260

$

$
2,010

 Allowance for product returns
 
841

709

(606
)
944

 Allowance for obsolescence
 
527

130

(105
)
552



23



Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Overview

MiMedx® is an integrated developer, processor and marketer of patent protected and proprietary regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues and human skin and bone. "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies are AmnioFix®, EpiFix®, OrthoFlo, Physio®, AlloBurn™, and CollaFix™. AmnioFix and EpiFix are our tissue technologies processed from human amniotic membrane derived from donated placentas. Elected in advance of delivery through our donor program, a mother delivering a healthy baby via scheduled full-term Caesarean section birth may donate the placenta in lieu of having it discarded as medical waste. We process the human amniotic membrane utilizing our proprietary PURION® Process, to produce a safe and effective implant. MiMedx is the leading supplier of amniotic tissue, having supplied over 600,000 allografts to date for application in the Wound Care, Burn, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare. We recently introduced OrthoFlo, an amniotic fluid derived allograft for homologous use. Amniotic fluid is donated by a consenting mother delivering a full-term healthy baby by scheduled Caesarean section. Through the recent acquisition of Stability Biologics, our newest proprietary platforms include Physio™, a unique bone grafting material comprised of 100% bone tissue with no added carrier, thus maximizing bone forming potential, a demineralized bone matrix (DBM) to complement our product portfolio offerings within the Orthopedic market and AlloBurn, a skin product for burns. CollaFix, our next technology platform we plan to commercialize, is our collagen fiber technology, developed with our patented cross-linking polymers, designed to mimic the natural composition, structure and mechanical properties of musculoskeletal tissues in order to augment their repair. CollaFix is the only known biological, biodegradable, biomimetic technology that matches human tendon in strength and stiffness. The Company distinguishes its revenue in two primary regenerative medicine specialties of “Wound Care” and “SSO.” The Company defines SSO as surgical, sports medicine and orthopedics with spinal procedures included in orthopedics and abdominal, and lower pelvic procedures included in surgical.

Recent Events

On December 22, 2014, the FDA issued for comment “Draft Guidance for Industry and FDA Staff: Minimal Manipulation of Human Cells, Tissues, and Cellular and Tissue-Based Products.” Essentially, the Minimal Manipulation draft guidance takes the same position with respect to micronized amniotic tissue that it took in the Untitled Letter to the Company 16 months earlier. The Company submitted comments to the Minimal Manipulation draft guidance asserting that the Minimal Manipulation draft guidance represents agency action that goes far beyond the FDA’s statutory authority, is inconsistent with existing HCT/ P regulations and the FDA’s prior positions, and is internally inconsistent and scientifically unsound. On October 28, 2015, the FDA issued for comment, "Draft Guidance for Industry and FDA Staff: Homologous Use of Human Cells, Tissues, and Cellular and Tissue-Based Products." The Company submitted comments on this Homologous Use draft guidance. The FDA has indicated that it will hold a public hearing on September 12 and 13, 2016 to obtain input on the Homologous Use draft guidance and the previously released Minimal Manipulation draft guidance, as well as other recently issued guidance documents on HCT/Ps. The hearing was originally scheduled for April 13, 2016, but was rescheduled to allow stakeholders additional time to provide comments due to the considerable interest in the hearing. The Company has requested an opportunity to speak at the rescheduled hearing.

On January 13, 2016, the Company completed the acquisition of Stability Inc., d/b/a Stability Biologics ("Stability"), a provider of human tissue products to surgeons, facilities, and distributors serving the surgical, spine, and orthopedic sectors of the healthcare industry. The acquisition of Stability was effected by the merger of Stability Inc. into a newly created wholly owned subsidiary of the Company. The new subsidiary was the surviving company in the merger and was subsequently renamed Stability Biologics, LLC. The Company paid $10 million at the closing, comprised of 60% cash and 40% in shares of common stock of MiMedx Group, Inc., plus assumed debt of approximately $1.8 million. The Company will also pay future contingent consideration through a two-year earn out arrangement based on the 2016 and 2017 performance of Stability's business. The earn out will also be paid in the form of 60% cash and 40% in shares of stock of MiMedx Group, Inc. 



24



Results of Operations Comparison for the Three Months Ended March 31, 2016, to the Three Months Ended March 31, 2015
Revenue
Total revenue increased approximately $12.6 million, or 31%, to $53.4 million for the three months ended March 31, 2016, as compared to $40.8 million for the three months ended March 31, 2015. The increase in revenue as compared to the prior year is due to increased Wound Care sales. Wound Care revenue for the three months ended March 31, 2016 grew by $9.6 million, or approximately 32%, to $39.3 million, compared with $29.8 million for the three months ended March 31, 2015. SSO revenue for the three months ended March 31, 2016 grew by $3 million, or approximately 28%, to $14.1 million compared with $11 million for the three months ended March 31, 2015.
Tissue Processing Costs and Cost of Products Sold
Cost of products sold as a percentage of revenue increased to 14.9% from 12.6% for the quarter as a result of additional costs incurred in connection with the integration of Stability Inc., an increase in the cost of sales related to the purchase accounting inventory step up of approximately $734,000 and changes in product mix.
Research and Development Expenses 
The Company's research and development expenses (“R&D expenses”) increased approximately $0.7 million, or 36%, to $2.5 million during the three months ended March 31, 2016, compared to approximately $1.8 million in the prior year. The increase is primarily related to increased investments in scientific studies, clinical trials and personnel costs.

R&D expenses consist primarily of internal personnel costs, expenses of clinical trials, fees paid to external consultants, and the cost of supplies and instruments used in the Company's laboratories.
Selling, General and Administrative Expenses
Selling, General and Administrative expenses for the three months ended March 31, 2016, increased approximately $11.3 million to $40.6 million compared to $29.3 million for the three months ended March 31, 2015. Selling expense increases were driven by costs associated with expanding the Company's direct sales organization, increased commissions due to higher sales volume and an increase in share-based compensation, and the addition of staff and normal operating costs of Stability Inc. Additional spending increases included one time costs of approximately $713,000 related to the acquisition of Stability Inc., support costs related to medical reimbursement, accounting, information technology infrastructure to help manage the growth of the business, and legal costs due to patent litigation. Selling, General and Administrative expenses consist of personnel costs, professional fees, sales commissions, sales training costs, industry trade show fees and expenses, product promotion and product literature costs, facilities costs and other sales, marketing and administrative costs, depreciation and amortization, and share-based compensation.
Liquidity and Capital Resources
As of March 31, 2016, the Company had approximately $15.1 million of cash and cash equivalents. In addition, we had short term investments in FDIC insured certificates of deposit at various U.S. financial institutions that totaled approximately $2.5 million. The Company reported total current assets of approximately $95.2 million and total current liabilities of approximately $28.8 million at March 31, 2016, which represents a current ratio of 3.3 as of March 31, 2016.

On October 12, 2015, the Company and its subsidiaries entered into a Credit Agreement (the "Credit Agreement") with certain lenders and Bank of America, N.A., as administrative agent. The Credit Agreement established a senior secured revolving credit facility in favor of the Company, with an aggregate lender commitment of up to $50 million. As of the date hereof, there are no outstanding revolving loans under the Credit Agreement. The Credit Agreement also provides for an uncommitted incremental facility of up to $35 million, which can be exercised as one or more revolving commitment increases or new term loans, all subject to certain customary terms and conditions set forth in the Credit Agreement. The Credit Agreement contains customary covenants and events of default for senior secured credit agreements of this type. The covenants include (a) a requirement for the Company to maintain a maximum consolidated leverage ratio of 2.50:1.00; (b) a requirement for the Company to maintain a minimum consolidated fixed charge coverage ratio of 2.00:1.00; and (c) a requirement for the Company to maintain minimum liquidity of $10 million. The Company is currently in compliance with all of its covenants.

For the three months ended March 31, 2016, the Company paid approximately $6 million in cash for the initial purchase, paid off debt of approximately $1.8 million and provided initial working capital of approximately $4 million in connection with the acquisition of Stability, Inc.

25



For the three months ended March 31, 2016, the Company purchased 415,252 shares of its common stock for a purchase price of approximately $3,518,000, before brokerage commissions of approximately $12,000 bringing the total amount spent under the program to approximately $49,244,000 since inception. As of March 31, 2016, the Company had approximately $10,756,000 of availability remaining under the repurchase program. The timing and amount of future repurchases, if any, will depend upon the Company's stock price, economic and market conditions, regulatory requirements, and other corporate considerations. The Company may initiate, suspend or discontinue purchases under the stock repurchase program at any time.
In addition, the Company purchased during the quarter 81,594 shares surrendered by employees to satisfy tax withholding obligations upon vesting of restricted stock.
We believe that our anticipated cash from operating activities, existing cash and cash equivalents, short term investments, and availability under the Credit Agreement will enable us to meet our operational liquidity needs and fund our planned investing activities for the next year.

Contingencies
See Part II, Item 1. Legal Proceedings herein.

Contractual Obligations
Contractual obligations associated with ongoing business activities are expected to result in cash payments in future periods.  The table below summarizes the amounts and estimated timing of these future cash payments as of March 31, 2016 (in thousands):
 
 
 
Less than
 
 
 
 
 
 
Contractual Obligations
TOTAL
 
1 year
 
1-3 years
 
3-5 years
 
Thereafter
Capital lease obligations
$
103

 
$
82

 
$
21

 
$

 
$

Operating lease obligations
8,331

 
2,015

 
3,880

 
1,957

 
479

Charitable contribution obligations
325

 
325

 

 

 

Software license
355

 
95

 
189

 
71

 

Meeting space commitments
939

 
562

 
376

 

 

 
$
10,053

 
$
3,079

 
$
4,466

 
$
2,028

 
$
479

Discussion of cash flows
Net cash from operations during the three months ended March 31, 2016, decreased approximately $5.2 million to approximately $(1.0) million compared to $4.2 million from operating activities for the three months ended March 31, 2015, primarily attributable to a decrease in net income compared to the prior year, as well as post acquisition working capital costs for Stability Inc.
Net cash used in investing activities during the three months ended March 31, 2016, was approximately $9.3 million compared to approximately $1.0 million for 2015. Cash used for the acquisition of Stability Inc. totaled $7.6 million, $2 million was used for the purchase of equipment to expand production capacity, partially offset by maturing certificates of deposit of $500,000.
Net cash used in financing activities during the three months ended March 31, 2016, decreased approximately $8 million to $3.1 million of cash used compared to $11.1 million of cash used during the three months ended March 31, 2015. Cash flows used in financing activities during the three months include approximately $3.5 million for stock repurchases, partially offset by approximately $1.1 million from the exercise of stock options.


26



Discussion of adjusted financial measures
In addition to our GAAP results, we provide adjusted earnings before interest, taxes, depreciation and amortization, share based compensation expense, one-time acquisition related costs and the effects of purchase accounting entries ("adjusted EBITDA"). The various measures of adjusted EBITDA consist of GAAP net (loss)/income, excluding: (i) depreciation and amortization, (ii) other income (expense), net, (iii) interest income and expense, (iv) income taxes, (v) one time acquisition related costs, (vi) the effect of purchase accounting due to acquisitions, and (vii) share based compensation expense. The Company believes that the presentation of adjusted EBITDA provides important supplemental information to management and investors regarding the operational use of cash. Reconciliations of GAAP net (loss)/income to adjusted EBITDA for the quarters ended March 31, 2016 and 2015 appear in the financial tables below.
The Company's Adjusted EBITDA for the three months ended March 31, 2016, was approximately $9.1 million which is comparable to the $8.8 million for the three months ended March 31, 2015 after taking into account the one time acquisition costs detailed below. Adjusted EBITDA is a non-GAAP measure. Non-GAAP financial measures are commonly used in the industry and are presented because management believes they provide relevant and useful information to investors. However, there are limitations to using these non-GAAP financial measures. Adjusted EBITDA is not indicative of cash provided or used by operating activities and may differ from comparable information provided by other companies. Adjusted EBITDA should not be considered in isolation, as an alternative to, or more meaningful than measures of financial performance determined in accordance with GAAP. The following table presents a reconciliation of Adjusted EBITDA to Net income, the most comparable financial measure reported under GAAP, for the three months ended March 31, 2016 and 2015 (in thousands), respectively.
 
Three Months Ended March 31,
 
2016
 
2015
Net Income (Per GAAP)
$
1,197

 
$
4,087

 
 
 
 
Add back:
 
 
 
Income taxes
214

 
146

One time costs incurred in connection with acquisition
713

 

Amortization of inventory fair value step - up
734

 

Other interest (income) expense, net
56

 
14

Depreciation expense
734

 
354

Amortization of intangible assets
810

 
233

Share-based compensation
4,615

 
3,933

Adjusted EBITDA
$
9,073

 
$
8,767

Critical Accounting Policies
In preparing financial statements, the Company follows accounting principles generally accepted in the United States, which require the Company to make certain estimates and apply judgments that affect its financial position and results of operations. Management continually reviews the Company's accounting policies and financial information disclosures. A summary of significant accounting policies that require the use of estimates and judgments in preparing the financial statements was provided in the Company's Annual Report on Form 10-K for the year ended December 31, 2015.  During the quarter covered by this report, there were no material changes to the accounting policies and assumptions previously disclosed.
Recent Accounting Pronouncements
For the effect of recent accounting pronouncements, see Note 2 to the Condensed Consolidated Financial Statements contained herein.
Off-Balance Sheet Arrangements
The Company has no off-balance sheet arrangements.
Item 3. Quantitative and Qualitative Disclosures about Market Risk

Based on our lack of market risk sensitive instruments outstanding at March 31, 2016, we have determined that there was no material market risk exposure to our consolidated financial position, results of operations or cash flows as of such date.


27



Item 4. Controls and Procedures
Disclosure Controls and Procedures
As required by Rule 13a-15(b) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), the Company carried out an evaluation of the effectiveness of the design and operation of its disclosure controls and procedures as of the end of the period covered by this report. This evaluation was carried out under the supervision and with the participation of Company management, including its Chief Executive Officer and Chief Financial Officer. Based upon that evaluation, the Company's Chief Executive Officer and Chief Financial Officer concluded that the Company's controls and procedures were effective as of the end of the period covered by this report.
Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in the Company's reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include controls and procedures designed to ensure that information required to be disclosed in the Company's reports filed under the Exchange Act is accumulated and communicated to management, including the Company's Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding disclosures.
Changes in Internal Control over Financial Reporting
There was no change in the Company's internal control over financial reporting that occurred during the quarter ended March 31, 2016, that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.
Limitations on the Effectiveness of Controls
The Company has confidence in its internal controls and procedures. Nevertheless, management, including the Company's Chief Executive Officer and Chief Financial Officer, does not expect that the Company's disclosure procedures and controls or its internal controls will prevent all errors or intentional fraud. An internal control system, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of such internal controls are met. Further, the design of an internal control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all internal control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected.

PART II – OTHER INFORMATION
Item 1. Legal Proceedings

Securities Class Action

Following the publication of an Untitled Letter from the FDA regarding the Company’s micronized products in September 2013, the trading price of the Company’s stock declined and several putative shareholder class action lawsuits were filed against the Company and certain of its executive officers asserting violations of the Securities Exchange Act of 1934. The cases were consolidated in the United States District Court for the Northern District of Georgia. On November 17, 2015, the parties entered into a stipulation of settlement to settle the consolidated case in its entirety. The stipulation of settlement was filed with the Court on November 18, 2015 and preliminarily approved by the Court on November 19, 2015. The final settlement hearing was held on April 5, 2016 and the Court approved the settlement. The Company does not believe the terms of the settlement will have a material adverse effect on its operating results or financial condition.

Patent Infringement Litigation

MiMedx continues to diligently enforce its intellectual property against several entities. Currently, there are four actions pending, as described below:

The Liventa Action

First, there is an action pending against several entities in the in the United States District Court for the Northern District of Georgia, i.e., “the Liventa Action”. On April 22, 2014, the Company filed a patent infringement lawsuit against Liventa Bioscience, Inc. ("Liventa"), Medline Industries, Inc. ("Medline") and Musculoskeletal Transplant Foundation, Inc. ("MTF") for permanent injunctive relief and unspecified damages. In addition to the allegations of infringement of MiMedx's patents, the lawsuit asserts that Liventa and Medline knowingly and willfully made false and misleading representations about their

28



respective products to providers, patients, and in some cases, prospective investors. The Liventa Action was filed in the United States District Court for the Northern District of Georgia.

MiMedx asserts that Liventa (formerly known as AFCell Medical, Inc.), Medline and MTF infringed and continue to infringe certain of the Company's patents relating to the MiMedx dehydrated human amnion/chorion membrane ("dHACM") allografts. MTF is the tissue processor while Liventa and Medline are the distributors of the allegedly infringing products. On May 30, 2014, defendants filed answers to the Complaint, denying the allegations in the Complaint. They also raised affirmative defenses of non-infringement, invalidity, laches and estoppel. MTF and Medline also filed counterclaims seeking declaratory judgments of non-infringement and invalidity.

On June 30, 2014, fact discovery began and the parties have engaged in extensive fact discovery.

MiMedx served Infringement Contentions on August 29, 2014, and Defendants served Invalidity Contentions and Responses to Infringement Contentions on September 29, 2014. After a protracted series of meet and confers, MiMedx required Defendants to supplement their invalidity contentions in view of parallel Inter Partes Review ("IPR")(see further discussion, infra) proceedings. MTF complied on June 26, 2015.

In September 2015, the Defendants filed a renewed Motion to Stay in light of the Patent Trial and Appeal Board's ("PTAB") decisions to institute IPRs on the ’437 and ’687 Patents, seeking a partial stay of the litigation as to the ’437, ’687, and ’494 Patents (i.e., the ’437 Patent family). MiMedx opposed the Motion to Stay with respect to the ’494 Patent and once again successfully defeated Defendants’ motion to stay.

Claim Construction proceedings began in October 2014. The parties submitted proposed constructions for key terms for the ’701, ’092, ’437, ’687, ’207, and ’494 Patents. Briefing was completed in March 2015.

On December 22, 2015, a Markman Hearing was held before Special Master Sumner C. Rosenberg. Over thirty disputed claim terms were at issue. One week later, on December 30, 2015, the Special Master issued its Report and Recommendation. Except for one term, the Special Master’s Report essentially adopted MiMedx’s proposed constructions. The parties are awaiting a final Court decision pending their respective objections. On March 9, 2016, the Court adopted the Special Master’s Report. Since then the Court has entered a scheduling order in this action.  Notably, fact discovery is set to close on May 25, 2016. Expert discovery begins in June 2016 and is expected to close in early September 2016.

The Bone Bank Action

On May 16, 2014, the Company also filed a patent infringement lawsuit against Transplant Technology, Inc. d/b/a Bone Bank Allografts ("Bone Bank") and Texas Human Biologics, Ltd. ("Biologics") for permanent injunctive relief and unspecified damages (the "Bone Bank Action"). The Bone Bank Action was filed in the United States District Court for the Western District of Texas. This lawsuit similarly asserts that Bone Bank and Biologics infringed certain of the Company's patents through the manufacturing and sale of their placental-derived tissue graft products. On July 10, 2014, defendants filed an answer to the Complaint, denying the allegations in the Complaint. They also raised affirmative defenses of non-infringement and invalidity and filed counterclaims seeking declaratory judgments of non-infringement and invalidity. The Bone Bank Action is in an advanced stage. The parties have (i) substantially completed document production; (ii) taken several fact depositions (both party and non-party); and (iii) completed claim construction briefing. The Markman hearing in this case was held on October 2, 2015. Except for one term, the Court adopted MiMedx’s proposed construction of the disputed terms. The parties have submitted a proposed scheduling order to the Court and are awaiting the Court’s order in this regard. Meanwhile, the parties continue with fact discovery in view of recent depositions.

The NuTech Action

On March 2, 2015, the Company filed a patent infringement lawsuit against NuTech Medical, Inc. ("NuTech") and DCI Donor Services, Inc. ("DCI") for permanent injunctive relief and unspecified damages. This lawsuit was filed in the United States District Court for the Northern District of Alabama. The lawsuit alleges that NuTech and DCI have infringed and continue to infringe the Company's patents through the manufacture, use, sale, and/or offering of their tissue graft product. The lawsuit also asserts that NuTech knowingly and willfully made false and misleading representations about its products to customers and/or prospective customers.

On April 17, 2015, NuTech filed a motion to dismiss the case purportedly for lack of patentable subject matter, which the Company opposed. NuTech also filed a motion to stay the case pending disposition of the motion to dismiss, which MiMedx also opposed, and on which the Court declined to rule. Hearing on the motion to dismiss occurred on August 20, 2015. On

29



November 24, 2015, the court ruled on NuTech’s Motion to Dismiss, granting in part, and denying in part. MiMedx still has claims against NuTech for infringement of the ‘494 and ‘687 patents, as well as violations of the Lanham Act; these claims shall proceed.

On December 30, 2015, the parties submitted a Joint Rule 26(f) Report of Parties’ Planning Meeting and Proposed Case Management Order to the Court. In the Report, the parties requested that the Court stay the proceedings with respect to the ’687 patent pending the completion of the inter partes review on that patent.

On January 8, 2016, MiMedx served its infringement contentions. Judge Hopkins entered the parties’ Case Management Order and granted the parties’ request to stay proceedings with respect to the ’687 patent pending the completion of the inter partes review. 

On January 8, 2016, the parties submitted their Initial Disclosures, and MiMedx submitted its preliminary infringement contentions.  On March 14, 2016, Defendants submitted their preliminary invalidity contentions.  On April 15, 2016, the parties exchanged proposed terms for construction and over the next several months the parties will engage in claim construction briefing. Discovery is ongoing.

 The Vivex Action

On April 1, 2016, the Company also filed a patent infringement lawsuit against Vivex BioMedical (“Vivex”) for permanent injunctive relief and unspecified damages (the "Vivex Action").  The lawsuit was filed in the United States District Court for the Northern District of Georgia. The patent at issue is the ’494 patent.

Pending IPRs

In addition to defending the claims in the pending district court litigations, defendants in the Liventa and Bone Bank cases have challenged certain of the Company's patents in several IPR proceedings to avoid the high burden of proof of proving invalidity by "clear and convincing evidence" in the district court litigations. An inter partes review (or "IPR") is a request for a specialized group within the United States Patent and Trademark Office to review the validity of a plaintiff's patent claims. The defendants in the Bone Bank Action have challenged the validity of the Company's 8,597,687 and 8,709,494 patents (the "'687" and "'494" patents, respectively); while the defendants in the Liventa Action have challenged the validity of the Company's 8,372,437 and 8,323,701 patents (the "'437" and "'701" patents, respectively).

On June 29, 2015, the Patent Trial and Appeals Board ("PTAB") denied defendants' request for institution of an IPR with respect to the '494 patent on all seven challenged grounds. On August 18, 2015, the PTAB also denied defendants' request for institution of an IPR with respect to the '701 patent on all six challenged grounds. That is, the PTAB decided in each case that the defendants failed to establish a reasonable likelihood that defendants would prevail in showing any of the challenged claims of the '494 or the '701 patent were unpatentable.

On July 10, 2015 the PTAB issued an opinion allowing a review of the '687 patent to proceed, although on only two of the five challenged grounds. The PTAB also adopted MiMedx's construction of the claims which will govern the Board's review of the '687 patent. The parties decided to forego oral arguments. A decision is expected no later than July 10, 2016.  On August 18, 2015, the PTAB issued an opinion allowing a review of the '437 patent to proceed, although only on one of the seven challenged grounds. Briefing and expert discovery is ongoing.  Oral argument is scheduled for April 26, 2016.  A decision is expected no later than August of 2016.





Item 1A. Risk Factors
There have been no material changes to the risk factors previously disclosed in the Company's Annual Report on Form 10-K for the year ended December 31, 2015.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds



30



The following table sets forth information regarding the purchases of the Company’s equity securities made by or on behalf of the Company or any affiliated purchaser (as defined in Exchange Act Rule 10b-18) during the three-month period ended March 31, 2016:



Total number of
shares purchased (a)
 
Average price paid
per share
 
Total number of shares purchased under publicly announced plan(b)
 
Total amount spent under the plan
 
Remaining amount
to be spent
under the plan
Total amount remaining January 1, 2016

 

 
 
 

 
$
14,273,639

 
 
 
 
 
 
 
 
 
 
January 1, 2016 - January 31, 2016
400,252
 
$
8.51

 
400,252

 
$
3,404,558

 
$
10,869,081



 

 
 
 

 


February 1, 2016 - February 29, 2016
82,294
 
$
8.42

 
15,000

 
$
113,069

 
$
10,756,012

 
 
 
 
 
 
 
 
 
 
March 1, 2016 - March 31, 2016
14,300
 
$
9.01

 

 
$

 
$
10,756,012

 
 
 
 
 
 
 
 
 
 
    Total for the quarter
496,846
 
 
 
415,252

 
$
3,517,627

 
 


(a) Shares purchased during the quarter include 81,594 shares surrendered by employees to satisfy tax withholding obligations upon vesting of restricted stock.
(b) On May 12, 2014, our Board of Directors authorized the repurchase of up to $10 million of our common stock from time to time, through December 31, 2014. The Board subsequently extended the program until December 31, 2016. In December 2014, the Board increased the authorization to a total of $20 million and further increased the authorization in 2015 to a total of $60 million. The timing and amount of repurchases will depend upon the Company's stock price, economic and market conditions, regulatory requirements, and other corporate considerations. The Company may initiate, suspend or discontinue purchases under the stock repurchase program at any time. The above table sets forth information regarding the purchases of the Company’s equity securities made under the repurchase program prior to brokerage commissions of approximately $12,000.

Item 3. Defaults Upon Senior Securities
Not applicable.
Item 4. Mine Safety Disclosures
Not applicable.
Item 5. Other Information
None.

31



Item 6. Exhibits
Exhibit
Number
Reference
Description
 
 
 
2.1##
 
Agreement and Plan of Merger dated January 10, 2016, by and among MiMedx Group, Inc., Titan Acquisition Sub I, Inc., Titan Acquisition Sub II, LLC, Stability Inc., certain stockholders of Stability Inc. and Brian Martin as representative of the Stability stockholders (incorporated by reference to Exhibit 2.1 filed with Registrant's Form 8-K filed on January 13, 2016)

3.1
 
Articles of Incorporation as filed with the Secretary of State of Florida on March 31, 2008 (incorporated by reference to Exhibit 3.1 filed with the Registrant's Form 10-Q on August 8, 2013)
3.2
 
Articles of Amendment to Articles of Incorporation as filed with the Secretary of the State of Florida on May 14, 2010 (incorporated by reference to Exhibit 3.2 filed with the Registrant's Form 10-Q on August 8, 2013)
3.3
 
Articles of Amendment to Articles of Incorporation as filed with the Secretary of the State of Florida on August 8, 2012 (incorporated by reference to Exhibit 3.3 filed with the Registrant's Form 10-Q on August 8, 2013)
3.4
 
Articles of Amendment to Articles of Incorporation as filed with the Secretary of the State of Florida on November 8, 2012 (incorporated by reference to Exhibit 3.4 filed with the Registrant's Form 10-Q on August 8, 2013)
3.5
 
Articles of Amendment to Articles of Incorporation as filed with the Secretary of the State of Florida on May 15, 2015 (incorporated by reference to Exhibit 3.5 filed with the Registrant's Form 10-Q on August 7, 2015)
3.6
 
Bylaws of MiMedx Group, Inc. (incorporated by reference to Exhibit 3.2 filed with Registrant's Form 8-K filed on April 2, 2008)
3.7
 
Amendment to the Bylaws of MiMedx Group, Inc. adopted by the Board of Directors on May 11, 2010 (incorporated by reference to Exhibit 3.2 to the Registrant's Form 8-K filed on May 14, 2010)
10.1
 
First Amendment to the Credit Agreement dated October 12, 2015, by and among MiMedx Group, Inc., the Guarantors identified therein, Bank of America, N.A. and the other Lenders party thereto (incorporated by reference to Exhibit 10.1 to the Registrant's Form 8-K filed on January 13, 2016)

10.2#*
 
Fourth Amendment to Product Distribution Agreement effective as of January 1, 2016 between MiMedx Group, Inc. and AvKARE, Inc.

31.1 #
 
Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2 #
 
Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1 #
 
Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2 #
 
Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS
 
XBRL Instance Document
101.SCH
 
XBRL Taxonomy Extension Schema Document
101.CAL
 
XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF
 
XBRL Taxonomy Extension Definition Linkbase Document
101.LAB
 
XBRL Taxonomy Extension Label Linkbase Document
101.PRE
 
XBRL Taxonomy Extension Presentation Linkbase Document
 
#
Filed herewith
*
Certain confidential material appearing in this document, marked by [*****], has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment under rule 24b-2 promulgated under the Securities Exchange Act of 1934, as amended.
##
Certain exhibits and schedules have been omitted pursuant to Item 601(b)(2) of Regulation S-K, but a copy will be furnished supplementally to the Securities and Exchange Commission upon request)


32



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
May 10, 2016
 
 
 
By:
/s/ Michael J. Senken
 
 
Michael J. Senken
 
 
Chief Financial Officer
 
 
(principal financial and accounting officer)

33
EX-10.2 2 a2016331-10xqxexhibit102.htm EXHIBIT 10.2 SEC Exhibit




CERTAIN CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT, MARKED BY [*****], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENEDED.

FOURTH AMENDMENT TO PRODUCT DISTRIBUTION AGREEMENT
This Fourth Amendment to Product Distribution Agreement (“Fourth Amendment”) amends that certain Product Distribution Agreement that was effective April 19, 2012, and amended March 25, 2013, July 15, 2013 and on or about April 16, 2015 (the “Distribution Agreement”) between MiMedx Group, Inc. (the “Company”) and AvKARE, Inc. (“AvKARE”). This Fourth Amendment is effective as of January 1, 2016 (the “Effective Date”) and terminates on June 30, 2017 with such period referred to herein as the “Revised Term”.
WHEREAS, subject to the execution of this Fourth Amendment, [*****];
WHEREAS, the Company and AvKARE desire to amend the Distribution Agreement;
NOW THEREFORE for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and AvKARE agree that the Distribution Agreement shall be, and hereby is, amended as follows:
1.
Section 1.1 shall be amended by inserting the following language at the end of the current Section:

“Beginning on July 1, 2016, AvKARE shall become [*****] authorized distributor for the sale of the Products in the Market.”
2.
Sections 1.2 and 1.3 each shall be deleted in its entirety.

3.
Section 1.6 shall be amended by inserting the following language at the end of the current Section:
“[*****]”
4.
Section 1.8 shall be deleted in its entirety and replaced with the following:

“Company and AvKARE shall mutually agree on what portion of Federal Supply Schedule sales shall be filled by AvKARE during the Revised Term. The Company shall use commercially reasonable efforts to support those sales during the Revised Term. The Target Sales Levels are listed on Schedule 5, attached hereto.”
5.
Section 3.3 shall be amended by adding a new sentence at the end of Section 3.3 which new sentence reads:

“The Company may change the selling price of any Product on a proactive basis only by providing AvKARE, at least ninety (90) advance written notice of such change. [*****]. In the case of such a change, AvKARE will be credited for such reduction with respect to Product inventory it then holds.”
6.
Section 3.5 shall be deleted in its entirety and replaced with the following language:

“Payment on Product orders shall be made within [*****] days from the date of the invoice; provided, however, that Company shall grant AvKARE a [*****] discount on payments instead made within [*****] days.”
7.
Section 18.1 shall be deleted in its entirety and replaced with the following language:

“This Distribution Agreement as amended by the Fourth Amendment shall continue through June 30, 2017 unless otherwise terminated earlier in accordance with the terms of this Distribution Agreement (the “Revised





Term”). During the Revised Term, the price for Products sold to AvKARE shall continue to be [*****] of AvKARE’s sales price for the Products to its Customer, such that AvKARE achieves a [*****] gross commission (the “Revised Term Commission”). [*****]. Upon request, each party will provide supporting data to the other party concerning the applicable sales levels and inventories in order to assist with planning for and complying with this process. It is the intent of the parties for the inventory held by AvKARE at the close of the Revised Term to be minimal. At the close of the Revised Term the parties will jointly determine either: (a) an extension of the Agreement, if inventory at the close of the Revised Term is not minimal as expected, or for any other reason; or (b) discontinuation of active purchases under the Agreement, in which case the parties will agree upon an orderly repurchase by Company of any remaining inventory during the following 90 day period. Any such repurchases shall be at AvKARE’s cost plus the Revised Term Commission based on the standard pricing AvKARE charges for such Product at the date the Product was shipped to AvKARE or AvKARE’s customers on behalf of AvKARE. For sake of clarity, on or before the 90th day following the termination of this Distribution Agreement, the Company shall purchase any and all Product remaining in AvKARE’s inventory regardless of expiration date at AvKARE’s cost plus the Revised Term Commission with respect to such Product at the date the Product was shipped to AvKARE.”
8.
Section 18.3 shall be deleted in its entirety and replaced with the following language:
a.
This Agreement may be terminated (and in such case the repurchase obligation specified in Section 18.1 shall be triggered): (i) by either party, if the other party is in material breach of any provision of this Agreement and such breach is not cured within thirty (30) days following notice of such breach given to the breaching party in accordance with Section 19.4 below; (ii) by Company, upon five (5) days’ written notice in accordance with Section 19.4 below, if AvKARE’s governmental approval to sell on the Federal Supply Schedule is revoked and has remained so for thirty (30) consecutive days and has not been reinstated prior to the written notice; (iii) by either party immediately if all of the Products are removed from the Federal Supply Schedule for any reason and have not been reinstated within thirty (30) days of removal; (iv) by either party immediately if Company is otherwise unable to sell its Products for any reason; (v) by AvKARE, if its monthly sales drop below [*****]; or (vi) by Company, in accordance with Section 18.4. If some, but not all, Products are removed from the Federal Supply Schedule or the Company is otherwise unable to sell some, but not all, Products on the Federal Supply Schedule, the affected Products will be removed from the Agreement, but the Agreement will otherwise continue in accordance with these terms for any remaining Products on the Federal Supply Schedule. Termination of this Agreement under this subpart (a) shall not affect Company’s obligation to honor all Purchase Orders submitted to Company prior to such termination unless Company is prevented from doing so by law.
b.
The following sections shall survive termination or expiration of this Agreement: 7, 8, 9, 12, 13, 14, 16, and 19.5.”

9.
Section 18.4 shall be deleted in its entirety and replaced with the following:

“If the Company desires to terminate this Agreement without cause during the Revised Term, the Company shall so notify AvKARE in writing and shall (i) promptly pay to AvKARE an amount equal to [*****] of the average monthly gross FSS sales made by MiMedx over the three months period prior to the termination (with such average percentage result not to exceed [*****]) times the number of months or portion thereof remaining in the Term of this Distribution Agreement and (ii) repurchase AvKARE’s remaining Product inventory as provided in Section 18.1.”
10.
Section 18.5 shall be deleted in its entirety.

11.
Section 19.2 shall be amended by deleting the following phrase: “provided that any assignment by AvKARE, Inc. to an entity that sells Competing Products shall require Company’s prior written consent”.

12.
Schedule 5 to the Distribution Agreement shall be deleted in its entirety and replaced with the attached Schedule 5.






13.
[*****].

14.
In all other respects, the Distribution Agreement is and shall remain in full force and effect in accordance with its terms and interpreted in a manner consistent with the past practices of the parties.

IN WITNESS WHEREOF, the undersigned have executed this Fourth Amendment to the Distribution Agreement.

MiMedx Group, Inc.


/s/ William C. Taylor
By: William C. Taylor
Its: President & COO
AvKARE, Inc.


/s/ Troy A. Mizell
By: Troy A. Mizell
Its: President & CEO



Schedule 5
Target FSS sales levels during Revised Term
The following are the target Federal Supply Schedule sales levels (“Target Sales Levels”) for AvKARE during the Revised Term. [*****]





____________        ___________
Initials            Initials



EX-31.1 3 copyofexhibit311-certifica.htm EXHIBIT 31.1 Exhibit


Exhibit 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO RULES 13a-14(A) AND 15d-14(A)
OF THE SECURITIES EXCHANGE ACT OF 1934
 
I, Parker H. Petit, certify that:
 
1. I have reviewed this Form 10-Q for the quarter ended March 31, 2016, of MiMedx Group, Inc.;
 
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
 
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
 
a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
 
b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date:
May 10, 2016
/s/ Parker H. Petit
 
 
Parker H. Petit
 
 
Chief Executive Officer


EX-31.2 4 copyofexhibit312-certifica.htm EXHIBIT 31.2 Exhibit


Exhibit 31.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER
PURSUANT TO RULES 13a-14(A) AND 15d-14(A)
OF THE SECURITIES EXCHANGE ACT OF 1934
 
I, Michael J. Senken, certify that:

1. I have reviewed this Form 10-Q for the quarter ended March 31, 2016, of MiMedx Group, Inc.;
 
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4. The registrant’s other certifying officer  and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
 
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
 
a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
 
b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date:
May 10, 2016
/s/ Michael J. Senken
 
 
Michael J. Senken
 
 
Chief Financial Officer


EX-32.1 5 copyofexhibit321-certifica.htm EXHIBIT 32.1 Exhibit


Exhibit 32.1
 
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the Quarterly Report of MiMedx Group, Inc. (the “Company”) on Form 10-Q for the quarter ended March 31, 2016 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Parker H. Petit, Chief Executive Officer of the Company, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, hereby certify, that to the best of my knowledge:
 
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date:
May 10, 2016
/s/ Parker H. Petit
 
 
Parker H. Petit
 
 
Chief Executive Officer


EX-32.2 6 copyofexhibit322-certifica.htm EXHIBIT 32.2 Exhibit


 Exhibit 32.2
 
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the Quarterly Report of MiMedx Group, Inc. (the “Company”) on Form 10-Q for the quarter ended March 31, 2016 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Michael J. Senken, Chief Financial Officer of the Company, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, hereby certify, that to the best of my knowledge:
 
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date:
May 10, 2016
/s/ Michael J. Senken
 
 
Michael J. Senken
 
 
Chief Financial Officer


EX-101.INS 7 mdxg-20160331.xml XBRL INSTANCE DOCUMENT 0001376339 2016-01-01 2016-03-31 0001376339 2016-04-15 0001376339 2015-12-31 0001376339 2016-03-31 0001376339 2015-01-01 2015-03-31 0001376339 us-gaap:AdditionalPaidInCapitalMember 2016-01-01 2016-03-31 0001376339 us-gaap:TreasuryStockMember 2016-01-01 2016-03-31 0001376339 us-gaap:RetainedEarningsMember 2015-12-31 0001376339 us-gaap:TreasuryStockMember 2015-12-31 0001376339 us-gaap:CommonStockMember 2016-03-31 0001376339 us-gaap:RetainedEarningsMember 2016-03-31 0001376339 us-gaap:CommonStockMember 2016-01-01 2016-03-31 0001376339 us-gaap:AdditionalPaidInCapitalMember 2016-03-31 0001376339 us-gaap:CommonStockMember 2015-12-31 0001376339 us-gaap:AdditionalPaidInCapitalMember 2015-12-31 0001376339 us-gaap:RetainedEarningsMember 2016-01-01 2016-03-31 0001376339 us-gaap:TreasuryStockMember 2016-03-31 0001376339 2014-12-31 0001376339 2015-03-31 0001376339 us-gaap:FairValueAdjustmentToInventoryMember 2016-01-01 2016-03-31 0001376339 us-gaap:PatentsMember 2015-01-01 2015-03-31 0001376339 us-gaap:PatentsMember 2016-01-01 2016-03-31 0001376339 us-gaap:FairValueAdjustmentToInventoryMember 2016-01-13 2016-01-13 0001376339 mdxg:StabilityBiologicsLLCMember 2016-01-13 2016-01-13 0001376339 us-gaap:ProFormaMember 2015-01-01 2015-03-31 0001376339 mdxg:StabilityBiologicsLLCMember 2016-03-31 0001376339 us-gaap:FairValueAdjustmentToInventoryMember 2015-01-01 2015-03-31 0001376339 mdxg:StabilityBiologicsLLCMember us-gaap:LicensingAgreementsMember 2016-01-13 0001376339 mdxg:StabilityBiologicsLLCMember 2016-01-13 0001376339 mdxg:StabilityBiologicsLLCMember us-gaap:PatentsMember 2016-01-13 0001376339 mdxg:StabilityBiologicsLLCMember us-gaap:CustomerRelationshipsMember 2016-01-13 0001376339 mdxg:StabilityBiologicsLLCMember us-gaap:TrademarksAndTradeNamesMember 2016-01-13 0001376339 mdxg:StabilityBiologicsLLCMember us-gaap:NoncompeteAgreementsMember 2016-01-13 0001376339 mdxg:StabilityBiologicsLLCMember us-gaap:LoansPayableMember 2016-01-13 0001376339 mdxg:StabilityBiologicsLLCMember us-gaap:LineOfCreditMember 2016-01-13 0001376339 mdxg:StabilityBiologicsLLCMember mdxg:ShareholderDebtMember 2016-01-13 0001376339 mdxg:StabilityBiologicsLLCMember us-gaap:LicensingAgreementsMember 2016-01-13 2016-01-13 0001376339 mdxg:StabilityBiologicsLLCMember us-gaap:NoncompeteAgreementsMember 2016-01-13 2016-01-13 0001376339 mdxg:StabilityBiologicsLLCMember us-gaap:CustomerRelationshipsMember 2016-01-13 2016-01-13 0001376339 mdxg:StabilityBiologicsLLCMember us-gaap:PatentsMember 2016-01-13 2016-01-13 0001376339 us-gaap:CertificatesOfDepositMember 2015-12-31 0001376339 us-gaap:CertificatesOfDepositMember 2016-03-31 0001376339 us-gaap:LeaseholdImprovementsMember 2016-03-31 0001376339 us-gaap:ConstructionInProgressMember 2016-03-31 0001376339 us-gaap:FurnitureAndFixturesMember 2015-12-31 0001376339 us-gaap:ConstructionInProgressMember 2015-12-31 0001376339 us-gaap:EquipmentMember 2015-12-31 0001376339 us-gaap:EquipmentMember 2016-03-31 0001376339 us-gaap:LeaseholdImprovementsMember 2015-12-31 0001376339 us-gaap:FurnitureAndFixturesMember 2016-03-31 0001376339 mdxg:LeaseholdImprovementsPaidbyOthersMember 2016-03-31 0001376339 us-gaap:AssetsHeldUnderCapitalLeasesMember 2016-03-31 0001376339 mdxg:SurgicalBiologicsMember mdxg:TradeNamesAndTrademarksMember 2011-01-05 0001376339 mdxg:ShrinersHospitalsForChildrenAndUniversityOfSouthFloridaResearchFoundationInc.Member us-gaap:LicensingAgreementsMember 2007-01-28 2007-01-29 0001376339 mdxg:SurgicalBiologicsMember us-gaap:CustomerRelationshipsMember 2011-01-05 0001376339 mdxg:ShrinersHospitalsForChildrenAndUniversityOfSouthFloridaResearchFoundationInc.Member us-gaap:LicensingAgreementsMember 2016-03-31 0001376339 mdxg:SurgicalBiologicsMember us-gaap:PatentsMember 2016-01-01 2016-03-31 0001376339 mdxg:SurgicalBiologicsMember us-gaap:PatentsMember 2011-01-05 0001376339 mdxg:SurgicalBiologicsMember us-gaap:InProcessResearchAndDevelopmentMember 2011-01-05 0001376339 mdxg:SurgicalBiologicsMember us-gaap:LicensingAgreementsMember 2011-01-05 0001376339 mdxg:StabilityBiologicsLLCMember mdxg:TradeNamesAndTrademarksMember 2016-01-13 0001376339 us-gaap:NoncompeteAgreementsMember 2015-12-31 0001376339 mdxg:TradeNamesAndTrademarksMember 2016-03-31 0001376339 us-gaap:CustomerRelationshipsMember 2016-01-01 2016-03-31 0001376339 us-gaap:NoncompeteAgreementsMember 2016-03-31 0001376339 mdxg:PatentsinProcessMember 2016-03-31 0001376339 us-gaap:LicensingAgreementsMember 2016-03-31 0001376339 us-gaap:LicensingAgreementsMember 2016-01-01 2016-03-31 0001376339 us-gaap:PatentsMember 2016-03-31 0001376339 mdxg:TradeNamesAndTrademarksMember 2015-12-31 0001376339 us-gaap:InProcessResearchAndDevelopmentMember 2016-03-31 0001376339 us-gaap:InProcessResearchAndDevelopmentMember 2015-12-31 0001376339 mdxg:PatentsinProcessMember 2015-12-31 0001376339 us-gaap:CustomerRelationshipsMember 2015-12-31 0001376339 us-gaap:CustomerRelationshipsMember 2016-03-31 0001376339 us-gaap:NoncompeteAgreementsMember 2016-01-01 2016-03-31 0001376339 us-gaap:PatentsMember 2015-12-31 0001376339 us-gaap:LicensingAgreementsMember 2015-12-31 0001376339 us-gaap:RevolvingCreditFacilityMember mdxg:CreditAgreementMember 2015-10-12 2015-10-12 0001376339 us-gaap:RevolvingCreditFacilityMember mdxg:CreditAgreementMember 2015-10-12 0001376339 us-gaap:RevolvingCreditFacilityMember mdxg:CreditAgreementMember us-gaap:MinimumMember us-gaap:LondonInterbankOfferedRateLIBORMember 2015-10-12 2015-10-12 0001376339 us-gaap:RevolvingCreditFacilityMember mdxg:CreditAgreementMember us-gaap:MaximumMember us-gaap:LondonInterbankOfferedRateLIBORMember 2015-10-12 2015-10-12 0001376339 us-gaap:RevolvingCreditFacilityMember mdxg:CreditAgreementMember 2016-03-31 0001376339 us-gaap:RestrictedStockMember 2016-01-01 2016-03-31 0001376339 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-03-31 0001376339 us-gaap:WarrantMember 2015-01-01 2015-03-31 0001376339 us-gaap:RestrictedStockMember 2015-01-01 2015-03-31 0001376339 us-gaap:EmployeeStockOptionMember 2015-01-01 2015-03-31 0001376339 us-gaap:WarrantMember 2016-01-01 2016-03-31 0001376339 2014-05-12 0001376339 us-gaap:RestrictedStockMember 2016-01-01 2016-03-31 0001376339 mdxg:Assumed2006PlanMember 2016-01-01 2016-03-31 0001376339 2014-05-12 2016-03-31 0001376339 us-gaap:RestrictedStockMember 2016-03-31 0001376339 us-gaap:RestrictedStockMember 2015-12-31 0001376339 us-gaap:ResearchAndDevelopmentExpenseMember 2015-01-01 2015-03-31 0001376339 us-gaap:CostOfSalesMember 2016-01-01 2016-03-31 0001376339 us-gaap:CostOfSalesMember 2015-01-01 2015-03-31 0001376339 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2015-01-01 2015-03-31 0001376339 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2016-01-01 2016-03-31 0001376339 us-gaap:ResearchAndDevelopmentExpenseMember 2016-01-01 2016-03-31 0001376339 mdxg:PriceRange7Member 2016-01-01 2016-03-31 0001376339 mdxg:PriceRange2Member 2016-03-31 0001376339 mdxg:PriceRange4Member 2016-03-31 0001376339 mdxg:PriceRange7Member 2016-03-31 0001376339 mdxg:PriceRange5Member 2016-03-31 0001376339 mdxg:PriceRange3Member 2016-03-31 0001376339 mdxg:PriceRange6Member 2016-03-31 0001376339 mdxg:PriceRange5Member 2016-01-01 2016-03-31 0001376339 mdxg:PriceRange2Member 2016-01-01 2016-03-31 0001376339 mdxg:PriceRange1Member 2016-01-01 2016-03-31 0001376339 mdxg:PriceRange3Member 2016-01-01 2016-03-31 0001376339 mdxg:PriceRange1Member 2016-03-31 0001376339 mdxg:PriceRange4Member 2016-01-01 2016-03-31 0001376339 mdxg:PriceRange6Member 2016-01-01 2016-03-31 0001376339 2015-01-01 2015-12-31 0001376339 us-gaap:ScenarioForecastMember 2016-01-01 2016-12-31 0001376339 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2015-01-01 2015-12-31 0001376339 us-gaap:StandbyLettersOfCreditMember 2016-03-31 0001376339 us-gaap:PendingLitigationMember 2016-03-31 0001376339 mdxg:BoneBankActionMember us-gaap:PendingLitigationMember 2015-10-02 0001376339 mdxg:LiventaActionMember us-gaap:PendingLitigationMember 2015-12-30 0001376339 mdxg:LiventaAction437PatentMember us-gaap:PendingLitigationMember 2015-08-18 0001376339 mdxg:LiventaAction701PatentMember us-gaap:PendingLitigationMember 2015-08-18 0001376339 mdxg:BoneBankActionMember us-gaap:PendingLitigationMember 2015-07-10 0001376339 mdxg:LiventaActionMember us-gaap:PendingLitigationMember 2015-12-22 0001376339 mdxg:BoneBankActionMember us-gaap:PendingLitigationMember 2015-06-29 0001376339 us-gaap:AllowanceForDoubtfulAccountsMember 2014-12-31 0001376339 mdxg:AllowanceforObsolescenceMember 2015-03-31 0001376339 us-gaap:AllowanceForDoubtfulAccountsMember 2016-03-31 0001376339 us-gaap:AllowanceForSalesReturnsMember 2016-03-31 0001376339 mdxg:AllowanceforObsolescenceMember 2015-01-01 2015-03-31 0001376339 mdxg:AllowanceforObsolescenceMember 2015-12-31 0001376339 us-gaap:AllowanceForSalesReturnsMember 2016-01-01 2016-03-31 0001376339 us-gaap:AllowanceForDoubtfulAccountsMember 2015-01-01 2015-03-31 0001376339 us-gaap:AllowanceForSalesReturnsMember 2015-03-31 0001376339 mdxg:AllowanceforObsolescenceMember 2016-03-31 0001376339 us-gaap:AllowanceForDoubtfulAccountsMember 2015-12-31 0001376339 us-gaap:AllowanceForSalesReturnsMember 2015-01-01 2015-03-31 0001376339 us-gaap:AllowanceForDoubtfulAccountsMember 2016-01-01 2016-03-31 0001376339 mdxg:AllowanceforObsolescenceMember 2014-12-31 0001376339 mdxg:AllowanceforObsolescenceMember 2016-01-01 2016-03-31 0001376339 us-gaap:AllowanceForSalesReturnsMember 2015-12-31 0001376339 us-gaap:AllowanceForDoubtfulAccountsMember 2015-03-31 0001376339 us-gaap:AllowanceForSalesReturnsMember 2014-12-31 iso4217:USD xbrli:shares mdxg:plan xbrli:pure mdxg:segment iso4217:USD mdxg:term mdxg:claim xbrli:shares false --12-31 Q1 2016 2016-03-31 10-Q 0001376339 109548431 Large Accelerated Filer MIMEDX GROUP, INC. 2001000 28000 2382000 -5943000 611000 0.12 0.03 0.03 350000 0.118 4864000 5675000 35000000 1 2 30 1 1 3 70000 201000 147000 3518000 P30D 12000 6633000 13059000 53755000 53882000 4644000 5137000 4979000 5907000 P19Y P13Y P7Y P4Y 163133000 151659000 684000 684000 3933000 95000 186000 3652000 96000 205000 4314000 4615000 0 49000 233000 577000 810000 7818216 7392355 383461 42400 6501589 5981250 520339 0 135913000 177220000 96310000 95240000 441009 0.03 0.01 9.07 2879000 -1038000 1611000 45921000 53915000 713000 44357000 3346000 1771000 33240000 200000 33240000 0 33240000 140000 100000 10864000 194000 9899000 1000000 23610000 8920000 760000 2700000 10230000 10977000 85000 932000 560000 199000 1375000 44357000 46582000 38696000 28486000 15117000 -7886000 -13369000 0.001 0.001 150000000 150000000 109467416 109539420 107361471 109466073 109000 109000 0.12 9950000 765000 1742000 2998000 2246000 2199000 5148000 7946000 0.0225 0.015 P3Y 487000 477000 500000 14838000 4940000 354000 734000 0.04 0.01 0.04 0.01 0.0340 0.152 0.404 15034000 9394000 P2Y3M18D 24965395 4501863 P12Y P2Y P4Y P20Y 18489000 2434000 2091000 2766000 2766000 3156000 3761000 1009000 0 8001000 12681000 1769000 2700000 18233000 3761000 13000 7690000 8920000 760000 2700000 10230000 31702000 201000 147000 1000 4040000 30730000 26690000 35619000 45421000 4233000 1411000 146000 214000 363000 139000 1789000 -4265000 4329000 -1874000 1111000 493000 -2803000 -5640000 2300000 -885000 264000 1600000 26000 -209000 -223000 543000 801000 2066000 1823000 1008000 25000 1969000 2008000 25000 1008000 25000 1000000 15627000 39385000 10763000 33710000 14000 56000 3405000 12658000 7857000 18571000 7460000 17967000 602000 1127000 397000 604000 3850000 4786000 0 734000 284000 423000 P6Y 235000 27925000 62977000 135913000 177220000 26777000 28842000 0 50000000 4 7 7 6 5 -11048000 -3106000 -1048000 -9286000 4210000 -977000 4087000 1197000 1197000 1 4247000 1467000 466000 1252000 1148000 895000 103000 -14000 -56000 49244000 12295000 3530000 0 20000 0 684000 6000000 0 7631000 29000 10000 996000 1347000 2008000 0.001 0.001 5000000 5000000 0 0 0 0 0 0 3609000 5774000 500000 500000 1276000 1138000 14454000 2629000 4564000 4577000 2684000 18030000 1539000 7528000 5730000 3233000 9475000 12123000 1000000 427000 1831000 2496000 -38130000 -36933000 50000 40767000 53367000 29308000 40648000 3933000 4615000 45263 8.87 1576579 8.18 2613267 3499680 9.14 8.84 644903 8.42 0 0.581 0.568 0.0166 0.0157 26500000 13210155 3.24 4440694 12497 120563 0 67341642 14019629 13277852 3.62 3.69 67231821 11714483 3.67 1.87 6.34 6.05 0.00 0.50 0.87 1.40 2.66 4.19 6.45 9.90 11714483 441429 4431970 1460924 894120 2897570 1556144 32326 13277852 441429 4431970 1460924 894120 3426178 2512065 111166 0.76 1.35 2.45 3.99 6.38 9.78 10.99 P6Y 64456036 P6Y1M6D P6Y3M18D 3.24 0.72 1.19 1.92 3.06 5.26 7.24 10.51 3.69 0.72 1.19 1.92 3.06 5.35 7.29 10.44 P6Y3M18D P3Y2M12D P5Y4M24D P4Y8M12D P6Y7M6D P7Y2M12D P7Y10M24D P8Y7M6D 109467416 2105945 109539420 73347 81594 81594 3000000 3000000 2500000 2500000 441009 -441009 11321 20406 20406 -20406 45263 -1576579 608717 72004 -536713 2529444 0 3346000 -462000 3808000 108000 173000 173000 4000 169000 -378000 378000 -12750000 12750000 4615000 4615000 1138000 -3259000 4397000 20746000 20000000 60000000 10000000 10756000 107988000 163133000 109000 -38130000 -17124000 114243000 151659000 109000 -36933000 -592000 2105945 73347 415252 415252 17124000 592000 3530000 3530000 -15400000 527000 1750000 841000 552000 2010000 944000 397000 3270000 1262000 604000 3872000 1651000 130000 260000 709000 235000 602000 1300000 105000 0 606000 28000 0 911000 7818216 6501589 113638551 112039860 105820335 105538271 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liquidity and Management&#8217;s Plans</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company had approximately </font><font style="font-family:inherit;font-size:10pt;">$15,117,000</font><font style="font-family:inherit;font-size:10pt;"> of cash and cash equivalents.&#160;&#160;The Company reported total current assets of approximately </font><font style="font-family:inherit;font-size:10pt;">$95,240,000</font><font style="font-family:inherit;font-size:10pt;"> and current liabilities of approximately </font><font style="font-family:inherit;font-size:10pt;">$28,842,000</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;The Company believes that its anticipated cash from operating and financing activities, existing cash and cash equivalents, short term investments and availability under its line of credit will enable the Company to meet its operational liquidity needs and fund its planned investing activities for the next twelve months.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets are summarized as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="10" rowspan="1"></td></tr><tr><td style="width:48%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted<br clear="none"/>Average<br clear="none"/>Amortization<br clear="none"/>Lives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Licenses (a) (b) (d)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,769</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,009</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents &amp; Know How (b) (d)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,233</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,001</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer &amp; Supplier Relationships (b) (d)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,681</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,761</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tradenames &amp; Trademarks (b) (d)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">indefinite</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,008</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,008</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non - compete agreements (d)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,700</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In Process Research &amp; Development (b)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/a</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents in Process (c)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/a</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,969</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,823</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,385</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,627</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less Accumulated amortization </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,675</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,864</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,710</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,763</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 29, 2007, the Company acquired a license from Shriners Hospitals for Children and University of South Florida Research Foundation, Inc. in the amount of </font><font style="font-family:inherit;font-size:10pt;">$996,000</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;Within </font><font style="font-family:inherit;font-size:10pt;">30 days</font><font style="font-family:inherit;font-size:10pt;"> after the receipt by the Company of approval by the FDA allowing the sale of the first licensed product, the Company is required to pay an additional </font><font style="font-family:inherit;font-size:10pt;">$200,000</font><font style="font-family:inherit;font-size:10pt;"> to the licensor.&#160;&#160;Due to its contingent nature, this amount is not recorded as a liability. The Company will also be required to pay a royalty of </font><font style="font-family:inherit;font-size:10pt;">3%</font><font style="font-family:inherit;font-size:10pt;"> on all commercial sales revenue from the licensed products. The Company is also obligated to pay a </font><font style="font-family:inherit;font-size:10pt;">$50,000</font><font style="font-family:inherit;font-size:10pt;"> minimum annual royalty payment over the life of the license.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 5, 2011, the Company acquired Surgical Biologics, LLC.&#160;&#160;As a result, the Company recorded intangible assets for Customer &amp; Supplier Relationships of </font><font style="font-family:inherit;font-size:10pt;">$3,761,000</font><font style="font-family:inherit;font-size:10pt;">, Patents &amp; Know-How of </font><font style="font-family:inherit;font-size:10pt;">$7,690,000</font><font style="font-family:inherit;font-size:10pt;">, Licenses of </font><font style="font-family:inherit;font-size:10pt;">$13,000</font><font style="font-family:inherit;font-size:10pt;">, Tradenames &amp; Trademarks of </font><font style="font-family:inherit;font-size:10pt;">$1,008,000</font><font style="font-family:inherit;font-size:10pt;"> and In-Process Research &amp; Development of </font><font style="font-family:inherit;font-size:10pt;">$25,000</font><font style="font-family:inherit;font-size:10pt;">. For the three months ended March 31, 2016, approximately </font><font style="font-family:inherit;font-size:10pt;">$1,000</font><font style="font-family:inherit;font-size:10pt;"> of costs associated with patents granted during the period were capitalized and included in Patents &amp; Know-How subject to amortization.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents in Process consist of capitalized external legal and other registration costs in connection with internally developed tissue-based patents that are pending. Once issued, the costs associated with a given patent will be included in Patents &amp; Know-How under intangible assets subject to amortization.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 13, 2016, the Company acquired Stability Inc. As a result, the Company recorded intangible assets for Patents &amp; Know - How of </font><font style="font-family:inherit;font-size:10pt;">$10,230,000</font><font style="font-family:inherit;font-size:10pt;">, Customer Relationships of</font><font style="font-family:inherit;font-size:10pt;">$8,920,000</font><font style="font-family:inherit;font-size:10pt;">, Non - compete agreements of </font><font style="font-family:inherit;font-size:10pt;">$2,700,000</font><font style="font-family:inherit;font-size:10pt;">, Tradenames &amp; Trademarksy of </font><font style="font-family:inherit;font-size:10pt;">$1,000,000</font><font style="font-family:inherit;font-size:10pt;"> and Licenses of </font><font style="font-family:inherit;font-size:10pt;">$760,000</font><font style="font-family:inherit;font-size:10pt;">.</font></div></td></tr></table></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) from interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X.&#160;&#160;Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.&#160;&#160;Changes to GAAP are established by the Financial Accounting Standards Board (&#8220;FASB&#8221;) in the form of Accounting Standards Updates (&#8220;ASU&#8217;&#8217;) to the FASB&#8217;s Accounting Standards Codification (&#8220;ASC&#8221;).&#160;&#160;In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the results of operations for the periods presented have been included.&#160;&#160;Operating results for the </font><font style="font-family:inherit;font-size:10pt;">three months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, are not necessarily indicative of the results that may be expected for the fiscal year.&#160;&#160;The balance sheet at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, has been derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements.&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">You should read these condensed consolidated financial statements together with the historical consolidated financial statements of the Company for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, included in the Company's Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, filed with the SEC on February 29, 2016.&#160;</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:14px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unaudited pro forma information for the three months ended March&#160;31, 2016 and 2015 (in thousands) is as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:49.0234375%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:47%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:25%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three months ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,915</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,921</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,611</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,879</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income per share, fully diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.01</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.03</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Acquisition of Stability Inc.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 13, 2016, the Company completed the acquisition of Stability Inc., d/b/a Stability Biologics, a provider of human tissue products to surgeons, facilities, and distributors serving the surgical, spine, and orthopedic sectors of the healthcare industry. As a result of this transaction, the Company acquired all of the outstanding shares of Stability in exchange for </font><font style="font-family:inherit;font-size:10pt;">$6,000,000</font><font style="font-family:inherit;font-size:10pt;"> cash, </font><font style="font-family:inherit;font-size:10pt;">$3,346,000</font><font style="font-family:inherit;font-size:10pt;"> in stock, represented by </font><font style="font-family:inherit;font-size:10pt;">441,009</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock, and assumed debt of </font><font style="font-family:inherit;font-size:10pt;">$1,771,000</font><font style="font-family:inherit;font-size:10pt;">. Additional one time costs incurred in connection with the transaction totaled </font><font style="font-family:inherit;font-size:10pt;">$713,000</font><font style="font-family:inherit;font-size:10pt;">. Contingent consideration may be payable in a formula determined by sales less certain expenses for the years 2016 and 2017. As of March 31, 2016, the contingent consideration was valued at </font><font style="font-family:inherit;font-size:10pt;">$33,240,000</font><font style="font-family:inherit;font-size:10pt;"> and is shown in the schedule below as fair value of earn-out. The Company used a third party specialist to assist us with the valuation. The contingent consideration was classified as a liability. The Company has evaluated the contingent consideration for accounting purposes under GAAP and has determined that the contingent consideration is within the scope of ASC 480 Distinguishing Liabilities from Equity whereby a financial instrument other than an outstanding share, that embodies a conditional obligation that the issuer may settle by issuing a variable number of its equity shares, shall be classified as a liability if, at inception, the monetary value of the obligation is based solely or predominantly on variations in something other than the fair value of the issuer&#8217;s equity shares.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The actual purchase price was based on cash paid, the fair value of our stock on the date of the acquisition, and direct costs associated with the combination. The actual purchase price has been preliminarily allocated as of March 31, 2016 (in thousands) and is subject to change:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash paid at closing</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,000</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock issued (441,009 shares valued at $9.07 per share)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,346</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assumed debt</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,771</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value of earn - out</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,240</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total fair value of purchase price</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,357</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net assets acquired:</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Debt-free working capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,382</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other assets, net</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">199</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property, plant and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,375</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax liability</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,899</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subtotal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,943</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets:</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer relationships</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,920</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents and know-how</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,230</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trade names and trademarks</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non compete agreements</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,700</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Licenses and permits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">760</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subtotal</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,610</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,690</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Assets Purchased</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,357</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;padding-left:17px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Working capital and other assets were composed of the following (in thousands):</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:83%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Working capital:</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">140</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid Expenses and other current assets</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts Receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,001</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal and state taxes receivable</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,977</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable and accrued expenses</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,864</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Debt-free working capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,382</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current portion of long term debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(194</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term debt</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(560</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Line of credit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(932</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shareholder loan</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(85</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net working capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">611</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other assets:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other long term assets</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">199</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The acquisition was accounted for as a purchase business combination as defined by FASB Topic 805 - Business Combinations. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the contingent consideration is measured as a Level 3 instrument. The contingent consideration liability is recorded at fair value on the acquisition date and will be remeasured quarterly based on the assessed fair value and adjusted if necessary. The increases or decreases in the fair value of contingent consideration can result from changes in anticipated revenue levels and changes in assumed discount periods and rates. As the fair value measured is based on significant inputs that are not observable in the market, they are categorized as Level 3. The income valuation approach was applied in determining the fair value of the contingent consideration using a discounted cash flow valuation technique with significant unobservable inputs comprised of projected sales and certain expenses. The values assigned to intangible assets are subject to amortization. The intangible assets were assigned the following lives for amortization purposes:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:66.796875%;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:78%;" rowspan="1" colspan="1"></td><td style="width:22%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimated useful</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">life (in years)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible asset:</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer relationships</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents and know-how</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trade names and trademarks</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">indefinite</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non compete agreements</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Licenses and permits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill consists of the excess of the purchase price paid over the identifiable net assets and liabilities acquired at fair value. Goodwill was determined using the residual method based on an independent appraisal of the assets and liabilities acquired in the transaction and is preliminary as of March 31, 2016 and is subject to change. Goodwill is tested for impairment as defined by FASB Topic 350 - Intangibles - Goodwill and Other.</font></div><div style="line-height:120%;text-align:left;padding-left:17px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following unaudited pro forma summary financial information presents the consolidated results of operations as if the acquisition had occurred on January&#160;1, 2015. The pro forma results are shown for illustrative purposes only and do not purport to be indicative of the results that would have been reported if the acquisition had occurred on the date indicated or indicative of the results that may occur in the future.</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:14px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unaudited pro forma information for the three months ended March&#160;31, 2016 and 2015 (in thousands) is as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:49.0234375%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:47%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:25%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three months ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,915</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,921</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,611</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,879</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income per share, fully diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.01</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.03</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2016 supplemental pro forma earnings were adjusted to exclude </font><font style="font-family:inherit;font-size:10pt;">$713,000</font><font style="font-family:inherit;font-size:10pt;"> of acquisition-related legal, audit and other costs, net of tax. The 2015 supplemental pro forma earnings were adjusted to include </font><font style="font-family:inherit;font-size:10pt;">$577,000</font><font style="font-family:inherit;font-size:10pt;"> of amortization costs related to recorded intangible assets with defined useful lives, and </font><font style="font-family:inherit;font-size:10pt;">$1,038,000</font><font style="font-family:inherit;font-size:10pt;"> of inventory step up charges as a result of the acquisition for comparability to 2016. The shares outstanding used in calculating the income per share for 2015 was adjusted to include </font><font style="font-family:inherit;font-size:10pt;">441,009</font><font style="font-family:inherit;font-size:10pt;"> shares issued as part of the purchase price and assumed to be issued on January&#160;1, 2015.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Acquisitions</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Results of operations of acquired companies are included in the Company&#8217;s results of operations as of the respective acquisition dates. The purchase price of each acquisition is allocated to the net assets acquired based on estimates of their fair values at the date of the acquisition. Any purchase price in excess of these net assets is recorded as goodwill. The allocation of purchase price in certain cases may be subject to revision based on the final determination of fair values during the measurement period, which may be up to one year from the acquisition date.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent consideration is recognized at the estimated fair value on the acquisition date. Subsequent changes to the fair value of contingent payments are recognized in earnings. Contingent payments related to acquisitions consist of an earn out based on sales less direct production costs, and are valued using discounted cash flow techniques. The fair value of these payments is based upon probability-weighted future revenue estimates and increases or decreases as revenue estimates or expectation of timing of payments changes.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Short Term Investments</font></div><div style="line-height:120%;padding-bottom:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short term investments consist of approximately </font><font style="font-family:inherit;font-size:10pt;">$2,500,000</font><font style="font-family:inherit;font-size:10pt;"> of FDIC insured certificates of deposit held with various financial institutions as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">. Short term investments consisted of approximately </font><font style="font-family:inherit;font-size:10pt;">$3,000,000</font><font style="font-family:inherit;font-size:10pt;"> of FDIC insured certificates of deposit at December 31, 2015. The cost of these instruments approximates their fair market value at </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and December 31, 2015.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Supplemental disclosure of cash flow and non-cash investing and financing activities:</font></div><div style="line-height:120%;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selected cash payments, receipts, and noncash activities are as follows (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:72%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash paid for interest, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income taxes paid</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">139</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">363</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock issuance of 441,009 shares in connection with acquisition </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,346</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock issuance of 20,406 and 11,321 shares in exchange for services performed, respectively</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">173</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">108</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contractual Commitments and Contingencies</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Contractual Commitments</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to the capital leases noted above in Note 7, the Company has entered into operating lease agreements for facility space and equipment. These leases expire over the next </font><font style="font-family:inherit;font-size:10pt;">six years</font><font style="font-family:inherit;font-size:10pt;"> and generally contain renewal options. The Company anticipates that most of these leases will be renewed or replaced upon expiration. The Company also has commitments for meeting space and to various charitable organizations. The estimated annual lease payments, meeting space and charitable organization commitments are as follows (in thousands):</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="4" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12-month period ended March 31</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,998</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,246</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,199</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,742</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">765</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,950</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Rent expense for the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and 2015, was approximately </font><font style="font-family:inherit;font-size:10pt;">$423,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$284,000</font><font style="font-family:inherit;font-size:10pt;">, respectively, and is allocated among cost of sales, research and development, and selling, general and administrative expenses.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Letters of Credit</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a condition of the lease for the Company's main facility, the Company is obligated under standby letters of credit in the amount of approximately </font><font style="font-family:inherit;font-size:10pt;">$235,000</font><font style="font-family:inherit;font-size:10pt;">. These obligations are reduced at various times over the life of the lease.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">FDA Untitled Letter, Draft Guidance and Related Litigation</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">FDA Untitled Letter and Draft Guidance<br clear="none"/> <br clear="none"/></font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On August 28, 2013, the FDA issued an Untitled Letter alleging that the Company's micronized allografts do not meet the criteria for regulation solely under Section 361 of the Public Health Service Act and that, as a result, MiMedx would need a biologics license to lawfully market those micronized products. Since the issuance of the Untitled Letter, the Company has been in discussions with the FDA to communicate its disagreement with the FDA's assertion that the Company's allografts are more than minimally manipulated. To date, the FDA has not changed its position that the Company's micronized products are not eligible for marketing solely under Section 361 of the Public Health Service Act, but discussions are continuing. The Company continues to market its micronized products but is also pursuing the Biologics License Application (&#8220;BLA&#8221;) process for certain of its micronized products.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 22, 2014, the FDA issued for comment &#8220;Draft Guidance for Industry and FDA Staff: Minimal Manipulation of Human Cells, Tissues, and Cellular and Tissue-Based Products.&#8221; Essentially the Minimal Manipulation draft guidance takes the same position with respect to micronized amniotic tissue that it took in the Untitled Letter to MiMedx 16 months earlier. The Company submitted comments asserting that the Minimal Manipulation draft guidance represents agency action that goes far beyond the FDA&#8217;s statutory authority, is inconsistent with existing HCT/P regulations and the FDA&#8217;s prior positions, and is internally inconsistent and scientifically unsound. On&#160;October 28, 2015, the FDA issued for comment, "Draft Guidance for Industry and FDA Staff: Homologous Use of Human Cells, Tissues, and Cellular and Tissue-Based Products." The Company submitted comments on this Homologous Use draft guidance. The FDA has indicated that it will hold a public hearing on September 12 and 13, 2016 to obtain input on the Homologous Use draft guidance and the previously released Minimal Manipulation draft guidance, as well as other recently issued guidance documents on HCT/Ps. The hearing was originally scheduled for April 13, 2016, but was rescheduled to allow stakeholders additional time to provide comments due to the considerable interest in the hearing. The Company has requested an opportunity to speak at the rescheduled hearing.</font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If the FDA does allow the Company to continue to market a micronized form of its sheet allografts without a biologics license either prior to or after finalization of the draft guidance documents, it may impose conditions, such as labeling restrictions and compliance with cGMP. Although the Company is preparing for these requirements in connection with its pursuit of a BLA for certain of its micronized products, earlier compliance with these conditions would require significant additional time and cost investments by the Company. It is also possible that the FDA will not allow the Company to market any form of a micronized product without a biologics license even prior to finalization of the draft guidance documents and could even require the Company to recall its micronized products. Revenues from micronized products comprised approximately&#160;</font><font style="font-family:inherit;font-size:10pt;">12%</font><font style="font-family:inherit;font-size:10pt;">&#160;of the Company's revenues for fiscal-year 2015.<br clear="none"/> <br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Related Litigation</font><font style="font-family:inherit;font-size:10pt;"><br clear="none"/><br clear="none"/> <br clear="none"/><br clear="none"/> Following the publication of the Untitled Letter from the FDA regarding the Company&#8217;s micronized products in September 2013, the trading price of the Company&#8217;s stock declined and several putative shareholder class action lawsuits were filed against the Company and certain of its executive officers asserting violations of the Securities Exchange Act of 1934. The cases were consolidated in the United States District Court for the Northern District of Georgia. On November 17, 2015, the parties entered into a stipulation of settlement to settle the consolidated case in its entirety. The stipulation of settlement was filed with the Court on November 18, 2015 and preliminarily approved by the Court on November 19, 2015. The final settlement hearing was held on April 5, 2016 and the Court approved the settlement. The Company does not believe the terms of the settlement will have a material adverse effect on its operating results or financial condition.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Patent Litigation</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MiMedx continues to diligently enforce its intellectual property against several entities. Currently, there are </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;"> actions pending, as described below:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">The Liventa Action</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">First, there is an action pending against several entities in the in the United States District Court for the Northern District of Georgia, i.e., &#8220;the Liventa Action&#8221;. On April 22, 2014, the Company filed a patent infringement lawsuit against Liventa Bioscience, Inc. ("Liventa"), Medline Industries, Inc. ("Medline") and Musculoskeletal Transplant Foundation, Inc. ("MTF") for permanent injunctive relief and unspecified damages. In addition to the allegations of infringement of MiMedx's patents, the lawsuit asserts that Liventa and Medline knowingly and willfully made false and misleading representations about their respective products to providers, patients, and in some cases, prospective investors. The Liventa Action was filed in the United States District Court for the Northern District of Georgia.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MiMedx asserts that Liventa (formerly known as AFCell Medical, Inc.), Medline and MTF infringed and continue to infringe certain of the Company's patents relating to the MiMedx dehydrated human amnion/chorion membrane ("dHACM") allografts. MTF is the tissue processor while Liventa and Medline are the distributors of the allegedly infringing products. On May 30, 2014, defendants filed answers to the Complaint, denying the allegations in the Complaint. They also raised affirmative defenses of non-infringement, invalidity, laches and estoppel. MTF and Medline also filed counterclaims seeking declaratory judgments of non-infringement and invalidity.</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 30, 2014, fact discovery began and the parties have engaged in extensive fact discovery.</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MiMedx served Infringement Contentions on August 29, 2014, and Defendants served Invalidity Contentions and Responses to Infringement Contentions on September 29, 2014. After a protracted series of meet and confers, MiMedx required Defendants to supplement their invalidity contentions in view of parallel Inter Partes Review ("IPR")(see further discussion, infra) proceedings. MTF complied on June 26, 2015.</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2015, the Defendants filed a renewed Motion to Stay in light of the Patent Trial and Appeal Board's ("PTAB") decisions to institute IPRs on the &#8217;437 and &#8217;687 Patents, seeking a partial stay of the litigation as to the &#8217;437, &#8217;687, and &#8217;494 Patents (i.e., the &#8217;437 Patent family). MiMedx opposed the Motion to Stay with respect to the &#8217;494 Patent and once again successfully defeated Defendants&#8217; motion to stay.</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Claim Construction proceedings began in October 2014. The parties submitted proposed constructions for key terms for the &#8217;701, &#8217;092, &#8217;437, &#8217;687, &#8217;207, and &#8217;494 Patents. Briefing was completed in March 2015.</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 22, 2015, a Markman Hearing was held before Special Master Sumner C. Rosenberg. Over </font><font style="font-family:inherit;font-size:10pt;">thirty</font><font style="font-family:inherit;font-size:10pt;"> disputed claim terms were at issue. One week later, on December 30, 2015, the Special Master issued its Report and Recommendation. Except for </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> term, the Special Master&#8217;s Report essentially adopted MiMedx&#8217;s proposed constructions. The parties are awaiting a final Court decision pending their respective objections. On March 9, 2016, the Court adopted the Special Master&#8217;s Report. Since then the Court has entered a scheduling order in this action.&#160; Notably, fact discovery is set to close on May 25, 2016. Expert discovery begins in June 2016&#160;and is expected to close in early September 2016. </font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">The Bone Bank Action</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 16, 2014, the Company also filed a patent infringement lawsuit against Transplant Technology, Inc. d/b/a Bone Bank Allografts ("Bone Bank") and Texas Human Biologics, Ltd. ("Biologics") for permanent injunctive relief and unspecified damages (the "Bone Bank Action"). The Bone Bank Action was filed in the United States District Court for the Western District of Texas. This lawsuit similarly asserts that Bone Bank and Biologics infringed certain of the Company's patents through the manufacturing and sale of their placental-derived tissue graft products. On July 10, 2014, defendants filed an answer to the Complaint, denying the allegations in the Complaint. They also raised affirmative defenses of non-infringement and invalidity and filed counterclaims seeking declaratory judgments of non-infringement and invalidity. The Bone Bank Action is in an advanced stage. The parties have (i) substantially completed document production; (ii) taken several fact depositions (both party and non-party); and (iii) completed claim construction briefing. The Markman hearing in this case was held on October 2, 2015. Except for </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> term, the Court adopted MiMedx&#8217;s proposed construction of the disputed terms. The parties have submitted a proposed scheduling order to the Court and are awaiting the Court&#8217;s order in this regard. Meanwhile, the parties continue with fact discovery in view of recent depositions.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">The NuTech Action</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 2, 2015, the Company filed a patent infringement lawsuit against NuTech Medical, Inc. ("NuTech") and DCI Donor Services, Inc. ("DCI") for permanent injunctive relief and unspecified damages. This lawsuit was filed in the United States District Court for the Northern District of Alabama. The lawsuit alleges that NuTech and DCI have infringed and continue to infringe the Company's patents through the manufacture, use, sale, and/or offering of their tissue graft product. The lawsuit also asserts that NuTech knowingly and willfully made false and misleading representations about its products to customers and/or prospective customers.</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On April 17, 2015, NuTech filed a motion to dismiss the case purportedly for lack of patentable subject matter, which the Company opposed. NuTech also filed a motion to stay the case pending disposition of the motion to dismiss, which MiMedx also opposed, and on which the Court declined to rule. Hearing on the motion to dismiss occurred on August 20, 2015. On November 24, 2015, the court ruled on NuTech&#8217;s Motion to Dismiss, granting in part, and denying in part. MiMedx still has claims against NuTech for infringement of the &#8216;494 and &#8216;687 patents, as well as violations of the Lanham Act; these claims shall proceed.</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 30, 2015, the parties submitted a Joint Rule 26(f) Report of Parties&#8217; Planning Meeting and Proposed Case Management Order to the Court. In the Report, the parties requested that the Court stay the proceedings with respect to the &#8217;687 patent pending the completion of the inter partes review on that patent.</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 8, 2016, MiMedx served its infringement contentions. Judge Hopkins entered the parties&#8217; Case Management Order and granted the parties&#8217; request to stay proceedings with respect to the &#8217;687 patent pending the completion of the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">inter partes</font><font style="font-family:inherit;font-size:10pt;"> review.&#160; </font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 8, 2016, the parties submitted their Initial Disclosures, and MiMedx submitted its preliminary infringement contentions.&#160; On March 14, 2016, Defendants submitted their preliminary invalidity contentions.&#160; On April 15, 2016, the parties exchanged proposed terms for construction and over the next several months the parties will engage in claim construction briefing. Discovery is ongoing.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#160;The Vivex Action</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On April 1, 2016, the Company also filed a patent infringement lawsuit against Vivex BioMedical (&#8220;Vivex&#8221;) for permanent injunctive relief and unspecified damages (the "Vivex Action").&#160; The lawsuit was filed in the United States District Court for the Northern District of Georgia. The patent at issue is the &#8217;494 patent. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Pending IPRs</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to defending the claims in the pending district court litigations, defendants in the Liventa and Bone Bank cases have challenged certain of the Company's patents in several IPR proceedings to avoid the high burden of proof of proving invalidity by "clear and convincing evidence" in the district court litigations. An inter partes review (or "IPR") is a request for a specialized group within the United States Patent and Trademark Office to review the validity of a plaintiff's patent claims. The defendants in the Bone Bank Action have challenged the validity of the Company's 8,597,687 and 8,709,494 patents (the "'687" and "'494" patents, respectively); while the defendants in the Liventa Action have challenged the validity of the Company's 8,372,437 and 8,323,701 patents (the "'437" and "'701" patents, respectively).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 29, 2015, the Patent Trial and Appeals Board ("PTAB") denied defendants' request for institution of an IPR with respect to the '494 patent on all </font><font style="font-family:inherit;font-size:10pt;">seven</font><font style="font-family:inherit;font-size:10pt;"> challenged grounds. On August 18, 2015, the PTAB also denied defendants' request for institution of an IPR with respect to the '701 patent on all </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;"> challenged grounds. That is, the PTAB decided in each case that the defendants failed to establish a reasonable likelihood that defendants would prevail in showing any of the challenged claims of the '494 or the '701 patent were unpatentable.</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On July 10, 2015 the PTAB issued an opinion allowing a review of the '687 patent to proceed, although on only </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> of the </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> challenged grounds. The PTAB also adopted MiMedx's construction of the claims which will govern the Board's review of the '687 patent. The parties decided to forego oral arguments. A decision is expected no later than July 10, 2016. &#160;On August 18, 2015, the PTAB issued an opinion allowing a review of the '437 patent to proceed, although only on </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> of the </font><font style="font-family:inherit;font-size:10pt;">seven</font><font style="font-family:inherit;font-size:10pt;"> challenged grounds. Briefing and expert discovery is ongoing.&#160; Oral argument is scheduled for April 26, 2016.&#160; A decision is expected no later than August of 2016.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The estimated annual lease payments, meeting space and charitable organization commitments are as follows (in thousands):</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="4" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12-month period ended March 31</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,998</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,246</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,199</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,742</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">765</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,950</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Credit Facility</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 12, 2015, the Company and its subsidiaries entered into a Credit Agreement (the "Credit Agreement") with certain lenders and Bank of America, N.A., as administrative agent. The Credit Agreement establishes a senior secured revolving credit facility in favor of the Company with a maturity date of October 12, 2018 and an aggregate lender commitment of up to </font><font style="font-family:inherit;font-size:10pt;">$50 million</font><font style="font-family:inherit;font-size:10pt;">. The Credit Agreement also provides for an uncommitted incremental facility of up to </font><font style="font-family:inherit;font-size:10pt;">$35 million</font><font style="font-family:inherit;font-size:10pt;">, which can be exercised as one or more revolving commitment increases or new term loans, all subject to certain customary terms and conditions set forth in the Credit Agreement. Borrowings under the facility will bear interest at LIBOR plus </font><font style="font-family:inherit;font-size:10pt;">1.5%</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">2.25%</font><font style="font-family:inherit;font-size:10pt;">.&#160; Fees paid in connection with the initiation of the credit facility totaled approximately </font><font style="font-family:inherit;font-size:10pt;">$500,000</font><font style="font-family:inherit;font-size:10pt;">.&#160; These deferred financing costs are being amortized to interest expense over the </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">-year life of the facility. The Credit Agreement contains customary representations, warranties, covenants, and events of default. As of March 31, 2016, there were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> outstanding revolving loans under the credit facility.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Equity</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock Incentive Plans</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> share-based compensation plans: the MiMedx Group, Inc. Assumed 2006 Stock Incentive Plan (the &#8220;Assumed 2006 Plan&#8221;), the MiMedx Inc. 2007 Assumed Stock Plan (the &#8220;Assumed 2007 Plan&#8221;) and the MiMedx Group Inc. Amended and Restated Assumed 2005 Stock Plan (the &#8220;Assumed 2005 Plan&#8221;) which provide for the granting of qualified incentive and non-qualified stock options, stock appreciation awards and restricted stock awards to employees, directors, consultants and advisors. The awards are subject to a vesting schedule as set forth in each individual agreement. The Company intends to use only the Assumed 2006 Plan to make future grants. The number of assumed options under the Assumed 2005 Plan and Assumed 2007 Plan outstanding at </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> totaled </font><font style="font-family:inherit;font-size:10pt;">70,000</font><font style="font-family:inherit;font-size:10pt;">. The maximum number of shares of common stock that can be issued under the Assumed 2006 Plan was </font><font style="font-family:inherit;font-size:10pt;">26,500,000</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the three months ended March 31 2016, </font><font style="font-family:inherit;font-size:10pt;">20,406</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock valued at approximately </font><font style="font-family:inherit;font-size:10pt;">$173,000</font><font style="font-family:inherit;font-size:10pt;"> were issued under the Assumed 2006 Plan to a consultant in return for services performed.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Activity with respect to the stock options is summarized as follows:</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:46%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Number</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;of</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercise</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Price</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Remaining</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contractual Term</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(in years)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Aggregate</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intrinsic</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at January 1, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,019,629</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(608,717</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.87</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested options forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(120,563</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.05</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested options expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12,497</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at March 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,277,852</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.69</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67,341,642</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested at March 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,714,483</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,456,036</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested or expected to vest at March 31, 2016 (a)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,210,155</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.67</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67,231,821</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:13px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Includes forfeiture adjusted unvested shares.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The intrinsic value of the options exercised during the </font><font style="font-family:inherit;font-size:10pt;">three months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, was approximately </font><font style="font-family:inherit;font-size:10pt;">$4,440,694</font><font style="font-family:inherit;font-size:10pt;">.&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Following is a summary of stock options outstanding and exercisable at </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:34%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options Exercisable</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Range of Exercise Prices</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Number outstanding</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Remaining</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contractual Term</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(in years)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercise</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Price</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Number Exercisable</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.50 - $0.76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">441,429</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.72</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">441,429</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.72</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.87 - $1.35</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,431,970</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.19</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,431,970</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.19</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.40 - $2.45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,460,924</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.92</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,460,924</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.92</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$2.66 - $3.99</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">894,120</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.06</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">894,120</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.06</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$4.19 - $6.38</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,426,178</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,897,570</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$6.45 - $9.78</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,512,065</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.9</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.29</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,556,144</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.24</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$9.90- $10.99</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">111,166</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.44</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,326</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.51</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,277,852</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.69</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,714,483</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.24</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total unrecognized compensation expense related to granted stock options at </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, was approximately </font><font style="font-family:inherit;font-size:10pt;">$4,501,863</font><font style="font-family:inherit;font-size:10pt;"> and will be charged to expense ratably over a weighted average period through April 2017.&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of options granted by the Company is estimated on the date of grant using the Black-Scholes-Merton option-pricing model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate.&#160;&#160;Expected volatilities are based on historical volatility of peer companies and other factors estimated over the expected term of the options.&#160;&#160;The term of employee options granted is derived using the &#8220;simplified method,&#8221; which computes expected term as the mid point between the weighted average time to vesting and the contractual maturity. The simplified method was used due to the Company's lack of sufficient historical data to provide a reasonable basis upon which to estimate the expected term due to the limited period of time its equity shares have been publicly traded.&#160;&#160;The term for non-employee options is generally based upon the contractual term of the option.&#160;&#160;The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term or contractual term as described.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The assumptions used in calculating the fair value of options using the Black-Scholes-Merton option-pricing model are set forth in the following table:</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:69%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/a</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56.8 - 58.1%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected life (in years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/a</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/a</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/a</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.57% - 1.66%</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Their were no options granted during the </font><font style="font-family:inherit;font-size:10pt;">three months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Stock Awards&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Activity with respect to restricted stock awards is summarized as follows:&#160; </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:63%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Number </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of<br clear="none"/>Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-Average Grant Date<br clear="none"/> Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested at January 1, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,613,267</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$9.14</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,576,579</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.18</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(644,903</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.42</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(45,263</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.87</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested at March 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,499,680</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$8.84</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, there was approximately </font><font style="font-family:inherit;font-size:10pt;">$24,965,395</font><font style="font-family:inherit;font-size:10pt;"> of total unrecognized stock-based compensation related to time-based, nonvested restricted stock.&#160;&#160;That expense is expected to be recognized on a straight-line basis over a weighted-average period of </font><font style="font-family:inherit;font-size:10pt;">2.3</font><font style="font-family:inherit;font-size:10pt;"> years, which approximates the remaining vesting period of these grants. All shares noted above as unvested are considered issued and outstanding at </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized stock-based compensation as follows (in thousands):&#160;</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:78.515625%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:64%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">96</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">95</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">205</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">186</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,314</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,652</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,615</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,933</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Treasury Stock</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:left;padding-left:6px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> On May 12, 2014, our Board of Directors authorized the repurchase of up to </font><font style="font-family:inherit;font-size:10pt;">$10 million</font><font style="font-family:inherit;font-size:10pt;"> of our common stock from time to time, through December 31, 2014. The Board subsequently extended the program until December 31, 2016. In December 2014, the Board increased the authorization to </font><font style="font-family:inherit;font-size:10pt;">$20 million</font><font style="font-family:inherit;font-size:10pt;"> and further increased the authorization in 2015 to </font><font style="font-family:inherit;font-size:10pt;">$60 million</font><font style="font-family:inherit;font-size:10pt;">. The timing and amount of repurchases will depend upon the Company's stock price, economic and market conditions, regulatory requirements, and other corporate considerations. The Company may initiate, suspend or discontinue purchases under the stock repurchase program at any time.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company purchased </font><font style="font-family:inherit;font-size:10pt;">415,252</font><font style="font-family:inherit;font-size:10pt;"> shares of its common stock for a purchase price of approximately </font><font style="font-family:inherit;font-size:10pt;">$3,518,000</font><font style="font-family:inherit;font-size:10pt;">, before brokerage commissions of approximately </font><font style="font-family:inherit;font-size:10pt;">$12,000</font><font style="font-family:inherit;font-size:10pt;"> bringing the total amount spent under the program to approximately </font><font style="font-family:inherit;font-size:10pt;">$49,244,000</font><font style="font-family:inherit;font-size:10pt;"> since inception. As of March 31, 2016, the Company had approximately </font><font style="font-family:inherit;font-size:10pt;">$10,756,000</font><font style="font-family:inherit;font-size:10pt;"> remaining under the repurchase program. In addition, the Company purchased during the quarter </font><font style="font-family:inherit;font-size:10pt;">81,594</font><font style="font-family:inherit;font-size:10pt;"> shares surrendered by employees to satisfy tax withholding obligations upon vesting of restricted stock.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additionally, for the three months ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company reissued </font><font style="font-family:inherit;font-size:10pt;">2,529,444</font><font style="font-family:inherit;font-size:10pt;"> shares from the Treasury for common and restricted stock grants and stock option exercises, net of forfeitures, and the acquisition of Stability Inc. with an aggregate carrying value of approximately </font><font style="font-family:inherit;font-size:10pt;">$20,746,000</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Income Per Share</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic net income per common share is computed using the weighted-average number of common shares outstanding during the period.&#160;&#160;Diluted net income per common share is computed using the weighted-average number of common and dilutive common equivalent shares from stock options, restricted stock, and warrants using the treasury stock method.&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the computation of basic and diluted net income per share (in thousands except share data):</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:75.1953125%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,197</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,087</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Denominator for basic earnings per share - weighted average shares</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105,538,271</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105,820,335</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effect of dilutive securities: Stock options, restricted stock, and warrants outstanding(a)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,501,589</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,818,216</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112,039,860</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">113,638,551</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income per common share - basic </font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.01</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.04</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income per common share - diluted</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.01</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.04</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) Securities outstanding that are included in the computation above, utilizing the treasury stock method are as follows:</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:76.171875%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:61%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding Stock Options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,981,250</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,392,355</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,400</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted Stock Awards</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">520,339</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">383,461</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,501,589</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,818,216</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The intangible assets were assigned the following lives for amortization purposes:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:66.796875%;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:78%;" rowspan="1" colspan="1"></td><td style="width:22%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimated useful</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">life (in years)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible asset:</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer relationships</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents and know-how</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trade names and trademarks</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">indefinite</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non compete agreements</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Licenses and permits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Income taxes</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:8px;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The effective tax rates for continuing operations of&#160;</font><font style="font-family:inherit;font-size:10pt;">15.2%</font><font style="font-family:inherit;font-size:10pt;"> and&#160;</font><font style="font-family:inherit;font-size:10pt;">3.40%</font><font style="font-family:inherit;font-size:10pt;"> for the three months ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, respectively, were determined using an estimated annual effective tax rate and includes in 2016 the impact of a discrete item of approximately </font><font style="font-family:inherit;font-size:10pt;">$350,000</font><font style="font-family:inherit;font-size:10pt;">. The effective tax rate increased </font><font style="font-family:inherit;font-size:10pt;">11.8%</font><font style="font-family:inherit;font-size:10pt;"> when compared to the same period of 2015, primarily due to the </font><font style="font-family:inherit;font-size:10pt;">$15.4 million</font><font style="font-family:inherit;font-size:10pt;"> valauation allowance release recorded in 2015 and discussed in our annual report on Form 10-K for the year ended December 31, 2015. Due to the valuation allowance previously recorded against the Company's U.S. deferred tax assets, the effective tax rate for the three months ended March 31, 2015, did not include the expense of the current period U.S. taxable income. As of the end of March 2016, the projected annual effective tax rate for 2016 is </font><font style="font-family:inherit;font-size:10pt;">40.4%</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intangible Assets and Royalty Agreement</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets are summarized as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="10" rowspan="1"></td></tr><tr><td style="width:48%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted<br clear="none"/>Average<br clear="none"/>Amortization<br clear="none"/>Lives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Licenses (a) (b) (d)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,769</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,009</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents &amp; Know How (b) (d)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,233</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,001</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer &amp; Supplier Relationships (b) (d)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,681</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,761</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tradenames &amp; Trademarks (b) (d)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">indefinite</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,008</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,008</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non - compete agreements (d)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,700</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In Process Research &amp; Development (b)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/a</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents in Process (c)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/a</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,969</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,823</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,385</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,627</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less Accumulated amortization </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,675</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,864</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,710</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,763</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 29, 2007, the Company acquired a license from Shriners Hospitals for Children and University of South Florida Research Foundation, Inc. in the amount of </font><font style="font-family:inherit;font-size:10pt;">$996,000</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;Within </font><font style="font-family:inherit;font-size:10pt;">30 days</font><font style="font-family:inherit;font-size:10pt;"> after the receipt by the Company of approval by the FDA allowing the sale of the first licensed product, the Company is required to pay an additional </font><font style="font-family:inherit;font-size:10pt;">$200,000</font><font style="font-family:inherit;font-size:10pt;"> to the licensor.&#160;&#160;Due to its contingent nature, this amount is not recorded as a liability. The Company will also be required to pay a royalty of </font><font style="font-family:inherit;font-size:10pt;">3%</font><font style="font-family:inherit;font-size:10pt;"> on all commercial sales revenue from the licensed products. The Company is also obligated to pay a </font><font style="font-family:inherit;font-size:10pt;">$50,000</font><font style="font-family:inherit;font-size:10pt;"> minimum annual royalty payment over the life of the license.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 5, 2011, the Company acquired Surgical Biologics, LLC.&#160;&#160;As a result, the Company recorded intangible assets for Customer &amp; Supplier Relationships of </font><font style="font-family:inherit;font-size:10pt;">$3,761,000</font><font style="font-family:inherit;font-size:10pt;">, Patents &amp; Know-How of </font><font style="font-family:inherit;font-size:10pt;">$7,690,000</font><font style="font-family:inherit;font-size:10pt;">, Licenses of </font><font style="font-family:inherit;font-size:10pt;">$13,000</font><font style="font-family:inherit;font-size:10pt;">, Tradenames &amp; Trademarks of </font><font style="font-family:inherit;font-size:10pt;">$1,008,000</font><font style="font-family:inherit;font-size:10pt;"> and In-Process Research &amp; Development of </font><font style="font-family:inherit;font-size:10pt;">$25,000</font><font style="font-family:inherit;font-size:10pt;">. For the three months ended March 31, 2016, approximately </font><font style="font-family:inherit;font-size:10pt;">$1,000</font><font style="font-family:inherit;font-size:10pt;"> of costs associated with patents granted during the period were capitalized and included in Patents &amp; Know-How subject to amortization.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents in Process consist of capitalized external legal and other registration costs in connection with internally developed tissue-based patents that are pending. Once issued, the costs associated with a given patent will be included in Patents &amp; Know-How under intangible assets subject to amortization.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 13, 2016, the Company acquired Stability Inc. As a result, the Company recorded intangible assets for Patents &amp; Know - How of </font><font style="font-family:inherit;font-size:10pt;">$10,230,000</font><font style="font-family:inherit;font-size:10pt;">, Customer Relationships of</font><font style="font-family:inherit;font-size:10pt;">$8,920,000</font><font style="font-family:inherit;font-size:10pt;">, Non - compete agreements of </font><font style="font-family:inherit;font-size:10pt;">$2,700,000</font><font style="font-family:inherit;font-size:10pt;">, Tradenames &amp; Trademarksy of </font><font style="font-family:inherit;font-size:10pt;">$1,000,000</font><font style="font-family:inherit;font-size:10pt;"> and Licenses of </font><font style="font-family:inherit;font-size:10pt;">$760,000</font><font style="font-family:inherit;font-size:10pt;">.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization expense for the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and 2015, was approximately </font><font style="font-family:inherit;font-size:10pt;">$810,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$233,000</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected future amortization of intangible assets as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, is as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:13px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year ending&#160;December 31,</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimated</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expense</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016 (a)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,434</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,156</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,766</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,766</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,091</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,489</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,702</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) Estimated amortization expense for the year ending December 31, 2016, includes only amortization to be recorded after </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Inventories</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories consisted of the following items as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:64%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,127</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">602</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Work in process</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,786</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,850</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,658</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,405</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Inventory, gross</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,571</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,857</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reserve for obsolescence</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(604</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(397</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Inventory, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,967</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,460</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Inventories</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory is valued at the lower of cost or market value. The Company assesses the valuation of its inventory on a periodic basis and makes adjustments to the value for estimated excess and obsolete inventory based on estimates about future demand. The excess balance determined by this analysis becomes the basis for the Company's excess inventory charge. The Company's excess inventory review process includes analysis of sales forecasts, managing product rollovers and working with operations to maximize recovery of excess inventory.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Patent Costs</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company incurs certain legal and related costs in connection with patent applications for tissue-based products and processes. The Company capitalizes such costs to be amortized over the expected life of the patent to the extent that an economic benefit is anticipated from the resulting patent or alternative future use is available to the Company and are included in Intangible Assets in the Condensed Consolidated Balance Sheets.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company considers the applicability and impact of all Accounting Standards Updates ("ASUs") issued both effective and not yet effective. In May 2014, the FASB issued ASU 2014-09, &#8220;Revenue Recognition - Revenue from Contracts with Customers&#8221; (ASU 2014-09) that requires companies to recognize revenue when a customer obtains control rather than when companies have transferred substantially all risks and rewards of a good or service. This update is effective for annual reporting periods beginning on or after December 15, 2017 and interim periods therein and requires expanded disclosures. The Company is currently assessing the impact the adoption of ASU 2014-09 will have on our condensed consolidated financial statements. </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2015, the FASB issued ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes. ASU 2015-17 simplifies the presentation of deferred taxes by requiring deferred tax assets and liabilities be classified as noncurrent on the balance sheet. ASU 2015-17 is effective for public companies for annual reporting periods beginning after December 15, 2016, and interim periods within those fiscal years. The guidance may be adopted prospectively or retrospectively and early adoption is permitted. The Company adopted this standard, prospectively, at the beginning of the fourth quarter 2015 to simplify reporting with the release of the valuation allowance as disclosed in Note 12. Prior periods were not retrospectively adjusted.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from leases.&#160; ASU 2016-02 is effective for public companies for annual reporting periods beginning after December 15, 2018, and interim periods within those fiscal years.&#160; The guidance may be adopted prospectively or retrospectively and early adoption is permitted.&#160; The Company is currently assessing the impact the adoption of ASU 2016-02 will have on its consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718). The standard is intended to simplify several areas of accounting for share - based compensation arrangements, including the income tax impact, classification on the statement of cash flows and forfeitures. This ASU is effective for fiscal years beginning after December 15, 2016. The Company is currently assessing the impact the adoption of ASU 2016-09 will have on its consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All other ASUs issued and not yet effective for the three months ended March 31, 2016, and through the date of this report, were assessed and determined to be either not applicable or are expected to have minimal impact on the Company's financial position or results of operations.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) from interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X.&#160;&#160;Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.&#160;&#160;Changes to GAAP are established by the Financial Accounting Standards Board (&#8220;FASB&#8221;) in the form of Accounting Standards Updates (&#8220;ASU&#8217;&#8217;) to the FASB&#8217;s Accounting Standards Codification (&#8220;ASC&#8221;).&#160;&#160;In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the results of operations for the periods presented have been included.&#160;&#160;Operating results for the </font><font style="font-family:inherit;font-size:10pt;">three months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, are not necessarily indicative of the results that may be expected for the fiscal year.&#160;&#160;The balance sheet at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, has been derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements.&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">You should read these condensed consolidated financial statements together with the historical consolidated financial statements of the Company for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, included in the Company's Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, filed with the SEC on February 29, 2016.&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company operates in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">one</font><font style="font-family:inherit;font-size:10pt;"> business segment, Regenerative Biomaterials, which includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories. The Company's biomaterial platform technologies include tissue technologies, AmnioFix&#174; and EpiFix&#174;, amniotic fluid derived allograft, OrthoFlo, and anticipated device technology, CollaFix&#8482;, which the Company has yet to commercialize. Through the recent acquisition of Stability Inc., our newest proprietary platforms include Physio&#8482;, a unique bone grafting material comprised of 100% bone tissue with no added carrier, thus maximizing bone forming potential, a demineralized bone matrix (DBM) to complement our product portfolio offerings within the Orthopedic market and AlloBurn, a skin product for burns.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Property and Equipment</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> Property and equipment consist of the following as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;31, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;31, <br clear="none"/>2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,233</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,684</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lab and clean room equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,528</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,564</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and office equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,730</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,577</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Construction in progress</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,539</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,629</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Property and equipment, gross</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,030</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,454</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less accumulated depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,907</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,979</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Property and equipment, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,123</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,475</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Included in net property and equipment is approximately </font><font style="font-family:inherit;font-size:10pt;">$427,000</font><font style="font-family:inherit;font-size:10pt;"> of equipment covered under capital leases. The corresponding liability of approximately </font><font style="font-family:inherit;font-size:10pt;">$103,000</font><font style="font-family:inherit;font-size:10pt;"> is included in other liabilities in the accompanying Condensed Consolidated Balance Sheets. Interest rates for these leases range from approximately </font><font style="font-family:inherit;font-size:10pt;">3%</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">12%</font><font style="font-family:inherit;font-size:10pt;"> with maturity dates from September 2016 to January 2018.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Also included is approximately </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;"> in leasehold improvements paid for by the landlord of the Company's main facility with a corresponding liability included in other liabilities which is amortized over the term of the lease.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation expense for the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and 2015, was approximately </font><font style="font-family:inherit;font-size:10pt;">$734,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$354,000</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment consist of the following as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;31, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;31, <br clear="none"/>2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,233</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,684</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lab and clean room equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,528</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,564</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and office equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,730</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,577</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Construction in progress</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,539</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,629</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Property and equipment, gross</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,030</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,454</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less accumulated depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,907</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,979</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Property and equipment, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,123</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,475</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accounts Receivable</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable represent amounts due from customers for which revenue has been recognized. Generally, the Company does not require collateral or any other security to support its receivables.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The allowance for doubtful accounts is the Company&#8217;s best estimate of the amount of probable credit losses in the Company&#8217;s existing receivables. The Company determines the allowance based on factors such as historical collection experience, customers' current creditworthiness, customer concentrations, age of accounts receivable balance and general economic conditions that may affect the customers' ability to pay.&#160;</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company sells its products through a combination of a direct sales force and independent stocking distributors and representatives in the U.S. and independent distributors in international markets. The Company recognizes revenue when title to the goods transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance. In cases where the Company utilizes distributors or ships product directly to the end user, it recognizes revenue upon shipment provided all other revenue recognition criteria have been met. A portion of the Company's revenue is generated from inventory maintained at hospitals, clinics and doctor's offices. For these products, revenue is recognized at the time the product has been used or implanted. The Company records estimated sales returns, discounts and allowances as a reduction of net sales in the same period revenue is recognized.&#160;&#160;</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The actual purchase price has been preliminarily allocated as of March 31, 2016 (in thousands) and is subject to change:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash paid at closing</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,000</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock issued (441,009 shares valued at $9.07 per share)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,346</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assumed debt</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,771</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value of earn - out</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,240</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total fair value of purchase price</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,357</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net assets acquired:</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Debt-free working capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,382</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other assets, net</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">199</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property, plant and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,375</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax liability</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,899</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subtotal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,943</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets:</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer relationships</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,920</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents and know-how</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,230</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trade names and trademarks</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non compete agreements</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,700</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Licenses and permits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">760</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subtotal</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,610</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,690</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Assets Purchased</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,357</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;padding-left:17px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Working capital and other assets were composed of the following (in thousands):</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:83%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Working capital:</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">140</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid Expenses and other current assets</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts Receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,001</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal and state taxes receivable</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,977</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable and accrued expenses</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,864</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Debt-free working capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,382</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current portion of long term debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(194</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term debt</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(560</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Line of credit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(932</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shareholder loan</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(85</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net working capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">611</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other assets:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other long term assets</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">199</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selected cash payments, receipts, and noncash activities are as follows (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:72%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash paid for interest, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income taxes paid</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">139</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">363</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock issuance of 441,009 shares in connection with acquisition </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,346</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock issuance of 20,406 and 11,321 shares in exchange for services performed, respectively</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">173</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">108</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the computation of basic and diluted net income per share (in thousands except share data):</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:75.1953125%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,197</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,087</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Denominator for basic earnings per share - weighted average shares</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105,538,271</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105,820,335</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effect of dilutive securities: Stock options, restricted stock, and warrants outstanding(a)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,501,589</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,818,216</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112,039,860</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">113,638,551</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income per common share - basic </font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.01</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.04</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income per common share - diluted</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.01</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.04</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) Securities outstanding that are included in the computation above, utilizing the treasury stock method are as follows:</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:76.171875%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:61%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding Stock Options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,981,250</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,392,355</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,400</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted Stock Awards</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">520,339</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">383,461</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,501,589</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,818,216</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized stock-based compensation as follows (in thousands):&#160;</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:78.515625%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:64%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">96</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">95</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">205</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">186</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,314</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,652</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,615</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,933</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories consisted of the following items as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:64%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,127</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">602</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Work in process</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,786</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,850</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,658</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,405</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Inventory, gross</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,571</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,857</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reserve for obsolescence</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(604</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(397</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Inventory, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,967</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,460</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Following is a summary of stock options outstanding and exercisable at </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:34%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options Exercisable</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Range of Exercise Prices</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Number outstanding</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Remaining</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contractual Term</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(in years)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercise</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Price</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Number Exercisable</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.50 - $0.76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">441,429</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.72</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">441,429</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.72</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.87 - $1.35</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,431,970</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.19</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,431,970</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.19</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.40 - $2.45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,460,924</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.92</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,460,924</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.92</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$2.66 - $3.99</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">894,120</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.06</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">894,120</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.06</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$4.19 - $6.38</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,426,178</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,897,570</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$6.45 - $9.78</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,512,065</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.9</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.29</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,556,144</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.24</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$9.90- $10.99</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">111,166</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.44</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,326</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.51</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,277,852</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.69</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,714,483</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.24</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Activity with respect to the stock options is summarized as follows:</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:46%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Number</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;of</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercise</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Price</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Remaining</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contractual Term</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(in years)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Aggregate</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intrinsic</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at January 1, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,019,629</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(608,717</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.87</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested options forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(120,563</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.05</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested options expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12,497</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at March 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,277,852</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.69</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67,341,642</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested at March 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,714,483</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,456,036</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested or expected to vest at March 31, 2016 (a)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,210,155</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.67</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67,231,821</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The assumptions used in calculating the fair value of options using the Black-Scholes-Merton option-pricing model are set forth in the following table:</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:69%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/a</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56.8 - 58.1%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected life (in years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/a</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/a</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/a</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.57% - 1.66%</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Activity with respect to restricted stock awards is summarized as follows:&#160; </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:63%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Number </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of<br clear="none"/>Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-Average Grant Date<br clear="none"/> Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested at January 1, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,613,267</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$9.14</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,576,579</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.18</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(644,903</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.42</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(45,263</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.87</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested at March 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,499,680</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$8.84</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Schedule II Valuation and Qualifying Accounts</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="14" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">MIMEDX GROUP, INC. AND SUBSIDIARIES</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS</font></div></td></tr><tr><td colspan="14" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Three Months Ended March 31, 2016 and 2015 (in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at <br clear="none"/>Beginning of Period</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additions charged to Expense or Revenue</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deductions <br clear="none"/>and write-offs</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at<br clear="none"/> End of Period</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the three months ended March 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Allowance for doubtful accounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,270</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">602</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,872</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Allowance for product returns</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,262</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,300</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(911</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,651</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Allowance for obsolescence</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">397</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">235</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">604</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the three months ended March 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Allowance for doubtful accounts</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,750</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">260</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,010</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Allowance for product returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">841</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">709</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(606</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">944</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Allowance for obsolescence</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">527</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">130</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(105</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">552</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected future amortization of intangible assets as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, is as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:13px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year ending&#160;December 31,</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimated</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expense</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016 (a)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,434</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,156</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,766</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,766</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,091</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,489</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,702</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) Estimated amortization expense for the year ending December 31, 2016, includes only amortization to be recorded after </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant Accounting Policies</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Please see Note 2 to the Company's Consolidated Financial Statements included in the Company&#8217;s Form 10-K for the fiscal year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, for a description of all significant accounting policies.&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accounts Receivable</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable represent amounts due from customers for which revenue has been recognized. Generally, the Company does not require collateral or any other security to support its receivables.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The allowance for doubtful accounts is the Company&#8217;s best estimate of the amount of probable credit losses in the Company&#8217;s existing receivables. The Company determines the allowance based on factors such as historical collection experience, customers' current creditworthiness, customer concentrations, age of accounts receivable balance and general economic conditions that may affect the customers' ability to pay.&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Inventories</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory is valued at the lower of cost or market value. The Company assesses the valuation of its inventory on a periodic basis and makes adjustments to the value for estimated excess and obsolete inventory based on estimates about future demand. The excess balance determined by this analysis becomes the basis for the Company's excess inventory charge. The Company's excess inventory review process includes analysis of sales forecasts, managing product rollovers and working with operations to maximize recovery of excess inventory. The value of inventory as of March 31, 2016 includes a fair value step - up connected with the January 2016 acquisition of Stability Inc. of approximately </font><font style="font-family:inherit;font-size:10pt;">$1.6 million</font><font style="font-family:inherit;font-size:10pt;">, which is comprised of approximately </font><font style="font-family:inherit;font-size:10pt;">$2.3 million</font><font style="font-family:inherit;font-size:10pt;"> as of the date of the acquisition less amortization of approximately </font><font style="font-family:inherit;font-size:10pt;">$734,000</font><font style="font-family:inherit;font-size:10pt;"> during the quarter. Please see Note 4 contained herein.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company sells its products through a combination of a direct sales force and independent stocking distributors and representatives in the U.S. and independent distributors in international markets. The Company recognizes revenue when title to the goods transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance. In cases where the Company utilizes distributors or ships product directly to the end user, it recognizes revenue upon shipment provided all other revenue recognition criteria have been met. A portion of the Company's revenue is generated from inventory maintained at hospitals, clinics and doctor's offices. For these products, revenue is recognized at the time the product has been used or implanted. The Company records estimated sales returns, discounts and allowances as a reduction of net sales in the same period revenue is recognized.&#160;&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Acquisitions</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Results of operations of acquired companies are included in the Company&#8217;s results of operations as of the respective acquisition dates. The purchase price of each acquisition is allocated to the net assets acquired based on estimates of their fair values at the date of the acquisition. Any purchase price in excess of these net assets is recorded as goodwill. The allocation of purchase price in certain cases may be subject to revision based on the final determination of fair values during the measurement period, which may be up to one year from the acquisition date.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent consideration is recognized at the estimated fair value on the acquisition date. Subsequent changes to the fair value of contingent payments are recognized in earnings. Contingent payments related to acquisitions consist of an earn out based on sales less direct production costs, and are valued using discounted cash flow techniques. The fair value of these payments is based upon probability-weighted future revenue estimates and increases or decreases as revenue estimates or expectation of timing of payments changes.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Patent Costs</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company incurs certain legal and related costs in connection with patent applications for tissue-based products and processes. The Company capitalizes such costs to be amortized over the expected life of the patent to the extent that an economic benefit is anticipated from the resulting patent or alternative future use is available to the Company and are included in Intangible Assets in the Condensed Consolidated Balance Sheets. The Company capitalized approximately </font><font style="font-family:inherit;font-size:10pt;">$147,000</font><font style="font-family:inherit;font-size:10pt;"> of patent costs during the first three months of </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">. The Company capitalized approximately </font><font style="font-family:inherit;font-size:10pt;">$201,000</font><font style="font-family:inherit;font-size:10pt;"> of patent costs during the first three months of 2015.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Treasury Stock</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company accounts for the purchase of treasury stock under the cost method. Treasury stock which is reissued for the exercise of option grants and the issuance of restricted stock grants is accounted for on a first - in first - out (FIFO) basis.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company considers the applicability and impact of all Accounting Standards Updates ("ASUs") issued both effective and not yet effective. In May 2014, the FASB issued ASU 2014-09, &#8220;Revenue Recognition - Revenue from Contracts with Customers&#8221; (ASU 2014-09) that requires companies to recognize revenue when a customer obtains control rather than when companies have transferred substantially all risks and rewards of a good or service. This update is effective for annual reporting periods beginning on or after December 15, 2017 and interim periods therein and requires expanded disclosures. The Company is currently assessing the impact the adoption of ASU 2014-09 will have on our condensed consolidated financial statements. </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2015, the FASB issued ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes. ASU 2015-17 simplifies the presentation of deferred taxes by requiring deferred tax assets and liabilities be classified as noncurrent on the balance sheet. ASU 2015-17 is effective for public companies for annual reporting periods beginning after December 15, 2016, and interim periods within those fiscal years. The guidance may be adopted prospectively or retrospectively and early adoption is permitted. The Company adopted this standard, prospectively, at the beginning of the fourth quarter 2015 to simplify reporting with the release of the valuation allowance as disclosed in Note 12. Prior periods were not retrospectively adjusted.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from leases.&#160; ASU 2016-02 is effective for public companies for annual reporting periods beginning after December 15, 2018, and interim periods within those fiscal years.&#160; The guidance may be adopted prospectively or retrospectively and early adoption is permitted.&#160; The Company is currently assessing the impact the adoption of ASU 2016-02 will have on its consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718). The standard is intended to simplify several areas of accounting for share - based compensation arrangements, including the income tax impact, classification on the statement of cash flows and forfeitures. This ASU is effective for fiscal years beginning after December 15, 2016. The Company is currently assessing the impact the adoption of ASU 2016-09 will have on its consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All other ASUs issued and not yet effective for the three months ended March 31, 2016, and through the date of this report, were assessed and determined to be either not applicable or are expected to have minimal impact on the Company's financial position or results of operations.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Treasury Stock</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company accounts for the purchase of treasury stock under the cost method. Treasury stock which is reissued for the exercise of option grants and the issuance of restricted stock grants is accounted for on a first - in first - out (FIFO) basis.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Subsequent Events</font></div><div style="line-height:120%;padding-top:8px;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.&#160;</font></div></div> Estimated amortization expense for the year ending December 31, 2016, includes only amortization to be recorded after March 31, 2016. Securities outstanding that are included in the computation above, utilizing the treasury stock method are as follows: Three Months Ended March 31, 2016 2015Outstanding Stock Options5,981,250 7,392,355Outstanding Warrants— 42,400Restricted Stock Awards520,339 383,461 6,501,589 7,818,216 Patents in Process consist of capitalized external legal and other registration costs in connection with internally developed tissue-based patents that are pending. Once issued, the costs associated with a given patent will be included in Patents & Know-How under intangible assets subject to amortization. Includes forfeiture adjusted unvested shares. On January 29, 2007, the Company acquired a license from Shriners Hospitals for Children and University of South Florida Research Foundation, Inc. in the amount of $996,000. Within 30 days after the receipt by the Company of approval by the FDA allowing the sale of the first licensed product, the Company is required to pay an additional $200,000 to the licensor. Due to its contingent nature, this amount is not recorded as a liability. The Company will also be required to pay a royalty of 3% on all commercial sales revenue from the licensed products. The Company is also obligated to pay a $50,000 minimum annual royalty payment over the life of the license. On January 5, 2011, the Company acquired Surgical Biologics, LLC. As a result, the Company recorded intangible assets for Customer & Supplier Relationships of $3,761,000, Patents & Know-How of $7,690,000, Licenses of $13,000, Tradenames & Trademarks of $1,008,000 and In-Process Research & Development of $25,000. For the three months ended March 31, 2016, approximately $1,000 of costs associated with patents granted during the period were capitalized and included in Patents & Know-How subject to amortization. EX-101.SCH 8 mdxg-20160331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2104100 - Disclosure - Acquisition of Stability Inc. link:presentationLink link:calculationLink link:definitionLink 2404404 - Disclosure - Acquisition of Stability Inc. - Intangible Assets Acquired as Part of Acquisition (Details) link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - Acquisition of Stability Inc. - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2404403 - Disclosure - Acquisition of Stability Inc. - Preliminarily Allocation of Purchase Price (Details) link:presentationLink link:calculationLink link:definitionLink 2404405 - Disclosure - Acquisition of Stability Inc. - Pro Forma Information (Details) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - Acquisition of Stability Inc. (Tables) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 2401401 - Disclosure - Basis of Presentation (Details) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) link:presentationLink link:calculationLink link:definitionLink 1001501 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (unaudited) link:presentationLink link:calculationLink link:definitionLink 2117100 - Disclosure - Contractual Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2417402 - Disclosure - Contractual Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 2317301 - Disclosure - Contractual Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - Credit Facility link:presentationLink link:calculationLink link:definitionLink 2411401 - Disclosure - Credit Facility (Details) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 2114100 - Disclosure - Equity link:presentationLink link:calculationLink link:definitionLink 2414402 - Disclosure - Equity (Details) link:presentationLink link:calculationLink link:definitionLink 2314301 - Disclosure - Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 2115100 - Disclosure - Income taxes link:presentationLink link:calculationLink link:definitionLink 2415401 - Disclosure - Income taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - Intangible Assets and Royalty Agreement link:presentationLink link:calculationLink link:definitionLink 2410402 - Disclosure - Intangible Assets and Royalty Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 2310301 - Disclosure - Intangible Assets and Royalty Agreement (Tables) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - Liquidity and Management's Plans link:presentationLink link:calculationLink link:definitionLink 2403401 - Disclosure - Liquidity and Management's Plans (Details) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - Net Income Per Share link:presentationLink link:calculationLink link:definitionLink 2412402 - Disclosure - Net Income Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2312301 - Disclosure - Net Income Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 2409402 - Disclosure - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 2309301 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 2119100 - Schedule - Schedule II - Valuation and Qualifying Accounts link:presentationLink link:calculationLink link:definitionLink 2419401 - Schedule - Schedule II - Valuation and Qualifying Accounts (Details) link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - Short Term Investments link:presentationLink link:calculationLink link:definitionLink 2405401 - Disclosure - Short Term Investments (Details) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2402402 - Disclosure - Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2118100 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 2116100 - Disclosure - Supplemental disclosure of cash flow and non-cash investing and financing activities link:presentationLink link:calculationLink link:definitionLink 2416402 - Disclosure - Supplemental disclosure of cash flow and non-cash investing and financing activities (Details) link:presentationLink link:calculationLink link:definitionLink 2316301 - Disclosure - Supplemental disclosure of cash flow and non-cash investing and financing activities (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 mdxg-20160331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 10 mdxg-20160331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 11 mdxg-20160331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Inventory Disclosure [Abstract] Inventory Schedule of Inventory, Current [Table Text Block] Debt Disclosure [Abstract] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Minimum Minimum [Member] Maximum Maximum [Member] Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Revolving Credit Facility Revolving Credit Facility [Member] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Credit Agreement Credit Agreement [Member] Credit Agreement [Member] Variable Rate [Axis] Variable Rate [Axis] Variable Rate [Domain] Variable Rate [Domain] London Interbank Offered Rate (LIBOR) London Interbank Offered Rate (LIBOR) [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Maximum borrowing capacity (up to) Line of Credit Facility, Maximum Borrowing Capacity Uncommitted incremental facility (up to) Line of Credit Facility, Uncommitted Incremental Facility Line of Credit Facility, Uncommitted Incremental Facility Basis spread on variable rate Debt Instrument, Basis Spread on Variable Rate Debt issuance cost Debt Issuance Costs, Net Debt term Debt Instrument, Term Outstanding line of credit Long-term Line of Credit Raw materials Inventory, Raw Materials, Gross Work in process Inventory, Work in Process, Gross Finished goods Inventory, Finished Goods, Gross Inventory, gross Inventory, Gross Reserve for obsolescence Inventory Valuation Reserves Inventory, net Inventory, Net Commitments and Contingencies Disclosure [Abstract] Estimated Annual Lease, Royalty and Employment Agreement Expenses Contractual Obligation, Fiscal Year Maturity Schedule [Table Text Block] Organization, Consolidation and Presentation of Financial Statements [Abstract] Basis of Presentation Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Supplemental Cash Flow Elements [Abstract] Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Inventories Inventory Disclosure [Text Block] Goodwill and Intangible Assets Disclosure [Abstract] Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Stability Biologics, LLC Stability Biologics, LLC [Member] Stability Biologics, LLC Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Licenses and permits Licensing Agreements [Member] Patents & Know How Patents [Member] Customer relationships Customer Relationships [Member] Tradenames & Trademarks Trade names and trademarks [Member] Rights acquired through registration of a business name to gain or protect exclusive use thereof and rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style. Non compete agreements Noncompete Agreements [Member] In Process Research & Development In Process Research and Development [Member] Patents in Process Patents in Process [Member] Patents in Process Counterparty Name [Axis] Counterparty Name [Axis] Counterparty Name [Domain] Counterparty Name [Domain] Shriners Hospitals for Children and University of South Florida Research Foundation, Inc. Shriners Hospitals For Children And University Of South Florida Research Foundation, Inc. [Member] Shriners Hospitals For Children And University Of South Florida Research Foundation, Inc. [Member] Surgical Biologics, LLC Surgical Biologics [Member] Represents Surgical Biologics, LLC ("Surgical Biologics"), a privately held company headquartered in Kennesaw, Georgia. which the Company acquired through an Agreement and Plan of Merger ("the Merger Agreement") with Membrane Products Holdings, LLC and Ramp Capital Investments, LLC on December 21, 2010. Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Weighted average amortization lives Acquired Finite-lived Intangible Assets, Weighted Average Useful Life Gross carrying value Finite-Lived Intangible Assets, Gross Gross carrying value, indefinite lived Indefinite-Lived Intangible Assets (Excluding Goodwill) Total Intangible Assets, Gross (Excluding Goodwill) Less Accumulated amortization Intangible Assets, Accumulated Amortization And Impairment Charges Intangible Assets, Accumulated Amortization And Impairment Charges Net Intangible Assets, Net (Excluding Goodwill) Acquisition price Payments to Acquire Intangible Assets Maximum time of approval Period of approval, maximum The maximum amount of time the entity has to obtain approval by the FDA to allow the sale of the product. Fair value of earn - out Business Combination, Contingent Consideration, Liability Contingent royalty to be paid to licensor (percent) Contingent royalty to be paid to licensor Royalty payment percentage on all commercial sales revenue from the licensed products. Annual royalty payment Royalty Expense Finite-Lived intangible assets, costs Finite-lived Intangible Assets Acquired Amortization of intangible assets Amortization of Intangible Assets Estimated future amortization expense [Abstract] Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] 2016 Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year 2017 Finite-Lived Intangible Assets, Amortization Expense, Year Two 2018 Finite-Lived Intangible Assets, Amortization Expense, Year Three 2019 Finite-Lived Intangible Assets, Amortization Expense, Year Four 2020 Finite-Lived Intangible Assets, Amortization Expense, Year Five Thereafter Finite-Lived Intangible Assets, Amortization Expense, after Year Five Net book value Finite-Lived Intangible Assets, Net Earnings Per Share [Abstract] Computation of Basic and Diluted Net Income per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Business Combinations [Abstract] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Long-term debt Loans Payable [Member] Line of credit Line of Credit [Member] Shareholder loan Shareholder Debt [Member] Shareholder Debt [Member] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Trade names and trademarks Trademarks and Trade Names [Member] Patents and know-how Business Acquisition [Line Items] Business Acquisition [Line Items] Business Combination, Consideration Transferred [Abstract] Business Combination, Consideration Transferred [Abstract] Cash paid at closing Payments to Acquire Businesses, Gross Common stock issued (441,009 shares valued at $9.07 per share) Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Common stock issued (in shares) Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Common stock issued, price per share (in dollars per share) Business Acquisition, Share Price Assumed debt Business Combination, Consideration Transferred, Liabilities Incurred Total fair value of purchase price Business Combination, Consideration Transferred Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract] Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract] Debt-free working capital Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Debt-free Working Capital Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Debt-free Working Capital Other assets, net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Property, plant and equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Deferred tax liability Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent Subtotal Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets, Net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets, Net Finite-lived intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Indefinite-lived intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets Subtotal Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Goodwill Goodwill Total Assets Purchased Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Cash Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Prepaid Expenses and other current assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets Accounts Receivable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Accounts Receivable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Accounts Receivable Federal and state taxes receivable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Income Taxes Receivable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Income Taxes Receivable Inventory Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Accounts payable and accrued expenses Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable Debt-free working capital Current portion of long term debt Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt Long-term debt Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt Net working capital Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Working Capital Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Working Capital Intangible Assets Activity Summary Schedule of Intangible assets activity [Table Text Block] Tabular disclosure of intangible assets activity, which may be broken down by segment or major class. Estimated Future Amortization Expense for Intangible Assets Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Estimated useful life Finite-Lived Intangible Asset, Useful Life Subsequent Events [Abstract] Subsequent Events Subsequent Events [Text Block] Property, Plant and Equipment [Abstract] Property and Equipment Property, Plant and Equipment Disclosure [Text Block] Estimated annual lease, royalty, and employment agreement expenses [Abstract] Contractual Obligation, Fiscal Year Maturity [Abstract] 2017 Contractual Obligation, Due in Next Fiscal Year 2018 Contractual Obligation, Due in Second Year 2019 Contractual Obligation, Due in Third Year 2020 Contractual Obligation, Due in Fourth Year Thereafter Contractual Obligation, Due after Fifth Year Total Contractual commitments Contractual Obligation Loss Contingencies Loss Contingencies [Table] Litigation Status [Axis] Litigation Status [Axis] Litigation Status [Domain] Litigation Status [Domain] Pending Litigation Pending Litigation [Member] Litigation Case [Axis] Litigation Case [Axis] Litigation Case [Domain] Litigation Case [Domain] Bone Bank Action Bone Bank Action [Member] Bone Bank Action [Member] Liventa Action Liventa Action [Member] Liventa Action [Member] Liventa Action, 701 Patent Liventa Action, 701 Patent [Member] Liventa Action, 701 Patent [Member] Liventa Action, 437 Patent Liventa Action, 437 Patent [Member] Liventa Action, 437 Patent [Member] Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Standby Letters of Credit Standby Letters of Credit [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Sales Revenue, Net Sales Revenue, Net [Member] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Product Concentration Risk Product Concentration Risk [Member] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Lessee expiration period (years) Lessee Leasing Arrangements, Operating Leases, Term of Contract Rent expense Operating Leases, Rent Expense Standby letters of credit Letters of Credit Outstanding, Amount Percentage of revenue Concentration Risk, Percentage Number of patent challenged grounds Loss Contingency, Pending Claims, Number Number of pending disputed claim terms Loss Contingency, Pending Disputed Claim Terms, Number Loss Contingency, Pending Disputed Claim Terms, Number Opinion allowing a review of patent Loss Contingency, Pending Claims, Allowed for Review, Number Loss Contingency Pending Claims Number Allowed for Review Equity [Abstract] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Plan Name [Axis] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] Assumed 2006 Plan Assumed 2006 Plan [Member] Assumed 2006 Plan [Member] Exercise Price Range [Axis] Exercise Price Range [Axis] Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain] Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain] $0.50 - $0.76 Price Range 1 [Member] Price Range 1 [Member] $0.87 - $1.35 Price Range 2 [Member] Price Range 2 [Member] $1.40 - $2.45 Price Range 3 [Member] Price Range 3 [Member] $2.66 - $3.99 Price Range 4 [Member] Price Range 4 [Member] $4.19 - $6.38 Price Range 5 [Member] Price Range 5 [Member] $6.45 - $9.78 Price Range 6 [Member] Price Range 6 [Member] $9.90- $10.99 Price Range 7 [Member] Price Range 7 [Member] Award Type [Axis] Award Type [Axis] Award Type [Domain] Equity Award [Domain] Restricted Stock Awards Restricted Stock [Member] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Cost of Products Sold Cost of Sales [Member] Research and Development Research and Development Expense [Member] Selling, General and Administrative Selling, General and Administrative Expenses [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Number of share-based compensation plans Number of share based compensation plans The number of share-based compensation the company maintains. Outstanding assumed options (in shares) Outstanding assumed options Number of outstanding options assumed by the company. Shares authorized (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Common stock shares issued (in shares) Stock Issued During Period, Shares, Issued for Services Shares issued for services performed Stock Issued During Period, Value, Issued for Services Total unrecognized compensation expense Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options Total unrecognized stock-based compensation related to time-based, nonvested restricted stock Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options Expenses expected to be recognized over a weighted-average period (in years) Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Number of shares [Roll forward] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Outstanding, beginning of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Unvested options forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Vested options expired (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Outstanding, end of period (in shares) Vested at end of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Exercisable options, vested and expected to vest (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Weighted-Average Exercise Price [Roll forward] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Outstanding, weighted average exercise price, beginning of period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Granted, weighted average exercise price (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Exercised, weighted average exercise price (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Unvested options forfeited weighted-average exercise price (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Vested options expired weighted-average exercise price (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Outstanding, weighted average exercise price, end of period (in dollars per share) Vested at end of period weighted average exercise price (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Vested and expected to vest, weighted average exercise price (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Stock options, additional disclosures [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Vested at end of period weighted average remaining contractual term Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Vested and expected to vest, weighted average remaining contractual term Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Outstanding intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Vested at end of period aggregate intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Vested and expected to vest, aggregate intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Exercised options, intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Exercise Price Range, lower range limit (in dollars per share) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit Exercise Price Range, upper range limit (in dollars per share) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit Number of outstanding options (in shares) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options Outstanding Options, weighted average remaining contractual term Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term Outstanding Options, weighted average exercise price (in dollars per share) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price Number of exercisable options (in shares) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options Exercisable Options, weighted average exercise price (in dollars per share) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price Fair value options valuation assumptions [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract] Expected volatility Minimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Expected volatility Maximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Expected life (in years) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Expected dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Risk-free interest rate Minimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Risk-free interest rate Maximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Beginning Balance Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Granted Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Vested Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Forfeited Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Ending Balance Weighted- Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Beginning Balance (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Vested (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Forfeited (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Beginning Balance (in dollars per share) Share-based Compensation [Abstract] Share-based Compensation [Abstract] Share-based compensation expense Allocated Share-based Compensation Expense Authorized share amount for repurchase Stock Repurchase Program, Authorized Amount Stock repurchase (in shares) Treasury Stock, Shares, Acquired Payments for repurchase of common stock, net Payments for Repurchase of Common Stock, Net Payments for Repurchase of Common Stock, Net Brokerage commissions Treasury Stock, Brokerage Commissions Treasury Stock, Brokerage Commissions Shares repurchased, value Payments for Repurchase of Common Stock Remaining authorizations under the repurchase program Stock Repurchase Program, Remaining Authorized Repurchase Amount Shares paid for tax withholding Shares Paid for Tax Withholding for Share Based Compensation Shares reissued from the treasury Stock Issued During Period, Shares, Treasury Stock Reissued Shares reissued from the treasury, value Stock Issued During Period, Value, Treasury Stock Reissued Liquidity and management's plans [Abstract] -- None. No documentation exists for this element. -- Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Total current assets Assets, Current Total current liabilities Liabilities, Current Property and Equipment Property, Plant and Equipment [Table Text Block] Liquidity and Management's Plans Liquidity and management's plans [Text Block] The entire disclosure of management's assessment of funding needs and access to credit facilities to meet cash operational needs in the long term. Scenario [Axis] Scenario [Axis] Scenario, Unspecified [Domain] Scenario, Unspecified [Domain] Pro Forma Pro Forma [Member] Nonrecurring Adjustment [Axis] Nonrecurring Adjustment [Axis] Nonrecurring Adjustment [Domain] Nonrecurring Adjustment [Domain] Fair Value Adjustment to Inventory Fair Value Adjustment to Inventory [Member] Common stock issued Acquisition related costs Business Combination, Acquisition Related Costs Net income Business Acquisition, Pro Forma Net Income (Loss) Activity with respect to the stock options Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Following is a summary of stock options outstanding and exercisable Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block] Assumptions used in calculating the fair value of options using the Black-Scholes-Merton option-pricing model Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Activity with respect to restricted stock awards Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block] Allocation of share-based compensation Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Contractual Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Accounting Policies [Abstract] Increase (decrease) in inventories Increase (Decrease) in Inventories Amortization of inventory fair value step - up Inventory Write-down Intangible assets, net of accumulated amortization Finite-Lived Intangible Assets, Period Increase (Decrease) Schedule of Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Type [Domain] Leasehold improvements Leasehold Improvements [Member] Lab and clean room equipment Equipment [Member] Furniture and office equipment Furniture and Fixtures [Member] Construction in progress Construction in Progress [Member] Assets Held under Capital Leases Assets Held under Capital Leases [Member] Leasehold Improvements Paid by Others Leasehold Improvements Paid by Others [Member] Leasehold Improvements Paid by Others [Member] Property and equipment [Line Items] Property, Plant and Equipment [Line Items] Property and equipment, gross Property, Plant and Equipment, Gross Less accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property and equipment, net Property, Plant and Equipment, Net Other liabilities Other Liabilities, Noncurrent Interest rate for leases, minimum (percent) Capital Leases Interest Rate Effective Percentage Minimum Minimum effective interest rate for the capital lease. Interest rate for leases, maximum (percent) Capital Leases Interest Rate Effective Percentage Maximum Maximum effective interest rate for the capital lease. Depreciation Depreciation Income Tax Disclosure [Abstract] Income Tax Contingency [Table] Income Tax Contingency [Table] Forecast Scenario, Forecast [Member] Income Tax Contingency [Line Items] Income Tax Contingency [Line Items] Effective tax rate Effective Income Tax Rate Reconciliation, Percent Effective income tax rate increase (decrease), amount Effective Income Tax Rate Reconciliation, Increase (Decrease) During Period, Amount Effective Income Tax Rate Reconciliation, Increase (Decrease) During Period, Amount Effective income tax rate increase (decrease), percent Effective Income Tax Rate Reconciliation, Increase (Decrease) During Period, Percent Effective Income Tax Rate Reconciliation, Increase (Decrease) During Period, Percent Change in valuation allowance Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Schedule of Acquisition of Stability Inc. Schedule of Business Acquisitions, by Acquisition [Table Text Block] Finite-Lived and Indefinite-Lived Intangible Assets Acquired Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block] Business Acquisition Pro Forma Information Business Acquisition, Pro Forma Information [Table Text Block] Statement of Cash Flows [Abstract] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Net income Net Income (Loss) Attributable to Parent Adjustments to reconcile net income to net cash from operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Amortization of deferred financing costs Amortization of Debt Issuance Costs and Discounts Share-based compensation Share-based Compensation Increase (decrease) in cash, net of effects of acquisition, resulting from changes in: Increase (Decrease) in Operating Capital [Abstract] Accounts receivable Increase (Decrease) in Accounts Receivable Inventory Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense Other assets Increase (Decrease) in Other Operating Assets Accounts payable Increase (Decrease) in Accounts Payable Accrued compensation Increase (Decrease) in Deferred Compensation Accrued expenses Increase (Decrease) in Accrued Liabilities Other liabilities Increase (Decrease) in Other Operating Liabilities Net cash flows from operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Purchases of equipment Payments to Acquire Machinery and Equipment Purchase of Stability Inc., net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Fixed maturity securities redemption Proceeds from Sale and Maturity of Held-to-maturity Securities Patent application costs Payments for Application Costs, Patent Payments for Application Costs, Patent Net cash flows from investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Proceeds from exercise of stock options Proceeds from Stock Options Exercised Stock repurchase under repurchase plan Stock repurchase for tax withholdings on vesting of restricted stock Payments Related to Tax Withholding for Share-based Compensation Deferred financing costs Payments of Debt Issuance Costs Payments under capital lease obligations Payments to Acquire Equipment on Lease Net cash flows from financing activities Net Cash Provided by (Used in) Financing Activities Net change in cash Cash and Cash Equivalents, Period Increase (Decrease) Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Revenues Business Acquisition, Pro Forma Revenue Income per share, fully diluted (in dollars per share) Business Acquisition, Pro Forma Earnings Per Share, Diluted Intangible Assets and Royalty Agreement Intangible Assets Disclosure [Text Block] Valuation and Qualifying Accounts [Abstract] Valuation and Qualifying Accounts Disclosure [Table] Valuation and Qualifying Accounts Disclosure [Table] Valuation Allowances and Reserves Type [Axis] Valuation Allowances and Reserves Type [Axis] Valuation Allowances and Reserves [Domain] Valuation Allowances and Reserves [Domain] Allowance for doubtful accounts Allowance for Doubtful Accounts [Member] Allowance for product returns Allowance for Sales Returns [Member] Allowance for obsolescence Allowance for Obsolescence [Member] Allowance for Obsolescence [Member] Valuation and Qualifying Accounts Disclosure [Line Items] Valuation and Qualifying Accounts Disclosure [Line Items] Movement in Valuation Allowances and Reserves [Roll Forward] Movement in Valuation Allowances and Reserves [Roll Forward] Balance at Beginning of Period Valuation Allowances and Reserves, Balance Additions charged to Expense or Revenue Valuation Allowances and Reserves, Additions for Charges to Cost and Expense Deductions and write-offs Valuation Allowances and Reserves, Deductions Balance at End of Period Equity Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Significant Accounting Policies Significant Accounting Policies [Text Block] Document and Entity Information [Abstract] -- None. No documentation exists for this element. -- Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Entity Filer Category Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Period Focus Document Type Amendment Flag Document Period End Date Cash paid for interest, net Interest Paid Income taxes paid Income Taxes Paid Stock issuance of 441,009 shares in connection with acquisition Stock Issued During Period, Value, Acquisitions Shares issued in conjunction with acquisition (in shares) Stock Issued During Period, Shares, Acquisitions Stock issuance of 20,406 and 11,321 shares in exchange for services performed, respectively Shares issued for services performed (in shares) Computation of basic and diluted net loss per share [Abstract] Computation of basic and diluted net loss per share [Abstract] -- None. No documentation exists for this element. -- Denominator for basic earnings per share - weighted average shares Weighted Average Number of Shares Outstanding, Basic Effect of dilutive securities: Stock options, restricted stock, and warrants outstanding (in shares) Weighted Average Number Diluted Shares Outstanding Adjustment Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities Weighted Average Number of Shares Outstanding, Diluted Income per common share - basic (in dollars per share) Earnings Per Share, Basic Income per common share - diluted (in dollars per share) Earnings Per Share, Diluted Summary of Antidilutive Securities [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Outstanding Stock Options Employee Stock Option [Member] Outstanding Warrants Warrant [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive securities excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Supplemental disclosure of cash flow and non-cash investing and financing activities Cash Flow, Supplemental Disclosures [Text Block] Statement of Financial Position [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity [Abstract] Stockholders' equity: Stockholders' Equity Attributable to Parent [Abstract] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Common stock, shares authorized (in shares) Common Stock, Shares Authorized Common stock, shares issued (in shares) Common Stock, Shares, Issued Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Treasury stock, shares (in shares) Treasury Stock, Shares Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Accounts Receivable Receivables, Policy [Policy Text Block] Inventories Inventory, Policy [Policy Text Block] Revenue Recognition Revenue Recognition, Sales of Goods [Policy Text Block] Acquisitions Business Combinations Policy [Policy Text Block] Patent Costs Legal Costs, Policy [Policy Text Block] Treasury Stock Stockholders' Equity, Policy [Policy Text Block] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Credit Facility Debt Disclosure [Text Block] Cash and Cash Equivalents [Abstract] Investment [Table] Investment [Table] Investment Type [Axis] Investment Type [Axis] Investments [Domain] Investments [Domain] Certificates of Deposit Certificates of Deposit [Member] Investment [Line Items] Investment [Line Items] Short term investments Short-term Investments Number of business segments Number of Operating Segments ASSETS Assets [Abstract] Current assets: Assets, Current [Abstract] Accounts receivable, net Accounts Receivable, Net, Current Inventory, net Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Total current assets Property and equipment, net of accumulated depreciation Intangible assets, net of accumulated amortization Deferred tax asset, net Deferred Income Tax Assets, Net Deferred financing costs and other assets Deferred Costs and Other Assets Total assets Assets Current liabilities: Liabilities, Current [Abstract] Accounts payable Accounts Payable, Current Accrued compensation Employee-related Liabilities, Current Accrued expenses Accrued Liabilities, Current Other current liabilities Other Liabilities, Current Total current liabilities Earn out liability Business Combination, Contingent Consideration, Liability, Noncurrent Total liabilities Liabilities Commitments and contingencies Commitments and Contingencies Stockholders' equity: Preferred stock; $.001 par value; 5,000,000 shares authorized and 0 shares issued and outstanding Preferred Stock, Value, Issued Common stock; $.001 par value; 150,000,000 shares authorized; 109,539,420 issued and 109,466,073 outstanding at March 31, 2016 and 109,467,416 issued and 107,361,471 outstanding at December 31, 2015 Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital Treasury stock at cost: 73,347 shares at March 31, 2016 and 2,105,945 shares at December 31, 2015 Treasury Stock, Value Accumulated deficit Retained Earnings (Accumulated Deficit) Total stockholders' equity Stockholders' Equity Attributable to Parent Total liabilities and stockholders' equity Liabilities and Equity Schedule II - Valuation and Qualifying Accounts Schedule of Valuation and Qualifying Accounts Disclosure [Text Block] Net Income Per Share Earnings Per Share [Text Block] Acquisition of Stability Inc. Business Combination Disclosure [Text Block] Income taxes Income Tax Disclosure [Text Block] Statement of Stockholders' Equity [Abstract] Statement [Table] Statement [Table] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Common Stock Common Stock [Member] Additional Paid - in Capital Additional Paid-in Capital [Member] Treasury Stock Treasury Stock [Member] Accumulated Deficit Retained Earnings [Member] Statement Statement [Line Items] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Balance, beginning of period Balance (in shares) Shares, Outstanding Share-based compensation expense Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures Exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Exercise of stock options (in shares) Issuance of restricted stock Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Issuance of restricted stock (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Restricted stock shares cancelled/forfeited Stock Issued During Period, Value, Restricted Stock Award, Forfeitures Restricted stock shares cancelled/forfeited (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Forfeited Stock repurchase Treasury Stock, Value, Acquired, Cost Method Shares repurchased for tax withholding Adjustments Related to Tax Withholding for Share-based Compensation Shares repurchased for tax withholding (in shares) Shares issued in conjunction with acquisition Net income Balance, end of period Balance (in shares) Short Term Investments Cash, Cash Equivalents, and Short-term Investments [Text Block] Income Statement [Abstract] Net sales Sales Revenue, Goods, Net Cost of sales Cost of Goods Sold Gross margin Gross Profit Operating expenses: Operating Expenses [Abstract] Research and development expenses Research and Development Expense Selling, general and administrative expenses Selling, General and Administrative Expense Operating income Operating Income (Loss) Other income (expense), net Nonoperating Income (Expense) [Abstract] Interest (expense), net Other Nonoperating Income (Expense) Income before income tax provision Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Income tax provision Income Tax Expense (Benefit) Net income Net income per common share - basic (in dollars per share) Net income per common share - diluted (in dollars per share) Weighted average shares outstanding - basic Weighted average shares outstanding - diluted EX-101.PRE 12 mdxg-20160331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 13 R1.htm IDEA: XBRL DOCUMENT v3.4.0.3
Document and Entity Information - shares
3 Months Ended
Mar. 31, 2016
Apr. 15, 2016
Document and Entity Information [Abstract]    
Entity Registrant Name MIMEDX GROUP, INC.  
Entity Central Index Key 0001376339  
Current Fiscal Year End Date --12-31  
Entity Filer Category Large Accelerated Filer  
Entity Common Stock, Shares Outstanding   109,548,431
Document Fiscal Year Focus 2016  
Document Fiscal Period Focus Q1  
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Mar. 31, 2016  
XML 14 R2.htm IDEA: XBRL DOCUMENT v3.4.0.3
CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($)
$ in Thousands
Mar. 31, 2016
Dec. 31, 2015
Current assets:    
Cash and cash equivalents $ 15,117 $ 28,486
Short term investments 2,500 3,000
Accounts receivable, net 53,882 53,755
Inventory, net 17,967 7,460
Prepaid expenses and other current assets 5,774 3,609
Total current assets 95,240 96,310
Property and equipment, net of accumulated depreciation 12,123 9,475
Goodwill 30,730 4,040
Intangible assets, net of accumulated amortization 33,710 10,763
Deferred tax asset, net 4,940 14,838
Deferred financing costs and other assets 477 487
Total assets 177,220 135,913
Current liabilities:    
Accounts payable 13,059 6,633
Accrued compensation 9,394 15,034
Accrued expenses 5,137 4,644
Other current liabilities 1,252 466
Total current liabilities 28,842 26,777
Earn out liability 33,240 0
Other liabilities 895 1,148
Total liabilities $ 62,977 $ 27,925
Commitments and contingencies
Stockholders' equity:    
Preferred stock; $.001 par value; 5,000,000 shares authorized and 0 shares issued and outstanding $ 0 $ 0
Common stock; $.001 par value; 150,000,000 shares authorized; 109,539,420 issued and 109,466,073 outstanding at March 31, 2016 and 109,467,416 issued and 107,361,471 outstanding at December 31, 2015 109 109
Additional paid-in capital 151,659 163,133
Treasury stock at cost: 73,347 shares at March 31, 2016 and 2,105,945 shares at December 31, 2015 (592) (17,124)
Accumulated deficit (36,933) (38,130)
Total stockholders' equity 114,243 107,988
Total liabilities and stockholders' equity $ 177,220 $ 135,913
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.4.0.3
CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical) - $ / shares
Mar. 31, 2016
Dec. 31, 2015
Stockholders' equity:    
Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
Preferred stock, shares authorized (in shares) 5,000,000 5,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized (in shares) 150,000,000 150,000,000
Common stock, shares issued (in shares) 109,539,420 109,467,416
Common stock, shares outstanding (in shares) 109,466,073 107,361,471
Treasury stock, shares (in shares) 73,347 2,105,945
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.4.0.3
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Income Statement [Abstract]    
Net sales $ 53,367 $ 40,767
Cost of sales 7,946 5,148
Gross margin 45,421 35,619
Operating expenses:    
Research and development expenses 2,496 1,831
Selling, general and administrative expenses 40,648 29,308
Amortization of intangible assets 810 233
Operating income 1,467 4,247
Other income (expense), net    
Interest (expense), net (56) (14)
Income before income tax provision 1,411 4,233
Income tax provision (214) (146)
Net income $ 1,197 $ 4,087
Net income per common share - basic (in dollars per share) $ 0.01 $ 0.04
Net income per common share - diluted (in dollars per share) $ 0.01 $ 0.04
Weighted average shares outstanding - basic 105,538,271 105,820,335
Weighted average shares outstanding - diluted 112,039,860 113,638,551
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.4.0.3
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (unaudited) - 3 months ended Mar. 31, 2016 - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid - in Capital
Treasury Stock
Accumulated Deficit
Balance, beginning of period at Dec. 31, 2015 $ 107,988 $ 109 $ 163,133 $ (17,124) $ (38,130)
Balance (in shares) at Dec. 31, 2015   109,467,416   2,105,945  
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Share-based compensation expense 4,615   4,615    
Exercise of stock options $ 1,138   (3,259) $ 4,397  
Exercise of stock options (in shares) 608,717 72,004   (536,713)  
Issuance of restricted stock     (12,750) $ 12,750  
Issuance of restricted stock (in shares)       (1,576,579)  
Restricted stock shares cancelled/forfeited     378 $ (378)  
Restricted stock shares cancelled/forfeited (in shares)       45,263  
Shares issued for services performed $ 173   4 $ 169  
Shares issued for services performed (in shares) 20,406     (20,406)  
Stock repurchase $ (3,530)     $ (3,530)  
Shares repurchased for tax withholding (684)     $ (684)  
Shares repurchased for tax withholding (in shares)       81,594  
Shares issued in conjunction with acquisition $ 3,346   (462) $ 3,808  
Shares issued in conjunction with acquisition (in shares) 441,009     (441,009)  
Stock repurchase (in shares) 415,252     415,252  
Net income $ 1,197       1,197
Balance, end of period at Mar. 31, 2016 $ 114,243 $ 109 $ 151,659 $ (592) $ (36,933)
Balance (in shares) at Mar. 31, 2016   109,539,420   73,347  
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.4.0.3
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Cash flows from operating activities:    
Net income $ 1,197 $ 4,087
Adjustments to reconcile net income to net cash from operating activities:    
Depreciation 734 354
Amortization of intangible assets 810 233
Amortization of inventory fair value step - up 734 0
Amortization of deferred financing costs 49 0
Share-based compensation 4,615 3,933
Increase (decrease) in cash, net of effects of acquisition, resulting from changes in:    
Accounts receivable 1,874 (4,329)
Inventory (264) 885
Prepaid expenses and other current assets (2,066) (801)
Other assets 209 (26)
Accounts payable (4,265) 1,789
Accrued compensation (5,640) (2,803)
Accrued expenses 493 1,111
Other liabilities 543 (223)
Net cash flows from operating activities (977) 4,210
Cash flows from investing activities:    
Purchases of equipment (2,008) (1,347)
Purchase of Stability Inc., net of cash acquired (7,631) 0
Fixed maturity securities redemption 500 500
Patent application costs (147) (201)
Net cash flows from investing activities (9,286) (1,048)
Cash flows from financing activities:    
Proceeds from exercise of stock options 1,138 1,276
Stock repurchase under repurchase plan (3,530) (12,295)
Stock repurchase for tax withholdings on vesting of restricted stock (684) 0
Deferred financing costs (20) 0
Payments under capital lease obligations (10) (29)
Net cash flows from financing activities (3,106) (11,048)
Net change in cash (13,369) (7,886)
Cash and cash equivalents, beginning of period 28,486 46,582
Cash and cash equivalents, end of period $ 15,117 $ 38,696
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.4.0.3
Basis of Presentation
3 Months Ended
Mar. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) from interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X.  Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.  Changes to GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of Accounting Standards Updates (“ASU’’) to the FASB’s Accounting Standards Codification (“ASC”).  In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the results of operations for the periods presented have been included.  Operating results for the three months ended March 31, 2016 and 2015, are not necessarily indicative of the results that may be expected for the fiscal year.  The balance sheet at December 31, 2015, has been derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements. 
You should read these condensed consolidated financial statements together with the historical consolidated financial statements of the Company for the year ended December 31, 2015, included in the Company's Annual Report on Form 10-K for the year ended December 31, 2015, filed with the SEC on February 29, 2016. 
The Company operates in one business segment, Regenerative Biomaterials, which includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories. The Company's biomaterial platform technologies include tissue technologies, AmnioFix® and EpiFix®, amniotic fluid derived allograft, OrthoFlo, and anticipated device technology, CollaFix™, which the Company has yet to commercialize. Through the recent acquisition of Stability Inc., our newest proprietary platforms include Physio™, a unique bone grafting material comprised of 100% bone tissue with no added carrier, thus maximizing bone forming potential, a demineralized bone matrix (DBM) to complement our product portfolio offerings within the Orthopedic market and AlloBurn, a skin product for burns.
XML 20 R8.htm IDEA: XBRL DOCUMENT v3.4.0.3
Significant Accounting Policies
3 Months Ended
Mar. 31, 2016
Accounting Policies [Abstract]  
Significant Accounting Policies
Significant Accounting Policies
Please see Note 2 to the Company's Consolidated Financial Statements included in the Company’s Form 10-K for the fiscal year ended December 31, 2015, for a description of all significant accounting policies. 
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. 
Accounts Receivable
Accounts receivable represent amounts due from customers for which revenue has been recognized. Generally, the Company does not require collateral or any other security to support its receivables.
The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing receivables. The Company determines the allowance based on factors such as historical collection experience, customers' current creditworthiness, customer concentrations, age of accounts receivable balance and general economic conditions that may affect the customers' ability to pay. 
Inventories
Inventory is valued at the lower of cost or market value. The Company assesses the valuation of its inventory on a periodic basis and makes adjustments to the value for estimated excess and obsolete inventory based on estimates about future demand. The excess balance determined by this analysis becomes the basis for the Company's excess inventory charge. The Company's excess inventory review process includes analysis of sales forecasts, managing product rollovers and working with operations to maximize recovery of excess inventory. The value of inventory as of March 31, 2016 includes a fair value step - up connected with the January 2016 acquisition of Stability Inc. of approximately $1.6 million, which is comprised of approximately $2.3 million as of the date of the acquisition less amortization of approximately $734,000 during the quarter. Please see Note 4 contained herein.


Revenue Recognition
The Company sells its products through a combination of a direct sales force and independent stocking distributors and representatives in the U.S. and independent distributors in international markets. The Company recognizes revenue when title to the goods transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance. In cases where the Company utilizes distributors or ships product directly to the end user, it recognizes revenue upon shipment provided all other revenue recognition criteria have been met. A portion of the Company's revenue is generated from inventory maintained at hospitals, clinics and doctor's offices. For these products, revenue is recognized at the time the product has been used or implanted. The Company records estimated sales returns, discounts and allowances as a reduction of net sales in the same period revenue is recognized.  
Acquisitions
Results of operations of acquired companies are included in the Company’s results of operations as of the respective acquisition dates. The purchase price of each acquisition is allocated to the net assets acquired based on estimates of their fair values at the date of the acquisition. Any purchase price in excess of these net assets is recorded as goodwill. The allocation of purchase price in certain cases may be subject to revision based on the final determination of fair values during the measurement period, which may be up to one year from the acquisition date.

Contingent consideration is recognized at the estimated fair value on the acquisition date. Subsequent changes to the fair value of contingent payments are recognized in earnings. Contingent payments related to acquisitions consist of an earn out based on sales less direct production costs, and are valued using discounted cash flow techniques. The fair value of these payments is based upon probability-weighted future revenue estimates and increases or decreases as revenue estimates or expectation of timing of payments changes.
Patent Costs
The Company incurs certain legal and related costs in connection with patent applications for tissue-based products and processes. The Company capitalizes such costs to be amortized over the expected life of the patent to the extent that an economic benefit is anticipated from the resulting patent or alternative future use is available to the Company and are included in Intangible Assets in the Condensed Consolidated Balance Sheets. The Company capitalized approximately $147,000 of patent costs during the first three months of 2016. The Company capitalized approximately $201,000 of patent costs during the first three months of 2015.
Treasury Stock
The Company accounts for the purchase of treasury stock under the cost method. Treasury stock which is reissued for the exercise of option grants and the issuance of restricted stock grants is accounted for on a first - in first - out (FIFO) basis.
Recent Accounting Pronouncements 
The Company considers the applicability and impact of all Accounting Standards Updates ("ASUs") issued both effective and not yet effective. In May 2014, the FASB issued ASU 2014-09, “Revenue Recognition - Revenue from Contracts with Customers” (ASU 2014-09) that requires companies to recognize revenue when a customer obtains control rather than when companies have transferred substantially all risks and rewards of a good or service. This update is effective for annual reporting periods beginning on or after December 15, 2017 and interim periods therein and requires expanded disclosures. The Company is currently assessing the impact the adoption of ASU 2014-09 will have on our condensed consolidated financial statements.

In November 2015, the FASB issued ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes. ASU 2015-17 simplifies the presentation of deferred taxes by requiring deferred tax assets and liabilities be classified as noncurrent on the balance sheet. ASU 2015-17 is effective for public companies for annual reporting periods beginning after December 15, 2016, and interim periods within those fiscal years. The guidance may be adopted prospectively or retrospectively and early adoption is permitted. The Company adopted this standard, prospectively, at the beginning of the fourth quarter 2015 to simplify reporting with the release of the valuation allowance as disclosed in Note 12. Prior periods were not retrospectively adjusted.
In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from leases.  ASU 2016-02 is effective for public companies for annual reporting periods beginning after December 15, 2018, and interim periods within those fiscal years.  The guidance may be adopted prospectively or retrospectively and early adoption is permitted.  The Company is currently assessing the impact the adoption of ASU 2016-02 will have on its consolidated financial statements.
In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718). The standard is intended to simplify several areas of accounting for share - based compensation arrangements, including the income tax impact, classification on the statement of cash flows and forfeitures. This ASU is effective for fiscal years beginning after December 15, 2016. The Company is currently assessing the impact the adoption of ASU 2016-09 will have on its consolidated financial statements.
All other ASUs issued and not yet effective for the three months ended March 31, 2016, and through the date of this report, were assessed and determined to be either not applicable or are expected to have minimal impact on the Company's financial position or results of operations.
XML 21 R9.htm IDEA: XBRL DOCUMENT v3.4.0.3
Liquidity and Management's Plans
3 Months Ended
Mar. 31, 2016
Liquidity and management's plans [Abstract]  
Liquidity and Management's Plans
Liquidity and Management’s Plans
As of March 31, 2016, the Company had approximately $15,117,000 of cash and cash equivalents.  The Company reported total current assets of approximately $95,240,000 and current liabilities of approximately $28,842,000 as of March 31, 2016.  The Company believes that its anticipated cash from operating and financing activities, existing cash and cash equivalents, short term investments and availability under its line of credit will enable the Company to meet its operational liquidity needs and fund its planned investing activities for the next twelve months.
XML 22 R10.htm IDEA: XBRL DOCUMENT v3.4.0.3
Acquisition of Stability Inc.
3 Months Ended
Mar. 31, 2016
Business Combinations [Abstract]  
Acquisition of Stability Inc.
Acquisition of Stability Inc.

On January 13, 2016, the Company completed the acquisition of Stability Inc., d/b/a Stability Biologics, a provider of human tissue products to surgeons, facilities, and distributors serving the surgical, spine, and orthopedic sectors of the healthcare industry. As a result of this transaction, the Company acquired all of the outstanding shares of Stability in exchange for $6,000,000 cash, $3,346,000 in stock, represented by 441,009 shares of our common stock, and assumed debt of $1,771,000. Additional one time costs incurred in connection with the transaction totaled $713,000. Contingent consideration may be payable in a formula determined by sales less certain expenses for the years 2016 and 2017. As of March 31, 2016, the contingent consideration was valued at $33,240,000 and is shown in the schedule below as fair value of earn-out. The Company used a third party specialist to assist us with the valuation. The contingent consideration was classified as a liability. The Company has evaluated the contingent consideration for accounting purposes under GAAP and has determined that the contingent consideration is within the scope of ASC 480 Distinguishing Liabilities from Equity whereby a financial instrument other than an outstanding share, that embodies a conditional obligation that the issuer may settle by issuing a variable number of its equity shares, shall be classified as a liability if, at inception, the monetary value of the obligation is based solely or predominantly on variations in something other than the fair value of the issuer’s equity shares.

The actual purchase price was based on cash paid, the fair value of our stock on the date of the acquisition, and direct costs associated with the combination. The actual purchase price has been preliminarily allocated as of March 31, 2016 (in thousands) and is subject to change:

 
 
 
Cash paid at closing
 
$
6,000

Common stock issued (441,009 shares valued at $9.07 per share)
 
3,346

Assumed debt
 
1,771

Fair value of earn - out
 
33,240

Total fair value of purchase price
 
$
44,357

 
 
 
Net assets acquired:
 
 
Debt-free working capital
 
$
2,382

Other assets, net
 
199

Property, plant and equipment
 
1,375

Deferred tax liability
 
(9,899
)
Subtotal
 
(5,943
)
Intangible assets:
 
 
Customer relationships
 
8,920

Patents and know-how
 
10,230

Trade names and trademarks
 
1,000

Non compete agreements
 
2,700

Licenses and permits
 
760

Subtotal
 
23,610

Goodwill
 
26,690

Total Assets Purchased
 
$
44,357

 


Working capital and other assets were composed of the following (in thousands):

Working capital:
 
 
Cash
 
$
140

Prepaid Expenses and other current assets
 
100

Accounts Receivable
 
2,001

Federal and state taxes receivable
 
28

Inventory
 
10,977

Accounts payable and accrued expenses
 
(10,864
)
Debt-free working capital
 
$
2,382

 
 
 
Current portion of long term debt
 
$
(194
)
Long-term debt
 
(560
)
Line of credit
 
(932
)
Shareholder loan
 
(85
)
Net working capital
 
$
611

 
 
 
Other assets:
 
 
Other long term assets
 
$
199



The acquisition was accounted for as a purchase business combination as defined by FASB Topic 805 - Business Combinations.
The fair value of the contingent consideration is measured as a Level 3 instrument. The contingent consideration liability is recorded at fair value on the acquisition date and will be remeasured quarterly based on the assessed fair value and adjusted if necessary. The increases or decreases in the fair value of contingent consideration can result from changes in anticipated revenue levels and changes in assumed discount periods and rates. As the fair value measured is based on significant inputs that are not observable in the market, they are categorized as Level 3. The income valuation approach was applied in determining the fair value of the contingent consideration using a discounted cash flow valuation technique with significant unobservable inputs comprised of projected sales and certain expenses. The values assigned to intangible assets are subject to amortization. The intangible assets were assigned the following lives for amortization purposes:


 
Estimated useful
 
life (in years)
Intangible asset:
 
Customer relationships
12
Patents and know-how
20
Trade names and trademarks
indefinite
Non compete agreements
4
Licenses and permits
2


Goodwill consists of the excess of the purchase price paid over the identifiable net assets and liabilities acquired at fair value. Goodwill was determined using the residual method based on an independent appraisal of the assets and liabilities acquired in the transaction and is preliminary as of March 31, 2016 and is subject to change. Goodwill is tested for impairment as defined by FASB Topic 350 - Intangibles - Goodwill and Other.
 
The following unaudited pro forma summary financial information presents the consolidated results of operations as if the acquisition had occurred on January 1, 2015. The pro forma results are shown for illustrative purposes only and do not purport to be indicative of the results that would have been reported if the acquisition had occurred on the date indicated or indicative of the results that may occur in the future.

Unaudited pro forma information for the three months ended March 31, 2016 and 2015 (in thousands) is as follows:
 
Three months ended March 31,
 
2016
2015
Revenues
$
53,915

$
45,921

 
 
 
Net income
$
1,611

$
2,879

 
 
 
Income per share, fully diluted
$
0.01

$
0.03



The 2016 supplemental pro forma earnings were adjusted to exclude $713,000 of acquisition-related legal, audit and other costs, net of tax. The 2015 supplemental pro forma earnings were adjusted to include $577,000 of amortization costs related to recorded intangible assets with defined useful lives, and $1,038,000 of inventory step up charges as a result of the acquisition for comparability to 2016. The shares outstanding used in calculating the income per share for 2015 was adjusted to include 441,009 shares issued as part of the purchase price and assumed to be issued on January 1, 2015.
XML 23 R11.htm IDEA: XBRL DOCUMENT v3.4.0.3
Short Term Investments
3 Months Ended
Mar. 31, 2016
Cash and Cash Equivalents [Abstract]  
Short Term Investments
Short Term Investments
Short term investments consist of approximately $2,500,000 of FDIC insured certificates of deposit held with various financial institutions as of March 31, 2016. Short term investments consisted of approximately $3,000,000 of FDIC insured certificates of deposit at December 31, 2015. The cost of these instruments approximates their fair market value at March 31, 2016 and December 31, 2015.
XML 24 R12.htm IDEA: XBRL DOCUMENT v3.4.0.3
Inventories
3 Months Ended
Mar. 31, 2016
Inventory Disclosure [Abstract]  
Inventories
Inventories
Inventories consisted of the following items as of March 31, 2016, and December 31, 2015 (in thousands):
 
March 31, 2016
 
December 31, 2015
Raw materials
$
1,127

 
$
602

Work in process
4,786

 
3,850

Finished goods
12,658

 
3,405

 Inventory, gross
18,571

 
7,857

Reserve for obsolescence
(604
)
 
(397
)
 Inventory, net
$
17,967

 
$
7,460

XML 25 R13.htm IDEA: XBRL DOCUMENT v3.4.0.3
Property and Equipment
3 Months Ended
Mar. 31, 2016
Property, Plant and Equipment [Abstract]  
Property and Equipment
Property and Equipment 
Property and equipment consist of the following as of March 31, 2016, and December 31, 2015 (in thousands):
 
March 31,
2016
 
December 31,
2015
Leasehold improvements
$
3,233

 
$
2,684

Lab and clean room equipment
7,528

 
4,564

Furniture and office equipment
5,730

 
4,577

Construction in progress
1,539

 
2,629

   Property and equipment, gross
18,030

 
14,454

Less accumulated depreciation
(5,907
)
 
(4,979
)
   Property and equipment, net
$
12,123

 
$
9,475


Included in net property and equipment is approximately $427,000 of equipment covered under capital leases. The corresponding liability of approximately $103,000 is included in other liabilities in the accompanying Condensed Consolidated Balance Sheets. Interest rates for these leases range from approximately 3% to 12% with maturity dates from September 2016 to January 2018.
Also included is approximately $1.0 million in leasehold improvements paid for by the landlord of the Company's main facility with a corresponding liability included in other liabilities which is amortized over the term of the lease.
Depreciation expense for the three months ended March 31, 2016 and 2015, was approximately $734,000 and $354,000, respectively.
XML 26 R14.htm IDEA: XBRL DOCUMENT v3.4.0.3
Intangible Assets and Royalty Agreement
3 Months Ended
Mar. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets and Royalty Agreement
Intangible Assets and Royalty Agreement
Intangible assets are summarized as follows (in thousands):
 
Weighted
Average
Amortization
Lives
 
March 31, 2016
 
December 31, 2015
 
 
 
Cost
 
Cost
Licenses (a) (b) (d)
7 years
 
$
1,769

 
$
1,009

Patents & Know How (b) (d)
19 years
 
18,233

 
8,001

Customer & Supplier Relationships (b) (d)
13 years
 
12,681

 
3,761

Tradenames & Trademarks (b) (d)
indefinite
 
2,008

 
1,008

Non - compete agreements (d)
4 years
 
2,700

 

In Process Research & Development (b)
n/a
 
25

 
25

Patents in Process (c)
n/a
 
1,969

 
1,823

Total
 
 
39,385

 
15,627

Less Accumulated amortization
 
 
(5,675
)
 
(4,864
)
Net
 
 
$
33,710

 
$
10,763

(a)
On January 29, 2007, the Company acquired a license from Shriners Hospitals for Children and University of South Florida Research Foundation, Inc. in the amount of $996,000.  Within 30 days after the receipt by the Company of approval by the FDA allowing the sale of the first licensed product, the Company is required to pay an additional $200,000 to the licensor.  Due to its contingent nature, this amount is not recorded as a liability. The Company will also be required to pay a royalty of 3% on all commercial sales revenue from the licensed products. The Company is also obligated to pay a $50,000 minimum annual royalty payment over the life of the license.
(b)
On January 5, 2011, the Company acquired Surgical Biologics, LLC.  As a result, the Company recorded intangible assets for Customer & Supplier Relationships of $3,761,000, Patents & Know-How of $7,690,000, Licenses of $13,000, Tradenames & Trademarks of $1,008,000 and In-Process Research & Development of $25,000. For the three months ended March 31, 2016, approximately $1,000 of costs associated with patents granted during the period were capitalized and included in Patents & Know-How subject to amortization.
(c)
Patents in Process consist of capitalized external legal and other registration costs in connection with internally developed tissue-based patents that are pending. Once issued, the costs associated with a given patent will be included in Patents & Know-How under intangible assets subject to amortization.
(d)
On January 13, 2016, the Company acquired Stability Inc. As a result, the Company recorded intangible assets for Patents & Know - How of $10,230,000, Customer Relationships of$8,920,000, Non - compete agreements of $2,700,000, Tradenames & Trademarksy of $1,000,000 and Licenses of $760,000.
Amortization expense for the three months ended March 31, 2016 and 2015, was approximately $810,000 and $233,000, respectively.
Expected future amortization of intangible assets as of March 31, 2016, is as follows (in thousands):
Year ending December 31,
Estimated
Amortization
Expense
2016 (a)
$
2,434

2017
3,156

2018
2,766

2019
2,766

2020
2,091

Thereafter
18,489

 
$
31,702

(a) Estimated amortization expense for the year ending December 31, 2016, includes only amortization to be recorded after March 31, 2016.
XML 27 R15.htm IDEA: XBRL DOCUMENT v3.4.0.3
Credit Facility
3 Months Ended
Mar. 31, 2016
Debt Disclosure [Abstract]  
Credit Facility
Credit Facility

On October 12, 2015, the Company and its subsidiaries entered into a Credit Agreement (the "Credit Agreement") with certain lenders and Bank of America, N.A., as administrative agent. The Credit Agreement establishes a senior secured revolving credit facility in favor of the Company with a maturity date of October 12, 2018 and an aggregate lender commitment of up to $50 million. The Credit Agreement also provides for an uncommitted incremental facility of up to $35 million, which can be exercised as one or more revolving commitment increases or new term loans, all subject to certain customary terms and conditions set forth in the Credit Agreement. Borrowings under the facility will bear interest at LIBOR plus 1.5% to 2.25%.  Fees paid in connection with the initiation of the credit facility totaled approximately $500,000.  These deferred financing costs are being amortized to interest expense over the three-year life of the facility. The Credit Agreement contains customary representations, warranties, covenants, and events of default. As of March 31, 2016, there were no outstanding revolving loans under the credit facility.
XML 28 R16.htm IDEA: XBRL DOCUMENT v3.4.0.3
Net Income Per Share
3 Months Ended
Mar. 31, 2016
Earnings Per Share [Abstract]  
Net Income Per Share
Net Income Per Share
Basic net income per common share is computed using the weighted-average number of common shares outstanding during the period.  Diluted net income per common share is computed using the weighted-average number of common and dilutive common equivalent shares from stock options, restricted stock, and warrants using the treasury stock method. 
The following table sets forth the computation of basic and diluted net income per share (in thousands except share data):
 
Three Months Ended March 31,
 
2016
 
2015
Net income
$
1,197

 
$
4,087

Denominator for basic earnings per share - weighted average shares
105,538,271

 
105,820,335

Effect of dilutive securities: Stock options, restricted stock, and warrants outstanding(a)
6,501,589

 
7,818,216

Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities
112,039,860

 
113,638,551

Income per common share - basic
$
0.01

 
$
0.04

Income per common share - diluted
$
0.01

 
$
0.04

(a) Securities outstanding that are included in the computation above, utilizing the treasury stock method are as follows:
 
Three Months Ended March 31,
 
2016
 
2015
Outstanding Stock Options
5,981,250

 
7,392,355

Outstanding Warrants

 
42,400

Restricted Stock Awards
520,339

 
383,461

 
6,501,589

 
7,818,216

XML 29 R17.htm IDEA: XBRL DOCUMENT v3.4.0.3
Equity
3 Months Ended
Mar. 31, 2016
Equity [Abstract]  
Equity
Equity
Stock Incentive Plans 
The Company has three share-based compensation plans: the MiMedx Group, Inc. Assumed 2006 Stock Incentive Plan (the “Assumed 2006 Plan”), the MiMedx Inc. 2007 Assumed Stock Plan (the “Assumed 2007 Plan”) and the MiMedx Group Inc. Amended and Restated Assumed 2005 Stock Plan (the “Assumed 2005 Plan”) which provide for the granting of qualified incentive and non-qualified stock options, stock appreciation awards and restricted stock awards to employees, directors, consultants and advisors. The awards are subject to a vesting schedule as set forth in each individual agreement. The Company intends to use only the Assumed 2006 Plan to make future grants. The number of assumed options under the Assumed 2005 Plan and Assumed 2007 Plan outstanding at March 31, 2016 totaled 70,000. The maximum number of shares of common stock that can be issued under the Assumed 2006 Plan was 26,500,000 at March 31, 2016.
During the three months ended March 31 2016, 20,406 shares of common stock valued at approximately $173,000 were issued under the Assumed 2006 Plan to a consultant in return for services performed.
Activity with respect to the stock options is summarized as follows:
 
Number
 of
Shares
 
Weighted-
Average
Exercise
Price
 
Weighted-Average
Remaining
Contractual Term
(in years)
 
Aggregate
Intrinsic
Value
Outstanding at January 1, 2016
14,019,629

 
$
3.62

 
 
 
 
Granted

 
$

 
 
 
 
Exercised
(608,717
)
 
$
1.87

 
 
 
 
Unvested options forfeited
(120,563
)
 
$
6.05

 
 
 
 
Vested options expired
(12,497
)
 
$
6.34

 
 
 
 

Outstanding at March 31, 2016
13,277,852

 
$
3.69

 
6.3
 
$
67,341,642

Vested at March 31, 2016
11,714,483

 
$
3.24

 
6.1
 
$
64,456,036

Vested or expected to vest at March 31, 2016 (a)
13,210,155

 
$
3.67

 
6.3
 
$
67,231,821


(a)
Includes forfeiture adjusted unvested shares.
The intrinsic value of the options exercised during the three months ended March 31, 2016, was approximately $4,440,694
Following is a summary of stock options outstanding and exercisable at March 31, 2016:
 
Options Outstanding
 
Options Exercisable
Range of Exercise Prices
Number outstanding
 
Weighted-Average
Remaining
Contractual Term
(in years)
 
Weighted-
Average
Exercise
Price
 
Number Exercisable
 
Weighted-
Average
Exercise Price
$0.50 - $0.76
441,429

 
3.2
 
$
0.72

 
441,429

 
$
0.72

$0.87 - $1.35
4,431,970

 
5.4
 
1.19

 
4,431,970

 
1.19

$1.40 - $2.45
1,460,924

 
4.7
 
1.92

 
1,460,924

 
1.92

$2.66 - $3.99
894,120

 
6.6
 
3.06

 
894,120

 
3.06

$4.19 - $6.38
3,426,178

 
7.2
 
5.35

 
2,897,570

 
5.26

$6.45 - $9.78
2,512,065

 
7.9
 
7.29

 
1,556,144

 
7.24

$9.90- $10.99
111,166

 
8.6
 
10.44

 
32,326

 
10.51

 
13,277,852

 
6.3
 
$
3.69

 
11,714,483

 
$
3.24

 
Total unrecognized compensation expense related to granted stock options at March 31, 2016, was approximately $4,501,863 and will be charged to expense ratably over a weighted average period through April 2017. 
The fair value of options granted by the Company is estimated on the date of grant using the Black-Scholes-Merton option-pricing model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate.  Expected volatilities are based on historical volatility of peer companies and other factors estimated over the expected term of the options.  The term of employee options granted is derived using the “simplified method,” which computes expected term as the mid point between the weighted average time to vesting and the contractual maturity. The simplified method was used due to the Company's lack of sufficient historical data to provide a reasonable basis upon which to estimate the expected term due to the limited period of time its equity shares have been publicly traded.  The term for non-employee options is generally based upon the contractual term of the option.  The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term or contractual term as described.
The assumptions used in calculating the fair value of options using the Black-Scholes-Merton option-pricing model are set forth in the following table:
 
Three Months Ended March 31,
 
2016
 
2015
Expected volatility
n/a
 
56.8 - 58.1%

Expected life (in years)
n/a
 
6.0

Expected dividend yield
n/a
 

Risk-free interest rate
n/a
 
1.57% - 1.66%


Their were no options granted during the three months ended March 31, 2016.
Restricted Stock Awards                                                    
Activity with respect to restricted stock awards is summarized as follows: 
 
Number
of
Shares
 
Weighted-Average Grant Date
Fair Value
Unvested at January 1, 2016
2,613,267

 
$9.14
Granted
1,576,579

 
8.18
Vested
(644,903
)
 
8.42
Forfeited
(45,263
)
 
8.87

Unvested at March 31, 2016
3,499,680

 
$8.84

As of March 31, 2016, there was approximately $24,965,395 of total unrecognized stock-based compensation related to time-based, nonvested restricted stock.  That expense is expected to be recognized on a straight-line basis over a weighted-average period of 2.3 years, which approximates the remaining vesting period of these grants. All shares noted above as unvested are considered issued and outstanding at March 31, 2016.
For the three months ended March 31, 2016 and 2015, the Company recognized stock-based compensation as follows (in thousands): 
 
Three Months Ended March 31,
 
2016
 
2015
Cost of sales
$
96

 
$
95

Research and development
205

 
186

Selling, general and administrative
4,314

 
3,652

 
$
4,615

 
$
3,933




Treasury Stock
On May 12, 2014, our Board of Directors authorized the repurchase of up to $10 million of our common stock from time to time, through December 31, 2014. The Board subsequently extended the program until December 31, 2016. In December 2014, the Board increased the authorization to $20 million and further increased the authorization in 2015 to $60 million. The timing and amount of repurchases will depend upon the Company's stock price, economic and market conditions, regulatory requirements, and other corporate considerations. The Company may initiate, suspend or discontinue purchases under the stock repurchase program at any time.
For the three months ended March 31, 2016, the Company purchased 415,252 shares of its common stock for a purchase price of approximately $3,518,000, before brokerage commissions of approximately $12,000 bringing the total amount spent under the program to approximately $49,244,000 since inception. As of March 31, 2016, the Company had approximately $10,756,000 remaining under the repurchase program. In addition, the Company purchased during the quarter 81,594 shares surrendered by employees to satisfy tax withholding obligations upon vesting of restricted stock.
Additionally, for the three months ended March 31, 2016, the Company reissued 2,529,444 shares from the Treasury for common and restricted stock grants and stock option exercises, net of forfeitures, and the acquisition of Stability Inc. with an aggregate carrying value of approximately $20,746,000.
XML 30 R18.htm IDEA: XBRL DOCUMENT v3.4.0.3
Income taxes
3 Months Ended
Mar. 31, 2016
Income Tax Disclosure [Abstract]  
Income taxes
Income taxes 

The effective tax rates for continuing operations of 15.2% and 3.40% for the three months ended March 31, 2016 and March 31, 2015, respectively, were determined using an estimated annual effective tax rate and includes in 2016 the impact of a discrete item of approximately $350,000. The effective tax rate increased 11.8% when compared to the same period of 2015, primarily due to the $15.4 million valauation allowance release recorded in 2015 and discussed in our annual report on Form 10-K for the year ended December 31, 2015. Due to the valuation allowance previously recorded against the Company's U.S. deferred tax assets, the effective tax rate for the three months ended March 31, 2015, did not include the expense of the current period U.S. taxable income. As of the end of March 2016, the projected annual effective tax rate for 2016 is 40.4%.
XML 31 R19.htm IDEA: XBRL DOCUMENT v3.4.0.3
Supplemental disclosure of cash flow and non-cash investing and financing activities
3 Months Ended
Mar. 31, 2016
Supplemental Cash Flow Elements [Abstract]  
Supplemental disclosure of cash flow and non-cash investing and financing activities
Supplemental disclosure of cash flow and non-cash investing and financing activities:
    
Selected cash payments, receipts, and noncash activities are as follows (in thousands):
 
Three Months Ended March 31,
 
2016
 
2015
Cash paid for interest, net
$
56

 
$
14

Income taxes paid
139

 
363

Stock issuance of 441,009 shares in connection with acquisition
3,346

 

Stock issuance of 20,406 and 11,321 shares in exchange for services performed, respectively
173

 
108

XML 32 R20.htm IDEA: XBRL DOCUMENT v3.4.0.3
Contractual Commitments and Contingencies
3 Months Ended
Mar. 31, 2016
Commitments and Contingencies Disclosure [Abstract]  
Contractual Commitments and Contingencies
Contractual Commitments and Contingencies
Contractual Commitments
In addition to the capital leases noted above in Note 7, the Company has entered into operating lease agreements for facility space and equipment. These leases expire over the next six years and generally contain renewal options. The Company anticipates that most of these leases will be renewed or replaced upon expiration. The Company also has commitments for meeting space and to various charitable organizations. The estimated annual lease payments, meeting space and charitable organization commitments are as follows (in thousands):
12-month period ended March 31
2017
$
2,998

2018
2,246

2019
2,199

2020
1,742

Thereafter
765

 
$
9,950



Rent expense for the three months ended March 31, 2016 and 2015, was approximately $423,000 and $284,000, respectively, and is allocated among cost of sales, research and development, and selling, general and administrative expenses.

Letters of Credit
As a condition of the lease for the Company's main facility, the Company is obligated under standby letters of credit in the amount of approximately $235,000. These obligations are reduced at various times over the life of the lease.


FDA Untitled Letter, Draft Guidance and Related Litigation
FDA Untitled Letter and Draft Guidance

On August 28, 2013, the FDA issued an Untitled Letter alleging that the Company's micronized allografts do not meet the criteria for regulation solely under Section 361 of the Public Health Service Act and that, as a result, MiMedx would need a biologics license to lawfully market those micronized products. Since the issuance of the Untitled Letter, the Company has been in discussions with the FDA to communicate its disagreement with the FDA's assertion that the Company's allografts are more than minimally manipulated. To date, the FDA has not changed its position that the Company's micronized products are not eligible for marketing solely under Section 361 of the Public Health Service Act, but discussions are continuing. The Company continues to market its micronized products but is also pursuing the Biologics License Application (“BLA”) process for certain of its micronized products.

On December 22, 2014, the FDA issued for comment “Draft Guidance for Industry and FDA Staff: Minimal Manipulation of Human Cells, Tissues, and Cellular and Tissue-Based Products.” Essentially the Minimal Manipulation draft guidance takes the same position with respect to micronized amniotic tissue that it took in the Untitled Letter to MiMedx 16 months earlier. The Company submitted comments asserting that the Minimal Manipulation draft guidance represents agency action that goes far beyond the FDA’s statutory authority, is inconsistent with existing HCT/P regulations and the FDA’s prior positions, and is internally inconsistent and scientifically unsound. On October 28, 2015, the FDA issued for comment, "Draft Guidance for Industry and FDA Staff: Homologous Use of Human Cells, Tissues, and Cellular and Tissue-Based Products." The Company submitted comments on this Homologous Use draft guidance. The FDA has indicated that it will hold a public hearing on September 12 and 13, 2016 to obtain input on the Homologous Use draft guidance and the previously released Minimal Manipulation draft guidance, as well as other recently issued guidance documents on HCT/Ps. The hearing was originally scheduled for April 13, 2016, but was rescheduled to allow stakeholders additional time to provide comments due to the considerable interest in the hearing. The Company has requested an opportunity to speak at the rescheduled hearing.

If the FDA does allow the Company to continue to market a micronized form of its sheet allografts without a biologics license either prior to or after finalization of the draft guidance documents, it may impose conditions, such as labeling restrictions and compliance with cGMP. Although the Company is preparing for these requirements in connection with its pursuit of a BLA for certain of its micronized products, earlier compliance with these conditions would require significant additional time and cost investments by the Company. It is also possible that the FDA will not allow the Company to market any form of a micronized product without a biologics license even prior to finalization of the draft guidance documents and could even require the Company to recall its micronized products. Revenues from micronized products comprised approximately 12% of the Company's revenues for fiscal-year 2015.

Related Litigation



Following the publication of the Untitled Letter from the FDA regarding the Company’s micronized products in September 2013, the trading price of the Company’s stock declined and several putative shareholder class action lawsuits were filed against the Company and certain of its executive officers asserting violations of the Securities Exchange Act of 1934. The cases were consolidated in the United States District Court for the Northern District of Georgia. On November 17, 2015, the parties entered into a stipulation of settlement to settle the consolidated case in its entirety. The stipulation of settlement was filed with the Court on November 18, 2015 and preliminarily approved by the Court on November 19, 2015. The final settlement hearing was held on April 5, 2016 and the Court approved the settlement. The Company does not believe the terms of the settlement will have a material adverse effect on its operating results or financial condition.
Patent Litigation
MiMedx continues to diligently enforce its intellectual property against several entities. Currently, there are four actions pending, as described below:

The Liventa Action

First, there is an action pending against several entities in the in the United States District Court for the Northern District of Georgia, i.e., “the Liventa Action”. On April 22, 2014, the Company filed a patent infringement lawsuit against Liventa Bioscience, Inc. ("Liventa"), Medline Industries, Inc. ("Medline") and Musculoskeletal Transplant Foundation, Inc. ("MTF") for permanent injunctive relief and unspecified damages. In addition to the allegations of infringement of MiMedx's patents, the lawsuit asserts that Liventa and Medline knowingly and willfully made false and misleading representations about their respective products to providers, patients, and in some cases, prospective investors. The Liventa Action was filed in the United States District Court for the Northern District of Georgia.

MiMedx asserts that Liventa (formerly known as AFCell Medical, Inc.), Medline and MTF infringed and continue to infringe certain of the Company's patents relating to the MiMedx dehydrated human amnion/chorion membrane ("dHACM") allografts. MTF is the tissue processor while Liventa and Medline are the distributors of the allegedly infringing products. On May 30, 2014, defendants filed answers to the Complaint, denying the allegations in the Complaint. They also raised affirmative defenses of non-infringement, invalidity, laches and estoppel. MTF and Medline also filed counterclaims seeking declaratory judgments of non-infringement and invalidity.

On June 30, 2014, fact discovery began and the parties have engaged in extensive fact discovery.

MiMedx served Infringement Contentions on August 29, 2014, and Defendants served Invalidity Contentions and Responses to Infringement Contentions on September 29, 2014. After a protracted series of meet and confers, MiMedx required Defendants to supplement their invalidity contentions in view of parallel Inter Partes Review ("IPR")(see further discussion, infra) proceedings. MTF complied on June 26, 2015.

In September 2015, the Defendants filed a renewed Motion to Stay in light of the Patent Trial and Appeal Board's ("PTAB") decisions to institute IPRs on the ’437 and ’687 Patents, seeking a partial stay of the litigation as to the ’437, ’687, and ’494 Patents (i.e., the ’437 Patent family). MiMedx opposed the Motion to Stay with respect to the ’494 Patent and once again successfully defeated Defendants’ motion to stay.

Claim Construction proceedings began in October 2014. The parties submitted proposed constructions for key terms for the ’701, ’092, ’437, ’687, ’207, and ’494 Patents. Briefing was completed in March 2015.

On December 22, 2015, a Markman Hearing was held before Special Master Sumner C. Rosenberg. Over thirty disputed claim terms were at issue. One week later, on December 30, 2015, the Special Master issued its Report and Recommendation. Except for one term, the Special Master’s Report essentially adopted MiMedx’s proposed constructions. The parties are awaiting a final Court decision pending their respective objections. On March 9, 2016, the Court adopted the Special Master’s Report. Since then the Court has entered a scheduling order in this action.  Notably, fact discovery is set to close on May 25, 2016. Expert discovery begins in June 2016 and is expected to close in early September 2016.

The Bone Bank Action

On May 16, 2014, the Company also filed a patent infringement lawsuit against Transplant Technology, Inc. d/b/a Bone Bank Allografts ("Bone Bank") and Texas Human Biologics, Ltd. ("Biologics") for permanent injunctive relief and unspecified damages (the "Bone Bank Action"). The Bone Bank Action was filed in the United States District Court for the Western District of Texas. This lawsuit similarly asserts that Bone Bank and Biologics infringed certain of the Company's patents through the manufacturing and sale of their placental-derived tissue graft products. On July 10, 2014, defendants filed an answer to the Complaint, denying the allegations in the Complaint. They also raised affirmative defenses of non-infringement and invalidity and filed counterclaims seeking declaratory judgments of non-infringement and invalidity. The Bone Bank Action is in an advanced stage. The parties have (i) substantially completed document production; (ii) taken several fact depositions (both party and non-party); and (iii) completed claim construction briefing. The Markman hearing in this case was held on October 2, 2015. Except for one term, the Court adopted MiMedx’s proposed construction of the disputed terms. The parties have submitted a proposed scheduling order to the Court and are awaiting the Court’s order in this regard. Meanwhile, the parties continue with fact discovery in view of recent depositions.

The NuTech Action

On March 2, 2015, the Company filed a patent infringement lawsuit against NuTech Medical, Inc. ("NuTech") and DCI Donor Services, Inc. ("DCI") for permanent injunctive relief and unspecified damages. This lawsuit was filed in the United States District Court for the Northern District of Alabama. The lawsuit alleges that NuTech and DCI have infringed and continue to infringe the Company's patents through the manufacture, use, sale, and/or offering of their tissue graft product. The lawsuit also asserts that NuTech knowingly and willfully made false and misleading representations about its products to customers and/or prospective customers.

On April 17, 2015, NuTech filed a motion to dismiss the case purportedly for lack of patentable subject matter, which the Company opposed. NuTech also filed a motion to stay the case pending disposition of the motion to dismiss, which MiMedx also opposed, and on which the Court declined to rule. Hearing on the motion to dismiss occurred on August 20, 2015. On November 24, 2015, the court ruled on NuTech’s Motion to Dismiss, granting in part, and denying in part. MiMedx still has claims against NuTech for infringement of the ‘494 and ‘687 patents, as well as violations of the Lanham Act; these claims shall proceed.

On December 30, 2015, the parties submitted a Joint Rule 26(f) Report of Parties’ Planning Meeting and Proposed Case Management Order to the Court. In the Report, the parties requested that the Court stay the proceedings with respect to the ’687 patent pending the completion of the inter partes review on that patent.

On January 8, 2016, MiMedx served its infringement contentions. Judge Hopkins entered the parties’ Case Management Order and granted the parties’ request to stay proceedings with respect to the ’687 patent pending the completion of the inter partes review. 

On January 8, 2016, the parties submitted their Initial Disclosures, and MiMedx submitted its preliminary infringement contentions.  On March 14, 2016, Defendants submitted their preliminary invalidity contentions.  On April 15, 2016, the parties exchanged proposed terms for construction and over the next several months the parties will engage in claim construction briefing. Discovery is ongoing.

 The Vivex Action

On April 1, 2016, the Company also filed a patent infringement lawsuit against Vivex BioMedical (“Vivex”) for permanent injunctive relief and unspecified damages (the "Vivex Action").  The lawsuit was filed in the United States District Court for the Northern District of Georgia. The patent at issue is the ’494 patent.

Pending IPRs

In addition to defending the claims in the pending district court litigations, defendants in the Liventa and Bone Bank cases have challenged certain of the Company's patents in several IPR proceedings to avoid the high burden of proof of proving invalidity by "clear and convincing evidence" in the district court litigations. An inter partes review (or "IPR") is a request for a specialized group within the United States Patent and Trademark Office to review the validity of a plaintiff's patent claims. The defendants in the Bone Bank Action have challenged the validity of the Company's 8,597,687 and 8,709,494 patents (the "'687" and "'494" patents, respectively); while the defendants in the Liventa Action have challenged the validity of the Company's 8,372,437 and 8,323,701 patents (the "'437" and "'701" patents, respectively).

On June 29, 2015, the Patent Trial and Appeals Board ("PTAB") denied defendants' request for institution of an IPR with respect to the '494 patent on all seven challenged grounds. On August 18, 2015, the PTAB also denied defendants' request for institution of an IPR with respect to the '701 patent on all six challenged grounds. That is, the PTAB decided in each case that the defendants failed to establish a reasonable likelihood that defendants would prevail in showing any of the challenged claims of the '494 or the '701 patent were unpatentable.

On July 10, 2015 the PTAB issued an opinion allowing a review of the '687 patent to proceed, although on only two of the five challenged grounds. The PTAB also adopted MiMedx's construction of the claims which will govern the Board's review of the '687 patent. The parties decided to forego oral arguments. A decision is expected no later than July 10, 2016.  On August 18, 2015, the PTAB issued an opinion allowing a review of the '437 patent to proceed, although only on one of the seven challenged grounds. Briefing and expert discovery is ongoing.  Oral argument is scheduled for April 26, 2016.  A decision is expected no later than August of 2016.
XML 33 R21.htm IDEA: XBRL DOCUMENT v3.4.0.3
Subsequent Events
3 Months Ended
Mar. 31, 2016
Subsequent Events [Abstract]  
Subsequent Events
Subsequent Events
None
XML 34 R22.htm IDEA: XBRL DOCUMENT v3.4.0.3
Schedule II - Valuation and Qualifying Accounts
3 Months Ended
Mar. 31, 2016
Valuation and Qualifying Accounts [Abstract]  
Schedule II - Valuation and Qualifying Accounts
Schedule II Valuation and Qualifying Accounts
MIMEDX GROUP, INC. AND SUBSIDIARIES
SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS
 Three Months Ended March 31, 2016 and 2015 (in thousands)
 
 
 
 
 
 
 
 
Balance at
Beginning of Period
Additions charged to Expense or Revenue
Deductions
and write-offs
Balance at
End of Period
For the three months ended March 31, 2016
 
 
 
 
 
 Allowance for doubtful accounts
 
$
3,270

$
602

$

$
3,872

 Allowance for product returns
 
1,262

1,300

(911
)
1,651

 Allowance for obsolescence
 
397

235

(28
)
604

 
 
 
 
 
 
For the three months ended March 31, 2015
 
 
 
 
 
 Allowance for doubtful accounts
 
$
1,750

260

$

$
2,010

 Allowance for product returns
 
841

709

(606
)
944

 Allowance for obsolescence
 
527

130

(105
)
552

XML 35 R23.htm IDEA: XBRL DOCUMENT v3.4.0.3
Significant Accounting Policies (Policies)
3 Months Ended
Mar. 31, 2016
Accounting Policies [Abstract]  
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) from interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X.  Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.  Changes to GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of Accounting Standards Updates (“ASU’’) to the FASB’s Accounting Standards Codification (“ASC”).  In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the results of operations for the periods presented have been included.  Operating results for the three months ended March 31, 2016 and 2015, are not necessarily indicative of the results that may be expected for the fiscal year.  The balance sheet at December 31, 2015, has been derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements. 
You should read these condensed consolidated financial statements together with the historical consolidated financial statements of the Company for the year ended December 31, 2015, included in the Company's Annual Report on Form 10-K for the year ended December 31, 2015, filed with the SEC on February 29, 2016. 
Use of Estimates
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. 
Accounts Receivable
Accounts Receivable
Accounts receivable represent amounts due from customers for which revenue has been recognized. Generally, the Company does not require collateral or any other security to support its receivables.
The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing receivables. The Company determines the allowance based on factors such as historical collection experience, customers' current creditworthiness, customer concentrations, age of accounts receivable balance and general economic conditions that may affect the customers' ability to pay. 
Inventories
Inventories
Inventory is valued at the lower of cost or market value. The Company assesses the valuation of its inventory on a periodic basis and makes adjustments to the value for estimated excess and obsolete inventory based on estimates about future demand. The excess balance determined by this analysis becomes the basis for the Company's excess inventory charge. The Company's excess inventory review process includes analysis of sales forecasts, managing product rollovers and working with operations to maximize recovery of excess inventory.
Revenue Recognition
Revenue Recognition
The Company sells its products through a combination of a direct sales force and independent stocking distributors and representatives in the U.S. and independent distributors in international markets. The Company recognizes revenue when title to the goods transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance. In cases where the Company utilizes distributors or ships product directly to the end user, it recognizes revenue upon shipment provided all other revenue recognition criteria have been met. A portion of the Company's revenue is generated from inventory maintained at hospitals, clinics and doctor's offices. For these products, revenue is recognized at the time the product has been used or implanted. The Company records estimated sales returns, discounts and allowances as a reduction of net sales in the same period revenue is recognized.  
Acquisitions
Acquisitions
Results of operations of acquired companies are included in the Company’s results of operations as of the respective acquisition dates. The purchase price of each acquisition is allocated to the net assets acquired based on estimates of their fair values at the date of the acquisition. Any purchase price in excess of these net assets is recorded as goodwill. The allocation of purchase price in certain cases may be subject to revision based on the final determination of fair values during the measurement period, which may be up to one year from the acquisition date.

Contingent consideration is recognized at the estimated fair value on the acquisition date. Subsequent changes to the fair value of contingent payments are recognized in earnings. Contingent payments related to acquisitions consist of an earn out based on sales less direct production costs, and are valued using discounted cash flow techniques. The fair value of these payments is based upon probability-weighted future revenue estimates and increases or decreases as revenue estimates or expectation of timing of payments changes.
Patent Costs
Patent Costs
The Company incurs certain legal and related costs in connection with patent applications for tissue-based products and processes. The Company capitalizes such costs to be amortized over the expected life of the patent to the extent that an economic benefit is anticipated from the resulting patent or alternative future use is available to the Company and are included in Intangible Assets in the Condensed Consolidated Balance Sheets.
Treasury Stock
Treasury Stock
The Company accounts for the purchase of treasury stock under the cost method. Treasury stock which is reissued for the exercise of option grants and the issuance of restricted stock grants is accounted for on a first - in first - out (FIFO) basis.
Recent Accounting Pronouncements
Recent Accounting Pronouncements 
The Company considers the applicability and impact of all Accounting Standards Updates ("ASUs") issued both effective and not yet effective. In May 2014, the FASB issued ASU 2014-09, “Revenue Recognition - Revenue from Contracts with Customers” (ASU 2014-09) that requires companies to recognize revenue when a customer obtains control rather than when companies have transferred substantially all risks and rewards of a good or service. This update is effective for annual reporting periods beginning on or after December 15, 2017 and interim periods therein and requires expanded disclosures. The Company is currently assessing the impact the adoption of ASU 2014-09 will have on our condensed consolidated financial statements.

In November 2015, the FASB issued ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes. ASU 2015-17 simplifies the presentation of deferred taxes by requiring deferred tax assets and liabilities be classified as noncurrent on the balance sheet. ASU 2015-17 is effective for public companies for annual reporting periods beginning after December 15, 2016, and interim periods within those fiscal years. The guidance may be adopted prospectively or retrospectively and early adoption is permitted. The Company adopted this standard, prospectively, at the beginning of the fourth quarter 2015 to simplify reporting with the release of the valuation allowance as disclosed in Note 12. Prior periods were not retrospectively adjusted.
In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from leases.  ASU 2016-02 is effective for public companies for annual reporting periods beginning after December 15, 2018, and interim periods within those fiscal years.  The guidance may be adopted prospectively or retrospectively and early adoption is permitted.  The Company is currently assessing the impact the adoption of ASU 2016-02 will have on its consolidated financial statements.
In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718). The standard is intended to simplify several areas of accounting for share - based compensation arrangements, including the income tax impact, classification on the statement of cash flows and forfeitures. This ASU is effective for fiscal years beginning after December 15, 2016. The Company is currently assessing the impact the adoption of ASU 2016-09 will have on its consolidated financial statements.
All other ASUs issued and not yet effective for the three months ended March 31, 2016, and through the date of this report, were assessed and determined to be either not applicable or are expected to have minimal impact on the Company's financial position or results of operations.
XML 36 R24.htm IDEA: XBRL DOCUMENT v3.4.0.3
Acquisition of Stability Inc. (Tables)
3 Months Ended
Mar. 31, 2016
Business Combinations [Abstract]  
Schedule of Acquisition of Stability Inc.
The actual purchase price has been preliminarily allocated as of March 31, 2016 (in thousands) and is subject to change:

 
 
 
Cash paid at closing
 
$
6,000

Common stock issued (441,009 shares valued at $9.07 per share)
 
3,346

Assumed debt
 
1,771

Fair value of earn - out
 
33,240

Total fair value of purchase price
 
$
44,357

 
 
 
Net assets acquired:
 
 
Debt-free working capital
 
$
2,382

Other assets, net
 
199

Property, plant and equipment
 
1,375

Deferred tax liability
 
(9,899
)
Subtotal
 
(5,943
)
Intangible assets:
 
 
Customer relationships
 
8,920

Patents and know-how
 
10,230

Trade names and trademarks
 
1,000

Non compete agreements
 
2,700

Licenses and permits
 
760

Subtotal
 
23,610

Goodwill
 
26,690

Total Assets Purchased
 
$
44,357

 


Working capital and other assets were composed of the following (in thousands):

Working capital:
 
 
Cash
 
$
140

Prepaid Expenses and other current assets
 
100

Accounts Receivable
 
2,001

Federal and state taxes receivable
 
28

Inventory
 
10,977

Accounts payable and accrued expenses
 
(10,864
)
Debt-free working capital
 
$
2,382

 
 
 
Current portion of long term debt
 
$
(194
)
Long-term debt
 
(560
)
Line of credit
 
(932
)
Shareholder loan
 
(85
)
Net working capital
 
$
611

 
 
 
Other assets:
 
 
Other long term assets
 
$
199

Finite-Lived and Indefinite-Lived Intangible Assets Acquired
The intangible assets were assigned the following lives for amortization purposes:


 
Estimated useful
 
life (in years)
Intangible asset:
 
Customer relationships
12
Patents and know-how
20
Trade names and trademarks
indefinite
Non compete agreements
4
Licenses and permits
2
Business Acquisition Pro Forma Information
Unaudited pro forma information for the three months ended March 31, 2016 and 2015 (in thousands) is as follows:
 
Three months ended March 31,
 
2016
2015
Revenues
$
53,915

$
45,921

 
 
 
Net income
$
1,611

$
2,879

 
 
 
Income per share, fully diluted
$
0.01

$
0.03

XML 37 R25.htm IDEA: XBRL DOCUMENT v3.4.0.3
Inventories (Tables)
3 Months Ended
Mar. 31, 2016
Inventory Disclosure [Abstract]  
Inventory
Inventories consisted of the following items as of March 31, 2016, and December 31, 2015 (in thousands):
 
March 31, 2016
 
December 31, 2015
Raw materials
$
1,127

 
$
602

Work in process
4,786

 
3,850

Finished goods
12,658

 
3,405

 Inventory, gross
18,571

 
7,857

Reserve for obsolescence
(604
)
 
(397
)
 Inventory, net
$
17,967

 
$
7,460

XML 38 R26.htm IDEA: XBRL DOCUMENT v3.4.0.3
Property and Equipment (Tables)
3 Months Ended
Mar. 31, 2016
Property, Plant and Equipment [Abstract]  
Property and Equipment
Property and equipment consist of the following as of March 31, 2016, and December 31, 2015 (in thousands):
 
March 31,
2016
 
December 31,
2015
Leasehold improvements
$
3,233

 
$
2,684

Lab and clean room equipment
7,528

 
4,564

Furniture and office equipment
5,730

 
4,577

Construction in progress
1,539

 
2,629

   Property and equipment, gross
18,030

 
14,454

Less accumulated depreciation
(5,907
)
 
(4,979
)
   Property and equipment, net
$
12,123

 
$
9,475

XML 39 R27.htm IDEA: XBRL DOCUMENT v3.4.0.3
Intangible Assets and Royalty Agreement (Tables)
3 Months Ended
Mar. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets Activity Summary
Intangible assets are summarized as follows (in thousands):
 
Weighted
Average
Amortization
Lives
 
March 31, 2016
 
December 31, 2015
 
 
 
Cost
 
Cost
Licenses (a) (b) (d)
7 years
 
$
1,769

 
$
1,009

Patents & Know How (b) (d)
19 years
 
18,233

 
8,001

Customer & Supplier Relationships (b) (d)
13 years
 
12,681

 
3,761

Tradenames & Trademarks (b) (d)
indefinite
 
2,008

 
1,008

Non - compete agreements (d)
4 years
 
2,700

 

In Process Research & Development (b)
n/a
 
25

 
25

Patents in Process (c)
n/a
 
1,969

 
1,823

Total
 
 
39,385

 
15,627

Less Accumulated amortization
 
 
(5,675
)
 
(4,864
)
Net
 
 
$
33,710

 
$
10,763

(a)
On January 29, 2007, the Company acquired a license from Shriners Hospitals for Children and University of South Florida Research Foundation, Inc. in the amount of $996,000.  Within 30 days after the receipt by the Company of approval by the FDA allowing the sale of the first licensed product, the Company is required to pay an additional $200,000 to the licensor.  Due to its contingent nature, this amount is not recorded as a liability. The Company will also be required to pay a royalty of 3% on all commercial sales revenue from the licensed products. The Company is also obligated to pay a $50,000 minimum annual royalty payment over the life of the license.
(b)
On January 5, 2011, the Company acquired Surgical Biologics, LLC.  As a result, the Company recorded intangible assets for Customer & Supplier Relationships of $3,761,000, Patents & Know-How of $7,690,000, Licenses of $13,000, Tradenames & Trademarks of $1,008,000 and In-Process Research & Development of $25,000. For the three months ended March 31, 2016, approximately $1,000 of costs associated with patents granted during the period were capitalized and included in Patents & Know-How subject to amortization.
(c)
Patents in Process consist of capitalized external legal and other registration costs in connection with internally developed tissue-based patents that are pending. Once issued, the costs associated with a given patent will be included in Patents & Know-How under intangible assets subject to amortization.
(d)
On January 13, 2016, the Company acquired Stability Inc. As a result, the Company recorded intangible assets for Patents & Know - How of $10,230,000, Customer Relationships of$8,920,000, Non - compete agreements of $2,700,000, Tradenames & Trademarksy of $1,000,000 and Licenses of $760,000.
Estimated Future Amortization Expense for Intangible Assets
Expected future amortization of intangible assets as of March 31, 2016, is as follows (in thousands):
Year ending December 31,
Estimated
Amortization
Expense
2016 (a)
$
2,434

2017
3,156

2018
2,766

2019
2,766

2020
2,091

Thereafter
18,489

 
$
31,702

(a) Estimated amortization expense for the year ending December 31, 2016, includes only amortization to be recorded after March 31, 2016.
XML 40 R28.htm IDEA: XBRL DOCUMENT v3.4.0.3
Net Income Per Share (Tables)
3 Months Ended
Mar. 31, 2016
Earnings Per Share [Abstract]  
Computation of Basic and Diluted Net Income per Share
The following table sets forth the computation of basic and diluted net income per share (in thousands except share data):
 
Three Months Ended March 31,
 
2016
 
2015
Net income
$
1,197

 
$
4,087

Denominator for basic earnings per share - weighted average shares
105,538,271

 
105,820,335

Effect of dilutive securities: Stock options, restricted stock, and warrants outstanding(a)
6,501,589

 
7,818,216

Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities
112,039,860

 
113,638,551

Income per common share - basic
$
0.01

 
$
0.04

Income per common share - diluted
$
0.01

 
$
0.04

(a) Securities outstanding that are included in the computation above, utilizing the treasury stock method are as follows:
 
Three Months Ended March 31,
 
2016
 
2015
Outstanding Stock Options
5,981,250

 
7,392,355

Outstanding Warrants

 
42,400

Restricted Stock Awards
520,339

 
383,461

 
6,501,589

 
7,818,216

XML 41 R29.htm IDEA: XBRL DOCUMENT v3.4.0.3
Equity (Tables)
3 Months Ended
Mar. 31, 2016
Equity [Abstract]  
Activity with respect to the stock options
Activity with respect to the stock options is summarized as follows:
 
Number
 of
Shares
 
Weighted-
Average
Exercise
Price
 
Weighted-Average
Remaining
Contractual Term
(in years)
 
Aggregate
Intrinsic
Value
Outstanding at January 1, 2016
14,019,629

 
$
3.62

 
 
 
 
Granted

 
$

 
 
 
 
Exercised
(608,717
)
 
$
1.87

 
 
 
 
Unvested options forfeited
(120,563
)
 
$
6.05

 
 
 
 
Vested options expired
(12,497
)
 
$
6.34

 
 
 
 

Outstanding at March 31, 2016
13,277,852

 
$
3.69

 
6.3
 
$
67,341,642

Vested at March 31, 2016
11,714,483

 
$
3.24

 
6.1
 
$
64,456,036

Vested or expected to vest at March 31, 2016 (a)
13,210,155

 
$
3.67

 
6.3
 
$
67,231,821

Following is a summary of stock options outstanding and exercisable
Following is a summary of stock options outstanding and exercisable at March 31, 2016:
 
Options Outstanding
 
Options Exercisable
Range of Exercise Prices
Number outstanding
 
Weighted-Average
Remaining
Contractual Term
(in years)
 
Weighted-
Average
Exercise
Price
 
Number Exercisable
 
Weighted-
Average
Exercise Price
$0.50 - $0.76
441,429

 
3.2
 
$
0.72

 
441,429

 
$
0.72

$0.87 - $1.35
4,431,970

 
5.4
 
1.19

 
4,431,970

 
1.19

$1.40 - $2.45
1,460,924

 
4.7
 
1.92

 
1,460,924

 
1.92

$2.66 - $3.99
894,120

 
6.6
 
3.06

 
894,120

 
3.06

$4.19 - $6.38
3,426,178

 
7.2
 
5.35

 
2,897,570

 
5.26

$6.45 - $9.78
2,512,065

 
7.9
 
7.29

 
1,556,144

 
7.24

$9.90- $10.99
111,166

 
8.6
 
10.44

 
32,326

 
10.51

 
13,277,852

 
6.3
 
$
3.69

 
11,714,483

 
$
3.24

Assumptions used in calculating the fair value of options using the Black-Scholes-Merton option-pricing model
The assumptions used in calculating the fair value of options using the Black-Scholes-Merton option-pricing model are set forth in the following table:
 
Three Months Ended March 31,
 
2016
 
2015
Expected volatility
n/a
 
56.8 - 58.1%

Expected life (in years)
n/a
 
6.0

Expected dividend yield
n/a
 

Risk-free interest rate
n/a
 
1.57% - 1.66%

Activity with respect to restricted stock awards
Activity with respect to restricted stock awards is summarized as follows: 
 
Number
of
Shares
 
Weighted-Average Grant Date
Fair Value
Unvested at January 1, 2016
2,613,267

 
$9.14
Granted
1,576,579

 
8.18
Vested
(644,903
)
 
8.42
Forfeited
(45,263
)
 
8.87

Unvested at March 31, 2016
3,499,680

 
$8.84
Allocation of share-based compensation
For the three months ended March 31, 2016 and 2015, the Company recognized stock-based compensation as follows (in thousands): 
 
Three Months Ended March 31,
 
2016
 
2015
Cost of sales
$
96

 
$
95

Research and development
205

 
186

Selling, general and administrative
4,314

 
3,652

 
$
4,615

 
$
3,933

XML 42 R30.htm IDEA: XBRL DOCUMENT v3.4.0.3
Supplemental disclosure of cash flow and non-cash investing and financing activities (Tables)
3 Months Ended
Mar. 31, 2016
Supplemental Cash Flow Elements [Abstract]  
Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities
Selected cash payments, receipts, and noncash activities are as follows (in thousands):
 
Three Months Ended March 31,
 
2016
 
2015
Cash paid for interest, net
$
56

 
$
14

Income taxes paid
139

 
363

Stock issuance of 441,009 shares in connection with acquisition
3,346

 

Stock issuance of 20,406 and 11,321 shares in exchange for services performed, respectively
173

 
108

XML 43 R31.htm IDEA: XBRL DOCUMENT v3.4.0.3
Contractual Commitments and Contingencies (Tables)
3 Months Ended
Mar. 31, 2016
Commitments and Contingencies Disclosure [Abstract]  
Estimated Annual Lease, Royalty and Employment Agreement Expenses
The estimated annual lease payments, meeting space and charitable organization commitments are as follows (in thousands):
12-month period ended March 31
2017
$
2,998

2018
2,246

2019
2,199

2020
1,742

Thereafter
765

 
$
9,950

XML 44 R32.htm IDEA: XBRL DOCUMENT v3.4.0.3
Basis of Presentation (Details)
3 Months Ended
Mar. 31, 2016
segment
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Number of business segments 1
XML 45 R33.htm IDEA: XBRL DOCUMENT v3.4.0.3
Significant Accounting Policies (Details) - USD ($)
$ in Thousands
3 Months Ended
Jan. 13, 2016
Mar. 31, 2016
Mar. 31, 2015
Finite-Lived Intangible Assets [Line Items]      
Increase (decrease) in inventories   $ 264 $ (885)
Amortization of inventory fair value step - up   734 0
Patents and know-how      
Finite-Lived Intangible Assets [Line Items]      
Intangible assets, net of accumulated amortization   147 $ 201
Fair Value Adjustment to Inventory      
Finite-Lived Intangible Assets [Line Items]      
Increase (decrease) in inventories $ 2,300 $ 1,600  
XML 46 R34.htm IDEA: XBRL DOCUMENT v3.4.0.3
Liquidity and Management's Plans (Details) - USD ($)
$ in Thousands
Mar. 31, 2016
Dec. 31, 2015
Mar. 31, 2015
Dec. 31, 2014
Liquidity and management's plans [Abstract]        
Cash and cash equivalents $ 15,117 $ 28,486 $ 38,696 $ 46,582
Total current assets 95,240 96,310    
Total current liabilities $ 28,842 $ 26,777    
XML 47 R35.htm IDEA: XBRL DOCUMENT v3.4.0.3
Acquisition of Stability Inc. - Narrative (Details) - USD ($)
$ in Thousands
3 Months Ended
Jan. 13, 2016
Mar. 31, 2016
Mar. 31, 2015
Business Acquisition [Line Items]      
Amortization of intangible assets   $ 810 $ 233
Net income   1,611 2,879
Stability Biologics, LLC      
Business Acquisition [Line Items]      
Cash paid at closing $ 6,000    
Common stock issued $ 3,346    
Common stock issued (in shares) 441,009    
Assumed debt $ 1,771    
Acquisition related costs 713    
Fair value of earn - out $ 33,240 $ 33,240  
Fair Value Adjustment to Inventory      
Business Acquisition [Line Items]      
Net income     (1,038)
Pro Forma      
Business Acquisition [Line Items]      
Amortization of intangible assets     $ 577
XML 48 R36.htm IDEA: XBRL DOCUMENT v3.4.0.3
Acquisition of Stability Inc. - Preliminarily Allocation of Purchase Price (Details) - USD ($)
$ / shares in Units, $ in Thousands
Jan. 13, 2016
Mar. 31, 2016
Dec. 31, 2015
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]      
Goodwill   $ 30,730 $ 4,040
Stability Biologics, LLC      
Business Combination, Consideration Transferred [Abstract]      
Cash paid at closing $ 6,000    
Common stock issued (441,009 shares valued at $9.07 per share) $ 3,346    
Common stock issued (in shares) 441,009    
Common stock issued, price per share (in dollars per share) $ 9.07    
Assumed debt $ 1,771    
Fair value of earn - out 33,240 $ 33,240  
Total fair value of purchase price 44,357    
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]      
Debt-free working capital 2,382    
Other assets, net 199    
Property, plant and equipment 1,375    
Deferred tax liability (9,899)    
Subtotal (5,943)    
Subtotal 23,610    
Goodwill 26,690    
Total Assets Purchased 44,357    
Cash 140    
Prepaid Expenses and other current assets 100    
Accounts Receivable 2,001    
Federal and state taxes receivable 28    
Inventory 10,977    
Accounts payable and accrued expenses (10,864)    
Debt-free working capital 2,382    
Current portion of long term debt (194)    
Net working capital 611    
Customer relationships | Stability Biologics, LLC      
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]      
Finite-lived intangible assets 8,920    
Patents and know-how | Stability Biologics, LLC      
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]      
Finite-lived intangible assets 10,230    
Non compete agreements | Stability Biologics, LLC      
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]      
Finite-lived intangible assets 2,700    
Licenses and permits | Stability Biologics, LLC      
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]      
Finite-lived intangible assets 760    
Trade names and trademarks | Stability Biologics, LLC      
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]      
Indefinite-lived intangible assets 1,000    
Long-term debt | Stability Biologics, LLC      
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]      
Long-term debt (560)    
Line of credit | Stability Biologics, LLC      
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]      
Long-term debt (932)    
Shareholder loan | Stability Biologics, LLC      
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]      
Long-term debt $ (85)    
XML 49 R37.htm IDEA: XBRL DOCUMENT v3.4.0.3
Acquisition of Stability Inc. - Intangible Assets Acquired as Part of Acquisition (Details) - Stability Biologics, LLC
Jan. 13, 2016
Customer relationships  
Finite-Lived Intangible Assets [Line Items]  
Estimated useful life 12 years
Patents and know-how  
Finite-Lived Intangible Assets [Line Items]  
Estimated useful life 20 years
Non compete agreements  
Finite-Lived Intangible Assets [Line Items]  
Estimated useful life 4 years
Licenses and permits  
Finite-Lived Intangible Assets [Line Items]  
Estimated useful life 2 years
XML 50 R38.htm IDEA: XBRL DOCUMENT v3.4.0.3
Acquisition of Stability Inc. - Pro Forma Information (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Business Combinations [Abstract]    
Revenues $ 53,915 $ 45,921
Net income $ 1,611 $ 2,879
Income per share, fully diluted (in dollars per share) $ 0.01 $ 0.03
XML 51 R39.htm IDEA: XBRL DOCUMENT v3.4.0.3
Short Term Investments (Details) - USD ($)
$ in Thousands
Mar. 31, 2016
Dec. 31, 2015
Investment [Line Items]    
Short term investments $ 2,500 $ 3,000
Certificates of Deposit    
Investment [Line Items]    
Short term investments $ 2,500 $ 3,000
XML 52 R40.htm IDEA: XBRL DOCUMENT v3.4.0.3
Inventories (Details) - USD ($)
$ in Thousands
Mar. 31, 2016
Dec. 31, 2015
Inventory Disclosure [Abstract]    
Raw materials $ 1,127 $ 602
Work in process 4,786 3,850
Finished goods 12,658 3,405
Inventory, gross 18,571 7,857
Reserve for obsolescence (604) (397)
Inventory, net $ 17,967 $ 7,460
XML 53 R41.htm IDEA: XBRL DOCUMENT v3.4.0.3
Property and Equipment (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Dec. 31, 2015
Property and equipment [Line Items]      
Property and equipment, gross $ 18,030   $ 14,454
Less accumulated depreciation (5,907)   (4,979)
Property and equipment, net 12,123   9,475
Other liabilities $ 895   1,148
Interest rate for leases, minimum (percent) 3.00%    
Interest rate for leases, maximum (percent) 12.00%    
Depreciation $ 734 $ 354  
Leasehold improvements      
Property and equipment [Line Items]      
Property and equipment, gross 3,233   2,684
Lab and clean room equipment      
Property and equipment [Line Items]      
Property and equipment, gross 7,528   4,564
Furniture and office equipment      
Property and equipment [Line Items]      
Property and equipment, gross 5,730   4,577
Construction in progress      
Property and equipment [Line Items]      
Property and equipment, gross 1,539   $ 2,629
Assets Held under Capital Leases      
Property and equipment [Line Items]      
Property and equipment, net 427    
Other liabilities 103    
Leasehold Improvements Paid by Others      
Property and equipment [Line Items]      
Property and equipment, net $ 1,000    
XML 54 R42.htm IDEA: XBRL DOCUMENT v3.4.0.3
Intangible Assets and Royalty Agreement (Details) - USD ($)
3 Months Ended
Jan. 29, 2007
Mar. 31, 2016
Mar. 31, 2015
Jan. 13, 2016
Dec. 31, 2015
Jan. 05, 2011
Finite-Lived Intangible Assets [Line Items]            
Total   $ 39,385,000     $ 15,627,000  
Less Accumulated amortization   (5,675,000)     (4,864,000)  
Net   33,710,000     10,763,000  
Amortization of intangible assets   810,000 $ 233,000      
Estimated future amortization expense [Abstract]            
2016 [1]   2,434,000        
2017   3,156,000        
2018   2,766,000        
2019   2,766,000        
2020   2,091,000        
Thereafter   18,489,000        
Net book value   $ 31,702,000        
Licenses and permits            
Finite-Lived Intangible Assets [Line Items]            
Weighted average amortization lives   7 years        
Gross carrying value [2],[3]   $ 1,769,000     1,009,000  
Licenses and permits | Shriners Hospitals for Children and University of South Florida Research Foundation, Inc.            
Finite-Lived Intangible Assets [Line Items]            
Acquisition price $ 996,000          
Maximum time of approval 30 days          
Fair value of earn - out   $ 200,000        
Contingent royalty to be paid to licensor (percent)   3.00%        
Annual royalty payment $ 50,000          
Licenses and permits | Surgical Biologics, LLC            
Finite-Lived Intangible Assets [Line Items]            
Gross carrying value           $ 13,000
Patents & Know How            
Finite-Lived Intangible Assets [Line Items]            
Weighted average amortization lives   19 years        
Gross carrying value [3]   $ 18,233,000     8,001,000  
Patents & Know How | Surgical Biologics, LLC            
Finite-Lived Intangible Assets [Line Items]            
Gross carrying value           7,690,000
Finite-Lived intangible assets, costs   $ 1,000        
Customer relationships            
Finite-Lived Intangible Assets [Line Items]            
Weighted average amortization lives   13 years        
Gross carrying value [3]   $ 12,681,000     3,761,000  
Customer relationships | Surgical Biologics, LLC            
Finite-Lived Intangible Assets [Line Items]            
Gross carrying value           3,761,000
Tradenames & Trademarks            
Finite-Lived Intangible Assets [Line Items]            
Gross carrying value, indefinite lived [3]   $ 2,008,000     1,008,000  
Tradenames & Trademarks | Surgical Biologics, LLC            
Finite-Lived Intangible Assets [Line Items]            
Gross carrying value, indefinite lived           1,008,000
Non compete agreements            
Finite-Lived Intangible Assets [Line Items]            
Weighted average amortization lives   4 years        
Gross carrying value   $ 2,700,000     0  
In Process Research & Development            
Finite-Lived Intangible Assets [Line Items]            
Gross carrying value, indefinite lived [3]   25,000     25,000  
In Process Research & Development | Surgical Biologics, LLC            
Finite-Lived Intangible Assets [Line Items]            
Gross carrying value, indefinite lived           $ 25,000
Patents in Process            
Finite-Lived Intangible Assets [Line Items]            
Gross carrying value, indefinite lived [4]   1,969,000     $ 1,823,000  
Stability Biologics, LLC            
Finite-Lived Intangible Assets [Line Items]            
Fair value of earn - out   $ 33,240,000   $ 33,240,000    
Stability Biologics, LLC | Licenses and permits            
Finite-Lived Intangible Assets [Line Items]            
Gross carrying value       760,000    
Stability Biologics, LLC | Patents & Know How            
Finite-Lived Intangible Assets [Line Items]            
Gross carrying value       10,230,000    
Stability Biologics, LLC | Customer relationships            
Finite-Lived Intangible Assets [Line Items]            
Gross carrying value       8,920,000    
Stability Biologics, LLC | Tradenames & Trademarks            
Finite-Lived Intangible Assets [Line Items]            
Gross carrying value, indefinite lived       1,000,000    
Stability Biologics, LLC | Non compete agreements            
Finite-Lived Intangible Assets [Line Items]            
Gross carrying value       $ 2,700,000    
[1] Estimated amortization expense for the year ending December 31, 2016, includes only amortization to be recorded after March 31, 2016.
[2] On January 29, 2007, the Company acquired a license from Shriners Hospitals for Children and University of South Florida Research Foundation, Inc. in the amount of $996,000. Within 30 days after the receipt by the Company of approval by the FDA allowing the sale of the first licensed product, the Company is required to pay an additional $200,000 to the licensor. Due to its contingent nature, this amount is not recorded as a liability. The Company will also be required to pay a royalty of 3% on all commercial sales revenue from the licensed products. The Company is also obligated to pay a $50,000 minimum annual royalty payment over the life of the license.
[3] On January 5, 2011, the Company acquired Surgical Biologics, LLC. As a result, the Company recorded intangible assets for Customer & Supplier Relationships of $3,761,000, Patents & Know-How of $7,690,000, Licenses of $13,000, Tradenames & Trademarks of $1,008,000 and In-Process Research & Development of $25,000. For the three months ended March 31, 2016, approximately $1,000 of costs associated with patents granted during the period were capitalized and included in Patents & Know-How subject to amortization.
[4] Patents in Process consist of capitalized external legal and other registration costs in connection with internally developed tissue-based patents that are pending. Once issued, the costs associated with a given patent will be included in Patents & Know-How under intangible assets subject to amortization.
XML 55 R43.htm IDEA: XBRL DOCUMENT v3.4.0.3
Credit Facility (Details) - Revolving Credit Facility - Credit Agreement - USD ($)
Oct. 12, 2015
Mar. 31, 2016
Debt Instrument [Line Items]    
Maximum borrowing capacity (up to) $ 50,000,000  
Uncommitted incremental facility (up to) 35,000,000  
Debt issuance cost $ 500,000  
Debt term 3 years  
Outstanding line of credit   $ 0
Minimum | London Interbank Offered Rate (LIBOR)    
Debt Instrument [Line Items]    
Basis spread on variable rate 1.50%  
Maximum | London Interbank Offered Rate (LIBOR)    
Debt Instrument [Line Items]    
Basis spread on variable rate 2.25%  
XML 56 R44.htm IDEA: XBRL DOCUMENT v3.4.0.3
Net Income Per Share (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Computation of basic and diluted net loss per share [Abstract]    
Net income $ 1,197 $ 4,087
Denominator for basic earnings per share - weighted average shares 105,538,271 105,820,335
Effect of dilutive securities: Stock options, restricted stock, and warrants outstanding (in shares) [1] 6,501,589 7,818,216
Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities 112,039,860 113,638,551
Income per common share - basic (in dollars per share) $ 0.01 $ 0.04
Income per common share - diluted (in dollars per share) $ 0.01 $ 0.04
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share (in shares) 6,501,589 7,818,216
Outstanding Stock Options    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share (in shares) 5,981,250 7,392,355
Outstanding Warrants    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share (in shares) 0 42,400
Restricted Stock Awards    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share (in shares) 520,339 383,461
[1] Securities outstanding that are included in the computation above, utilizing the treasury stock method are as follows: Three Months Ended March 31, 2016 2015Outstanding Stock Options5,981,250 7,392,355Outstanding Warrants— 42,400Restricted Stock Awards520,339 383,461 6,501,589 7,818,216
XML 57 R45.htm IDEA: XBRL DOCUMENT v3.4.0.3
Equity (Details)
3 Months Ended 23 Months Ended
Mar. 31, 2016
USD ($)
plan
$ / shares
shares
Mar. 31, 2015
USD ($)
shares
Mar. 31, 2016
USD ($)
$ / shares
shares
Dec. 31, 2015
USD ($)
Dec. 31, 2014
USD ($)
May. 12, 2014
USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Number of share-based compensation plans | plan 3          
Outstanding assumed options (in shares) | shares 70,000   70,000      
Shares authorized (in shares) | shares 26,500,000   26,500,000      
Common stock shares issued (in shares) | shares 20,406 11,321        
Shares issued for services performed | $ $ 173,000 $ 108,000        
Total unrecognized compensation expense | $ $ 4,501,863   $ 4,501,863      
Number of shares [Roll forward]            
Outstanding, beginning of period (in shares) | shares 14,019,629          
Granted (in shares) | shares 0          
Exercised (in shares) | shares (608,717)          
Unvested options forfeited (in shares) | shares (120,563)          
Vested options expired (in shares) | shares (12,497)          
Outstanding, end of period (in shares) | shares 13,277,852   13,277,852      
Vested at end of period (in shares) | shares 11,714,483   11,714,483      
Exercisable options, vested and expected to vest (in shares) | shares [1] 13,210,155   13,210,155      
Weighted-Average Exercise Price [Roll forward]            
Outstanding, weighted average exercise price, beginning of period (in dollars per share) $ 3.62          
Granted, weighted average exercise price (in dollars per share) 0.00          
Exercised, weighted average exercise price (in dollars per share) 1.87          
Unvested options forfeited weighted-average exercise price (in dollars per share) 6.05          
Vested options expired weighted-average exercise price (in dollars per share) 6.34          
Outstanding, weighted average exercise price, end of period (in dollars per share) 3.69   $ 3.69      
Vested at end of period weighted average exercise price (in dollars per share) 3.24   3.24      
Vested and expected to vest, weighted average exercise price (in dollars per share) [1] $ 3.67   $ 3.67      
Stock options, additional disclosures [Abstract]            
Vested at end of period weighted average remaining contractual term 6 years 1 month 6 days          
Vested and expected to vest, weighted average remaining contractual term [1] 6 years 3 months 18 days          
Outstanding intrinsic value | $ $ 67,341,642   $ 67,341,642      
Vested at end of period aggregate intrinsic value | $ 64,456,036   64,456,036      
Vested and expected to vest, aggregate intrinsic value | $ [1] 67,231,821   $ 67,231,821      
Exercised options, intrinsic value | $ $ 4,440,694          
Number of outstanding options (in shares) | shares 13,277,852   13,277,852      
Outstanding Options, weighted average remaining contractual term 6 years 3 months 18 days          
Outstanding Options, weighted average exercise price (in dollars per share) $ 3.69   $ 3.69      
Number of exercisable options (in shares) | shares 11,714,483   11,714,483      
Exercisable Options, weighted average exercise price (in dollars per share) $ 3.24   $ 3.24      
Fair value options valuation assumptions [Abstract]            
Expected volatility Minimum   56.80%        
Expected volatility Maximum   58.10%        
Expected life (in years)   6 years        
Expected dividend yield   0.00%        
Risk-free interest rate Minimum   1.57%        
Risk-free interest rate Maximum   1.66%        
Share-based Compensation [Abstract]            
Share-based compensation expense | $ $ 4,615,000 $ 3,933,000        
Authorized share amount for repurchase | $       $ 60,000,000 $ 20,000,000 $ 10,000,000
Stock repurchase (in shares) | shares 415,252          
Payments for repurchase of common stock, net | $ $ 3,518,000          
Brokerage commissions | $ 12,000          
Shares repurchased, value | $ 3,530,000 12,295,000 $ 49,244,000      
Remaining authorizations under the repurchase program | $ $ 10,756,000   10,756,000      
Shares reissued from the treasury | shares 2,529,444          
Shares reissued from the treasury, value | $ $ 20,746,000          
Cost of Products Sold            
Share-based Compensation [Abstract]            
Share-based compensation expense | $ 96,000 95,000        
Research and Development            
Share-based Compensation [Abstract]            
Share-based compensation expense | $ 205,000 186,000        
Selling, General and Administrative            
Share-based Compensation [Abstract]            
Share-based compensation expense | $ 4,314,000 $ 3,652,000        
Restricted Stock Awards            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Total unrecognized stock-based compensation related to time-based, nonvested restricted stock | $ $ 24,965,395   $ 24,965,395      
Expenses expected to be recognized over a weighted-average period (in years) 2 years 3 months 18 days          
Number of Shares            
Beginning Balance | shares 2,613,267          
Granted | shares 1,576,579          
Vested | shares (644,903)          
Forfeited | shares (45,263)          
Ending Balance | shares 3,499,680   3,499,680      
Weighted- Average Grant Date Fair Value            
Beginning Balance (in dollars per share) $ 9.14          
Granted (in dollars per share) 8.18          
Vested (in dollars per share) 8.42          
Forfeited (in dollars per share) 8.87          
Beginning Balance (in dollars per share) $ 8.84   $ 8.84      
Share-based Compensation [Abstract]            
Shares paid for tax withholding | shares 81,594          
$0.50 - $0.76            
Stock options, additional disclosures [Abstract]            
Exercise Price Range, lower range limit (in dollars per share) $ 0.50          
Exercise Price Range, upper range limit (in dollars per share) $ 0.76          
Number of outstanding options (in shares) | shares 441,429   441,429      
Outstanding Options, weighted average remaining contractual term 3 years 2 months 12 days          
Outstanding Options, weighted average exercise price (in dollars per share) $ 0.72   $ 0.72      
Number of exercisable options (in shares) | shares 441,429   441,429      
Exercisable Options, weighted average exercise price (in dollars per share) $ 0.72   $ 0.72      
$0.87 - $1.35            
Stock options, additional disclosures [Abstract]            
Exercise Price Range, lower range limit (in dollars per share) 0.87          
Exercise Price Range, upper range limit (in dollars per share) $ 1.35          
Number of outstanding options (in shares) | shares 4,431,970   4,431,970      
Outstanding Options, weighted average remaining contractual term 5 years 4 months 24 days          
Outstanding Options, weighted average exercise price (in dollars per share) $ 1.19   $ 1.19      
Number of exercisable options (in shares) | shares 4,431,970   4,431,970      
Exercisable Options, weighted average exercise price (in dollars per share) $ 1.19   $ 1.19      
$1.40 - $2.45            
Stock options, additional disclosures [Abstract]            
Exercise Price Range, lower range limit (in dollars per share) 1.40          
Exercise Price Range, upper range limit (in dollars per share) $ 2.45          
Number of outstanding options (in shares) | shares 1,460,924   1,460,924      
Outstanding Options, weighted average remaining contractual term 4 years 8 months 12 days          
Outstanding Options, weighted average exercise price (in dollars per share) $ 1.92   $ 1.92      
Number of exercisable options (in shares) | shares 1,460,924   1,460,924      
Exercisable Options, weighted average exercise price (in dollars per share) $ 1.92   $ 1.92      
$2.66 - $3.99            
Stock options, additional disclosures [Abstract]            
Exercise Price Range, lower range limit (in dollars per share) 2.66          
Exercise Price Range, upper range limit (in dollars per share) $ 3.99          
Number of outstanding options (in shares) | shares 894,120   894,120      
Outstanding Options, weighted average remaining contractual term 6 years 7 months 6 days          
Outstanding Options, weighted average exercise price (in dollars per share) $ 3.06   $ 3.06      
Number of exercisable options (in shares) | shares 894,120   894,120      
Exercisable Options, weighted average exercise price (in dollars per share) $ 3.06   $ 3.06      
$4.19 - $6.38            
Stock options, additional disclosures [Abstract]            
Exercise Price Range, lower range limit (in dollars per share) 4.19          
Exercise Price Range, upper range limit (in dollars per share) $ 6.38          
Number of outstanding options (in shares) | shares 3,426,178   3,426,178      
Outstanding Options, weighted average remaining contractual term 7 years 2 months 12 days          
Outstanding Options, weighted average exercise price (in dollars per share) $ 5.35   $ 5.35      
Number of exercisable options (in shares) | shares 2,897,570   2,897,570      
Exercisable Options, weighted average exercise price (in dollars per share) $ 5.26   $ 5.26      
$6.45 - $9.78            
Stock options, additional disclosures [Abstract]            
Exercise Price Range, lower range limit (in dollars per share) 6.45          
Exercise Price Range, upper range limit (in dollars per share) $ 9.78          
Number of outstanding options (in shares) | shares 2,512,065   2,512,065      
Outstanding Options, weighted average remaining contractual term 7 years 10 months 24 days          
Outstanding Options, weighted average exercise price (in dollars per share) $ 7.29   $ 7.29      
Number of exercisable options (in shares) | shares 1,556,144   1,556,144      
Exercisable Options, weighted average exercise price (in dollars per share) $ 7.24   $ 7.24      
$9.90- $10.99            
Stock options, additional disclosures [Abstract]            
Exercise Price Range, lower range limit (in dollars per share) 9.90          
Exercise Price Range, upper range limit (in dollars per share) $ 10.99          
Number of outstanding options (in shares) | shares 111,166   111,166      
Outstanding Options, weighted average remaining contractual term 8 years 7 months 6 days          
Outstanding Options, weighted average exercise price (in dollars per share) $ 10.44   $ 10.44      
Number of exercisable options (in shares) | shares 32,326   32,326      
Exercisable Options, weighted average exercise price (in dollars per share) $ 10.51   $ 10.51      
Assumed 2006 Plan            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Common stock shares issued (in shares) | shares 20,406          
Shares issued for services performed | $ $ 173,000          
[1] Includes forfeiture adjusted unvested shares.
XML 58 R46.htm IDEA: XBRL DOCUMENT v3.4.0.3
Income taxes (Details) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Dec. 31, 2016
Dec. 31, 2015
Income Tax Contingency [Line Items]        
Effective tax rate 15.20% 3.40%    
Effective income tax rate increase (decrease), amount $ 350      
Effective income tax rate increase (decrease), percent 11.80%      
Change in valuation allowance       $ (15,400)
Forecast        
Income Tax Contingency [Line Items]        
Effective tax rate     40.40%  
XML 59 R47.htm IDEA: XBRL DOCUMENT v3.4.0.3
Supplemental disclosure of cash flow and non-cash investing and financing activities (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Supplemental Cash Flow Elements [Abstract]    
Cash paid for interest, net $ 56 $ 14
Income taxes paid 139 363
Stock issuance of 441,009 shares in connection with acquisition $ 3,346 0
Shares issued in conjunction with acquisition (in shares) 441,009  
Stock issuance of 20,406 and 11,321 shares in exchange for services performed, respectively $ 173 $ 108
Shares issued for services performed (in shares) 20,406 11,321
XML 60 R48.htm IDEA: XBRL DOCUMENT v3.4.0.3
Contractual Commitments and Contingencies (Details)
$ in Thousands
3 Months Ended 12 Months Ended
Mar. 31, 2016
USD ($)
claim
Mar. 31, 2015
USD ($)
Dec. 31, 2015
Dec. 30, 2015
term
Dec. 22, 2015
term
Oct. 02, 2015
term
Aug. 18, 2015
claim
Jul. 10, 2015
claim
Jun. 29, 2015
claim
Estimated annual lease, royalty, and employment agreement expenses [Abstract]                  
2017 $ 2,998                
2018 2,246                
2019 2,199                
2020 1,742                
Thereafter 765                
Total Contractual commitments $ 9,950                
Loss Contingencies [Line Items]                  
Lessee expiration period (years) 6 years                
Rent expense $ 423 $ 284              
Sales Revenue, Net | Product Concentration Risk                  
Loss Contingencies [Line Items]                  
Percentage of revenue     12.00%            
Standby Letters of Credit                  
Loss Contingencies [Line Items]                  
Standby letters of credit $ 235                
Pending Litigation                  
Loss Contingencies [Line Items]                  
Number of patent challenged grounds | claim 4                
Pending Litigation | Bone Bank Action                  
Loss Contingencies [Line Items]                  
Number of patent challenged grounds | claim               5 7
Number of pending disputed claim terms | term           1      
Opinion allowing a review of patent | claim               2  
Pending Litigation | Liventa Action                  
Loss Contingencies [Line Items]                  
Number of pending disputed claim terms | term       1 30        
Pending Litigation | Liventa Action, 701 Patent                  
Loss Contingencies [Line Items]                  
Number of patent challenged grounds | claim             6    
Pending Litigation | Liventa Action, 437 Patent                  
Loss Contingencies [Line Items]                  
Number of patent challenged grounds | claim             7    
Opinion allowing a review of patent | claim             1    
XML 61 R49.htm IDEA: XBRL DOCUMENT v3.4.0.3
Schedule II - Valuation and Qualifying Accounts (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Allowance for doubtful accounts    
Movement in Valuation Allowances and Reserves [Roll Forward]    
Balance at Beginning of Period $ 3,270 $ 1,750
Additions charged to Expense or Revenue 602 260
Deductions and write-offs 0 0
Balance at End of Period 3,872 2,010
Allowance for product returns    
Movement in Valuation Allowances and Reserves [Roll Forward]    
Balance at Beginning of Period 1,262 841
Additions charged to Expense or Revenue 1,300 709
Deductions and write-offs (911) (606)
Balance at End of Period 1,651 944
Allowance for obsolescence    
Movement in Valuation Allowances and Reserves [Roll Forward]    
Balance at Beginning of Period 397 527
Additions charged to Expense or Revenue 235 130
Deductions and write-offs (28) (105)
Balance at End of Period $ 604 $ 552
EXCEL 62 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 63 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 64 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 66 FilingSummary.xml IDEA: XBRL DOCUMENT 3.4.0.3 html 145 284 1 true 59 0 false 8 false false R1.htm 0001000 - Document - Document and Entity Information Sheet http://mimedx.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) Sheet http://mimedx.com/role/CondensedConsolidatedBalanceSheetsUnaudited CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) Statements 2 false false R3.htm 1001501 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical) Sheet http://mimedx.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical) Statements 3 false false R4.htm 1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) Sheet http://mimedx.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) Statements 4 false false R5.htm 1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (unaudited) Sheet http://mimedx.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (unaudited) Statements 5 false false R6.htm 1004000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) Sheet http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) Statements 6 false false R7.htm 2101100 - Disclosure - Basis of Presentation Sheet http://mimedx.com/role/BasisOfPresentation Basis of Presentation Notes 7 false false R8.htm 2102100 - Disclosure - Significant Accounting Policies Sheet http://mimedx.com/role/SignificantAccountingPolicies Significant Accounting Policies Notes 8 false false R9.htm 2103100 - Disclosure - Liquidity and Management's Plans Sheet http://mimedx.com/role/LiquidityAndManagementsPlans Liquidity and Management's Plans Notes 9 false false R10.htm 2104100 - Disclosure - Acquisition of Stability Inc. Sheet http://mimedx.com/role/AcquisitionOfStabilityInc Acquisition of Stability Inc. Notes 10 false false R11.htm 2105100 - Disclosure - Short Term Investments Sheet http://mimedx.com/role/ShortTermInvestments Short Term Investments Notes 11 false false R12.htm 2108100 - Disclosure - Inventories Sheet http://mimedx.com/role/Inventories Inventories Notes 12 false false R13.htm 2109100 - Disclosure - Property and Equipment Sheet http://mimedx.com/role/PropertyAndEquipment Property and Equipment Notes 13 false false R14.htm 2110100 - Disclosure - Intangible Assets and Royalty Agreement Sheet http://mimedx.com/role/IntangibleAssetsAndRoyaltyAgreement Intangible Assets and Royalty Agreement Notes 14 false false R15.htm 2111100 - Disclosure - Credit Facility Sheet http://mimedx.com/role/CreditFacility Credit Facility Notes 15 false false R16.htm 2112100 - Disclosure - Net Income Per Share Sheet http://mimedx.com/role/NetIncomePerShare Net Income Per Share Notes 16 false false R17.htm 2114100 - Disclosure - Equity Sheet http://mimedx.com/role/Equity Equity Notes 17 false false R18.htm 2115100 - Disclosure - Income taxes Sheet http://mimedx.com/role/IncomeTaxes Income taxes Notes 18 false false R19.htm 2116100 - Disclosure - Supplemental disclosure of cash flow and non-cash investing and financing activities Sheet http://mimedx.com/role/SupplementalDisclosureOfCashFlowAndNonCashInvestingAndFinancingActivities Supplemental disclosure of cash flow and non-cash investing and financing activities Notes 19 false false R20.htm 2117100 - Disclosure - Contractual Commitments and Contingencies Sheet http://mimedx.com/role/ContractualCommitmentsAndContingencies Contractual Commitments and Contingencies Notes 20 false false R21.htm 2118100 - Disclosure - Subsequent Events Sheet http://mimedx.com/role/SubsequentEvents Subsequent Events Notes 21 false false R22.htm 2119100 - Schedule - Schedule II - Valuation and Qualifying Accounts Sheet http://mimedx.com/role/ScheduleIiValuationAndQualifyingAccounts Schedule II - Valuation and Qualifying Accounts Uncategorized 22 false false R23.htm 2202201 - Disclosure - Significant Accounting Policies (Policies) Sheet http://mimedx.com/role/SignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) Uncategorized 23 false false R24.htm 2304301 - Disclosure - Acquisition of Stability Inc. (Tables) Sheet http://mimedx.com/role/AcquisitionOfStabilityIncTables Acquisition of Stability Inc. (Tables) Uncategorized 24 false false R25.htm 2308301 - Disclosure - Inventories (Tables) Sheet http://mimedx.com/role/InventoriesTables Inventories (Tables) Uncategorized 25 false false R26.htm 2309301 - Disclosure - Property and Equipment (Tables) Sheet http://mimedx.com/role/PropertyAndEquipmentTables Property and Equipment (Tables) Uncategorized 26 false false R27.htm 2310301 - Disclosure - Intangible Assets and Royalty Agreement (Tables) Sheet http://mimedx.com/role/IntangibleAssetsAndRoyaltyAgreementTables Intangible Assets and Royalty Agreement (Tables) Uncategorized 27 false false R28.htm 2312301 - Disclosure - Net Income Per Share (Tables) Sheet http://mimedx.com/role/NetIncomePerShareTables Net Income Per Share (Tables) Uncategorized 28 false false R29.htm 2314301 - Disclosure - Equity (Tables) Sheet http://mimedx.com/role/EquityTables Equity (Tables) Uncategorized 29 false false R30.htm 2316301 - Disclosure - Supplemental disclosure of cash flow and non-cash investing and financing activities (Tables) Sheet http://mimedx.com/role/SupplementalDisclosureOfCashFlowAndNonCashInvestingAndFinancingActivitiesTables Supplemental disclosure of cash flow and non-cash investing and financing activities (Tables) Uncategorized 30 false false R31.htm 2317301 - Disclosure - Contractual Commitments and Contingencies (Tables) Sheet http://mimedx.com/role/ContractualCommitmentsAndContingenciesTables Contractual Commitments and Contingencies (Tables) Uncategorized 31 false false R32.htm 2401401 - Disclosure - Basis of Presentation (Details) Sheet http://mimedx.com/role/BasisOfPresentationDetails Basis of Presentation (Details) Uncategorized 32 false false R33.htm 2402402 - Disclosure - Significant Accounting Policies (Details) Sheet http://mimedx.com/role/SignificantAccountingPoliciesDetails Significant Accounting Policies (Details) Uncategorized 33 false false R34.htm 2403401 - Disclosure - Liquidity and Management's Plans (Details) Sheet http://mimedx.com/role/LiquidityAndManagementsPlansDetails Liquidity and Management's Plans (Details) Uncategorized 34 false false R35.htm 2404402 - Disclosure - Acquisition of Stability Inc. - Narrative (Details) Sheet http://mimedx.com/role/AcquisitionOfStabilityIncNarrativeDetails Acquisition of Stability Inc. - Narrative (Details) Uncategorized 35 false false R36.htm 2404403 - Disclosure - Acquisition of Stability Inc. - Preliminarily Allocation of Purchase Price (Details) Sheet http://mimedx.com/role/AcquisitionOfStabilityIncPreliminarilyAllocationOfPurchasePriceDetails Acquisition of Stability Inc. - Preliminarily Allocation of Purchase Price (Details) Uncategorized 36 false false R37.htm 2404404 - Disclosure - Acquisition of Stability Inc. - Intangible Assets Acquired as Part of Acquisition (Details) Sheet http://mimedx.com/role/AcquisitionOfStabilityIncIntangibleAssetsAcquiredAsPartOfAcquisitionDetails Acquisition of Stability Inc. - Intangible Assets Acquired as Part of Acquisition (Details) Uncategorized 37 false false R38.htm 2404405 - Disclosure - Acquisition of Stability Inc. - Pro Forma Information (Details) Sheet http://mimedx.com/role/AcquisitionOfStabilityIncProFormaInformationDetails Acquisition of Stability Inc. - Pro Forma Information (Details) Uncategorized 38 false false R39.htm 2405401 - Disclosure - Short Term Investments (Details) Sheet http://mimedx.com/role/ShortTermInvestmentsDetails Short Term Investments (Details) Uncategorized 39 false false R40.htm 2408402 - Disclosure - Inventories (Details) Sheet http://mimedx.com/role/InventoriesDetails Inventories (Details) Uncategorized 40 false false R41.htm 2409402 - Disclosure - Property and Equipment (Details) Sheet http://mimedx.com/role/PropertyAndEquipmentDetails Property and Equipment (Details) Uncategorized 41 false false R42.htm 2410402 - Disclosure - Intangible Assets and Royalty Agreement (Details) Sheet http://mimedx.com/role/IntangibleAssetsAndRoyaltyAgreementDetails Intangible Assets and Royalty Agreement (Details) Uncategorized 42 false false R43.htm 2411401 - Disclosure - Credit Facility (Details) Sheet http://mimedx.com/role/CreditFacilityDetails Credit Facility (Details) Uncategorized 43 false false R44.htm 2412402 - Disclosure - Net Income Per Share (Details) Sheet http://mimedx.com/role/NetIncomePerShareDetails Net Income Per Share (Details) Uncategorized 44 false false R45.htm 2414402 - Disclosure - Equity (Details) Sheet http://mimedx.com/role/EquityDetails Equity (Details) Uncategorized 45 false false R46.htm 2415401 - Disclosure - Income taxes (Details) Sheet http://mimedx.com/role/IncomeTaxesDetails Income taxes (Details) Uncategorized 46 false false R47.htm 2416402 - Disclosure - Supplemental disclosure of cash flow and non-cash investing and financing activities (Details) Sheet http://mimedx.com/role/SupplementalDisclosureOfCashFlowAndNonCashInvestingAndFinancingActivitiesDetails Supplemental disclosure of cash flow and non-cash investing and financing activities (Details) Uncategorized 47 false false R48.htm 2417402 - Disclosure - Contractual Commitments and Contingencies (Details) Sheet http://mimedx.com/role/ContractualCommitmentsAndContingenciesDetails Contractual Commitments and Contingencies (Details) Uncategorized 48 false false R49.htm 2419401 - Schedule - Schedule II - Valuation and Qualifying Accounts (Details) Sheet http://mimedx.com/role/ScheduleIiValuationAndQualifyingAccountsDetails Schedule II - Valuation and Qualifying Accounts (Details) Uncategorized 49 false false All Reports Book All Reports mdxg-20160331.xml mdxg-20160331.xsd mdxg-20160331_cal.xml mdxg-20160331_def.xml mdxg-20160331_lab.xml mdxg-20160331_pre.xml true true ZIP 68 0001376339-16-000160-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001376339-16-000160-xbrl.zip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end